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Abstract 
 
 
The post infectious paralytic autoimmune disease, Guillain-Barré syndrome (GBS), 
has been associated with the generation of cross-reactive auto-antibodies after 
Campylobacter jejuni infection. These auto-antibodies interact with both the 
ganglioside mimicking C. jejuni lipo-oligosaccharides (LOS) and endogenous 
gangliosides.  This study sought to investigate novel interactions of the ganglioside 
mimicking LOS with immune system ganglioside specific receptors. In addition, 
studies investigated if such receptor recognition affects antigen trafficking or the 
immunostimulatory potency of the LOS, which could participate in auto-antibody 
generation. Results presented in this thesis demonstrate for the first time that 
certain members of the siglec receptor family are capable of recognising LOS from 
a GBS associated strain of C. jejuni. This interaction did not definitively result in 
enhanced, or altered, potency of ganglioside mimicking LOS in stimulating immune 
cells.  Interestingly, ganglioside mimicry was shown to enhance phagocytosis of C. 
jejuni, however, in vivo differences in bacterial trafficking were not observed. 
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1 Introduction 
 
1.1 Guillain-Barré syndrome (GBS) 
 
Guillain-Barré syndrome is an autoimmune inflammatory disease of the peripheral 
nervous system characterised by an acute progressive flaccid paralysis followed by a 
variable recovery1.  GBS represents a spectrum of clinical and pathological entities with a 
number of subtypes being recognised.  These include Acute Inflammatory Demyelinating 
Polyradiculopathy (AIDP)2, Acute Motor Axonal Neuropathy (AMAN)3-5, Acute Motor 
and Sensory Axonal Neuropathy (AMSAN)6 and Miller Fisher syndrome (MFS)7.  Since 
the widespread eradication of polio, GBS has become the foremost cause of acute flaccid 
paralysis in the world with an incidence of between 0.6 and 4 cases per 100,000 per 
year8. 
 
The disease subtype is determined by the clinical manifestations supplemented by 
laboratory investigations1.  AIDP typically presents with muscle weakness which spreads 
proximally and can lead to respiratory paralysis.  Numbness and paraesthesia are 
frequently present.  AIDP is complicated by an autonomic neuropathy in 15% of cases, 
leading to life threatening dysfunction of the cardiovascular, alimentary and urinary 
systems.  The disease reaches its nadir at two weeks and after a variable period of time 
recovery begins.  This can take weeks to months with up to 16% of patients suffering 
recurring episodes7,9-11.  The axonal forms, AMAN and AMSAN, cause a pure motor 
impairment or motor and sensory impairment respectively.  These axonal subtypes 
progress more rapidly, are more severe and more often require ventilation.  Autonomic 
complications are mild and less common6,9,10.  MFS is a triad of acute ophthalmoplegia, 
ataxia and areflexia7.  The GBS subtypes show regional variations in incidence.  AIDP is 
the most common subtype worldwide and constitutes 90% of cases in Western countries.  
The axonal forms (AMAN, AMSAN and MFS) constitute 5% of cases in North America 
and Europe and 30-47% of cases in China, Japan and South/Central America4,5,11,12. 
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The most severe and life threatening complication of GBS is paralysis of the respiratory 
muscles which, in 25% of cases, leads to a requirement for artificial ventilation13.  Ten to 
20% of patients suffer permanent disability, one third need to make substantial changes to 
their lifestyle14 and 4 to 15% of cases result in mortality within 1 year15,16. 
 
GBS patients represent a clinical challenge due to the multitude of systems affected by 
the disease.  Respiratory function must be closely monitored for early signs of failure.  
Autonomic dysfunction can cause arrhythmias and blood pressure crises as well as 
gastrointestinal and bladder paralysis.  Deep vein thrombosis is a risk in non-ambulatory 
patients1.  Other than supportive measures, the mainstay of treatment is immunotherapy, 
either plasmapheresis or intravenous immunoglobulin (IVIg).  Both are equally effective 
at reducing disability, reducing mortality and reducing the number of patients requiring 
artificial ventilation17.  However, even with immunotherapy intervention, 14% of patients 
still require ventilation8.  The current immunotherapy regimes are inadequate due their 
restricted efficacy, expense, inherent risks and lack of availability, particularly in 
developing countries.  There is a pressing need for a better understanding of the 
pathogenesis of GBS to allow development of novel targeted treatments and better 
prognostic indicators that will allow clinicians to predict who will require intensive 
treatment and who will benefit most from which intervention. 
 
1.2 Pathophysiology of GBS 
 
The pathophysiology of GBS is incompletely understood. AIDP is frequently associated 
with multifocal lymphocytic infiltrations2 in which both αβ and γδ T cells have been 
identified18.  AIDP is also characterised by a macrophage infiltrate around peripheral 
nerves.  At this site the macrophages penetrate the Schwann cell basal lamina and ingest 
and digest the myelin, leading to demyelination of the axons3,19,20.  The distribution of 
this infiltrate correlates with the neurological deficits.  T cell mediated pathology is 
 18 
considered central in AIDP and the disease bares similarities to the animal model, 
experimental autoimmune neuritis2,21,22. 
 
AMAN and AMSAN show substantially different pathology from AIDP.  Macrophages 
are associated with the nodes of Ranvier and axons rather than Schwann cells, and the 
macrophages are often observed beneath the intact myelin sheath in contact with the 
axons3,6,23,24.  The axonal forms of GBS produce lesions with a relative lack of 
lymphocyte infiltrate and, in contrast to AIDP, are believed to be antibody mediated 
diseases20.  The primary pathological event is thought to be targeting of the nodes of 
Ranvier and nerve terminals by auto-antibodies leading to complement activation.  
Activated complement components have been identified around the axons25, resulting in 
damage between the axon and Schwann cell, leaving the myelin sheath initially intact.  
Antibody mediated cellular cytotoxicity may also play a role.  The molecular targets of 
these auto-reactive antibodies have been identified as a class of sialylated 
glycosphingolipids called gangliosides2,24,26,27.  Gangliosides comprise a membrane 
bound lipid tail (ceramide) and an external sialylated carbohydrate side chain.  While 
gangliosides are found throughout the body, they are concentrated in the nervous 
system28.  Ganglioside nomenclature describes the number of sialic acid residues and 
migration on thin layer chromatography e.g. GM1 describes Ganglioside, Mono sialic 
acid and 1 is the position of the migration band.  
 
Antibodies specific for a number of different gangliosides have been identified in the 
various axonal form of GBS28-31 and are found in up to 50% of patients20.  For example, 
anti-GM1 antibodies have been detected in 10 to 42% of AMAN patients29,32-34 while 
Anti-GQ1b IgG antibodies are strongly associated with MFS35.  This picture is 
complicated by the finding that some GBS patients produce autoantibodies that are 
reactive with ganglioside complexes (e.g. GD1a and GD1b) but not the individual 
ganglioside in isolation36.  This reflects the capacity of gangliosides to form hetero-
complexes with other gangliosides.  
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Approximately two thirds of all subtypes of GBS patients experience an infectious 
episode in the six weeks prior to GBS onset37.  The infection is often gastroenteritis or a 
flu-like illness2,8,38.  The organisms most commonly associated with GBS are 
Campylobacter jejuni (4-66%), cytomegalovirus (5-15%), Epstein-Barr virus (2-10%) 
and mycoplasma pneumonia (1-5%)28.  
 
A mechanistic connection between an antecedent C. jejuni infection and GBS was 
established when it was found that the lipo-oligosaccharide (LOS) synthesised by GBS 
associated strains of C. jejuni often have inner core sugars which perfectly mimic 
gangliosides in their structure39.  Thus molecular mimicry between pathogen and self was 
proposed as the underlying aetiology.  In support of this hypothesis, anti-ganglioside 
antibodies from the sera of GBS and MFS patients cross react with LOS purified from 
ganglioside mimicking strains of C. jejuni27,40.  It has since been shown that a number of 
strains of C. jejuni mimic a range of gangliosides, including mixtures of gangliosides, as 
part of their LOS molecule41,42. 
 
1.3 Models of GBS 
 
The role of anti-ganglioside autoantibodies and the molecular mimicry hypothesis are 
supported by a number of animal and human studies which have revealed the importance 
of gangliosides, ganglioside mimics and genetic factors found in the pathogen and host.  
Immunisation of rabbits with gangliosides GD1b or GM1 induces acute neuropathies 
which are histologically similar to acute ataxic neuropathy (GD1b) and AMAN (GM1)43-
45
.  In addition, humans injected with animal gangliosides occasionally develop the 
AMAN subtype of GBS and this correlates with the production of anti-GM1 antibodies.  
These antibodies are not present in ganglioside recipients who do not develop GBS46.  
The injection of anti-ganglioside antibodies alone into mice is insufficient to cause GBS.  
It is thought that this may be due to an intact blood nerve barrier protecting nerves, due to 
insufficient ganglioside expression or due to weak murine complement activity.  In 
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support of this, it has been shown that mouse monoclonal antibodies to GD1a, or serum 
from a patient with AMAN (in conjunction with a fresh source of human complement), 
can cause conduction block in motor axons in mice genetically engineered to over-
express GD1a47.  
 
Important studies directly confirming the link between ganglioside mimicking C. jejuni 
LOS with anti-ganglioside antibodies have been conducted.  Rabbits immunised with 
ganglioside mimicking LOS have been shown to produce antibody responses which are 
cross reactive between gangliosides and their biochemically defined LOS mimics 48-50.   
 
As gangliosides are a widely expressed self-antigen, it is expected that there is a high 
degree of immune system tolerance preventing self-reactivity.  The role of tolerance has 
been investigated using GalNAc-Transferase knockout mice in which the ganglioside 
synthesising biochemical pathway has been disrupted.  These mice lack all complex 
gangliosides synthesised beyond the GalNacT step, and instead over-accumulate the 
simple gangliosides such as GM3 and GD351.  When normal mice are immunised with 
gangliosides or ganglioside mimicking LOS, they produce a weak antibody response.  
However, when complex ganglioside-naïve mice are immunised with complex 
gangliosides, or ganglioside mimicking LOS, they produce a robust antibody response 
with isotype class switching to T cell dependent IgG isotypes and immunological 
memory52.  This confirms that failure of tolerance is an important factor in GBS 
pathogenesis. 
 
1.4 Immunobiology of GBS 
 
Analysis of GBS patient sera reveals intriguing insights into the induction of 
autoimmunity and the requirements for tissue damage.  There are several reasons for 
believing antibody isotype class switching to IgG is an important factor in GBS 
pathogenesis.  IgG1 and IgG3 are associated with AMAN and IgG1, IgG3 and IgG2 are 
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associated with MFS53,54.  The predominant isotype appears to be related to the triggering 
infection, for example, IgG1 responses are associated with C. jejuni55.  Antibody isotype 
is also a prognostic indicator as IgG1 is associated with an increased duration of 
disease56. 
 
Class switch recombination to IgG1 and IgG3 is thought to be a T cell dependent process 
characteristic of a Th1 dominated response, although the requirements for class switch 
recombination are poorly defined in humans57.  Interestingly, these isotypes are more 
often associated with responses against protein antigens, whereas IgG2 is normally 
associated with responses to glycolipids such as gangliosides or LOS58,59.  In C. jejuni 
enteritis not associated with GBS, IgG2 is the antibody isotype seen in response to the 
glycolipid LOS60.  This suggests that ganglioside mimicking strains may sometimes 
induce idiosyncratic immune responses in GBS.  In contrast to IgG anti-ganglioside 
antibodies, poly-reactive IgM anti-ganglioside antibodies of low affinity are present in 
normal human serum as part of the “natural” antibody repertoire associated with 
responses to bacteria61 and these are not pathogenic.   
 
A rabbit model of GBS shows that affinity maturation and the appearance of high affinity 
antibodies coincides with disease onset62.  Affinity maturation of high affinity antibodies 
is generally thought to be a T dependent phenomenon.  The importance of affinity 
maturation is highlighted by occasional case reports of humans with low affinity IgG 
anti-ganglioside antibodies who remain disease free63. 
 
These studies suggest that isotype class switching and affinity maturation are important in 
most instances of GBS.  Different subclasses of IgG possess substantially different 
effector functions with the GBS associated isotypes, IgG1 and IgG3, being more effective 
at fixing complement and binding Fcγ receptors64.  Class switching to IgG has been  
associated with onset of autoimmunity in mouse models of various autoimmune 
diseases65.  Models studying anti-erythrocyte specific mouse IgG antibodies show that 
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high affinity IgG is essential for pathogenic complement activity although binding to Fcγ 
receptor bearing effector cells could compensate for low affinity binding to the target66,67 
(mouse IgG2a is the most effective isotype at complement activation and Fcγ receptor 
binding).  These studies demonstrate that both class switching and affinity maturation can 
contribute to pathogenicity. 
 
GBS is an uncommon outcome following C. jejuni enteritis and occurs in approximately 
one in every thousand cases68.  This may be due to factors associated with the host or 
pathogen.  There is very limited, and inconclusive, evidence to support genetic influences 
leading to an increased susceptibility to GBS.  A small study showed a 2.6 fold increased 
risk in siblings developing GBS and repeated episodes of GBS occasionally occur in the 
same patient (although this may represent immunological memory)69.  A TNFα2 allele 
has been linked to increased risk of GBS in Japanese patients69,70.  Other studies of 
immune receptor polymorphisms (FcγRIIIb and mannose binding lectin) show links to 
disease severity rather than occurrence71-73.  In contrast to the majority of autoimmune 
diseases, there is a lack of conclusive evidence linking GBS to particular MHC class I or 
II alleles72,74.  In addition, there is no evidence of an association of GBS with 
polymorphisms in the glycolipid antigen presenting molecules CD1A or CD1E75 and a 
study of 242 GBS patients found no association of GBS with polymorphisms in the LPS 
receptor molecules CD14 and TLR4 (Toll Like Receptor 4)71. 
 
1.5 C. jejuni pathogenesis 
 
C. jejuni is a genetically variable, gram negative, spiral shaped, motile bacterium with 
unipolar or bipolar flagellum20,76.  It is a leading cause of food poisoning world-wide77.  
While it is often a common commensal of birds and mammals, in humans it causes 
gastroenteritis with bloody or watery diarrhoea76.  A large number of strains of C. jejuni 
are recognised and these are typed either by the heat-stable antigenic system of Penner 
(over 70 serotypes), the heat-labile antigen of Loir (over 100 serotypes) or by direct DNA 
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comparisons78.  The Penner serotype O:19 and GD1a mimicking strains appear to be 
over-represented in GBS cases79,80,81.   C. jejuni strains express ganglioside mimics either 
alone or in differing ratios (for example GM1 and GD1a at a 1:1 ratio, GM1 and GD1a at 
a 9:1 ratio, GM2 alone etc).  Although C. jejuni is a gut mucosal pathogen, it occasionally 
causes systemic infections with systemic immune responses82,83.  IgA antibodies against 
GM1 are found in 17% of C. jejuni associated GBS cases and these antibodies belong to 
the IgA1 subclass which is more commonly found in systemic responses (rather than the 
secretory subclass seen in mucosal responses)84. 
 
Following colonisation of the small bowel, C. jejuni transits to the colon which is the 
main target organ of disease85.  C. jejuni adheres to epithelial cells using a number of 
adhesins86,87 and can disrupt tight junctions88-90.  C. jejuni is able to invade91 epithelial 
cells and macrophages where it replicates intracellularly92,93.  These interactions trigger a 
number of inflammatory signalling pathways, such as NF-κB (Nuclear Factor κB)94,95.  
The sensing of C. jejuni by innate pattern recognition receptors is poorly understood 
although it appears that C. jejuni has evolved to limit immune activation in humans.  For 
example, C. jejuni flagellin lacks the sites necessary to activate the flagellin receptor 
TLR596,97, while the low CpG (Cytosine-phosphate-Guanine) content of C. jejuni DNA 
results in reduced ability to stimulate the unmethylated-CpG-dinucleotide-receptor 
TLR998.  However, C. jejuni derived LOS triggers cytokine release from dendritic cells99 
suggesting LOS is the principal immunostimulatory element of C. jejuni. 
 
The role of C. jejuni LOS genes in GBS has been studied.  Biosynthesis of ganglioside 
mimicking LOS requires specific enzymes; sialyltransferase (CSTII); N-
acetylgalactosaminyl-transferase (CgtA) and galactosyltransferase (CgtB)100.  Genes 
responsible for LOS biosynthesis cluster into specific LOS biosynthesis gene loci.  
Specific loci are associated with GBS and with the presence of ganglioside mimicking 
LOS101.  Mutant strains of GBS associated C. jejuni which are incapable of LOS 
sialylation (CSTII knock out) have been generated and studied.  These knock out strains 
produce non-sialylated LOS structures such as asialo-GM3 (lactosyl ceramide), asialo-
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GM2 (GA2) and asialo-GM1 (GA1).  Unlike the wild type variant, the LOS molecules in 
the CSTII knock out strains do not cross react with GBS patient sera nor do they generate 
anti-ganglioside antibodies when injected into susceptible mouse strains101.  This study 
demonstrates the importance of C. jejuni LOS biosynthesis genes in GBS. 
 
1.6 C. jejuni LOS signalling in the immune system 
 
Lipopolysaccharide (LPS) is a glycolipid molecule which is a vital component of the 
outer membrane of gram negative bacteria and also functions as one of the main targets 
of the mammalian innate immune system102.  LPS is generally divided into three 
covalently linked parts; the Lipid A, the carbohydrate O-side chain and the core 
sugars103,104.  While LPS has an extended O-side chain, LOS has a truncated structure 
consisting of the core sugars alone (see figure 1 for a diagrammatic representation of 
Escherichia coli smooth mutant LPS and C. jejuni rough mutant LOS).  Immune sensing 
of LPS results in activation of a wide range of cells such as macrophages, dendritic cells 
and specific classes of B and T lymphocytes105-110.  The immunostimulatory properties of 
LPS reside in the Lipid A tail111.  The structure of Lipid A varies between, and within, 
strains of gram negative bacteria and this imparts species specific properties and potency 
on LPS molecules102.  E. coli LPS is considered the most potent LPS.  The C. jejuni Lipid 
A backbone has a unique structure amongst gram negative bacteria.  Despite this, C. 
jejuni retains its endotoxic activity although it is somewhat less potent than other forms 
of LPS102,112. 
 
Toll Like Receptors (TLRs) are sensing receptors of the innate immune system capable 
of recognising conserved Pathogen Associated Molecular Patterns (PAMPs) expressed by 
bacteria, viruses and fungi113,114.  These receptors form the first line of pathogen 
recognition and trigger a broad range of activation events including secretion of cytokines 
and functional maturation of immune cells114,115.  TLR4 was demonstrated to be the 
principal receptor mediating recognition of bacterial LPS when it was shown that the LPS 
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hyporesponsive mouse strains, C3H/HeJ and C57BL/10ScCr, have mutations affecting 
the Tlr4 gene116.  TLR4 recognition of LPS involves a number of associated molecules 
and is partly dependent on the specific structure of the LPS being recognised.  LPS 
Binding Protein (LBP) is a serum protein which binds to, and delivers, LPS to 
CD14117,118.  CD14 is expressed by myeloid cells and is found in serum in a soluble form.  
CD14 transfers LPS to a complex consisting of TLR4 and MD-2119 and this in turn 
causes TLR4 oligomerisation which brings TLR4 intracellular Toll-interleukin-1 receptor 
(TIR) domains  together and facilitates signal transduction120.   
 
There are five adaptor proteins involved in TLR4 signalling:  MyD88 (myeloid 
differentiation primary response gene 88), Mal (MyD88 adapter like), TRIF (TIR 
domain-containing adaptor inducing IFN-β), TRAM (TRIF related adaptor molecule), 
and SARM  (sterile α and HEAT-Armadillo motifs-containing protein)121.  TLR4 is 
unique amongst TLRs in its use of all of these adaptor molecules while other TLRs 
employ only some.  Signalling via TLR4 is divided into two pathways; the MyD88 
dependent pathway and the MyD88 independent (TRIF dependent) pathway.  While both 
pathways cross over at the level of NF-κB, the MyD88 dependent pathway is generally 
considered to trigger pro-inflammatory cytokine production, while the TRIF dependent 
pathway induces Type I interferons and interferon inducible genes122.  Studies of CD14 
mutated mouse strains have shown that “rough mutant” LPS, such as the truncated LOS 
found in C. jejuni, are capable of signalling via the TLR4-MyD88 pathway in the absence 
of CD14, whereas “smooth mutants”, such as E. coli LPS, cannot123. 
 
Negative regulators of TLR4 signalling are numerous and act at multiple levels in the 
signalling cascade122.  For example, the plasma membrane expressed receptor RP105 
(radioprotective 105) is believed to function on myeloid cells to inhibit LPS association 
with TLR4.  Consistent with this, RP105 deficient mice show higher levels of serum 
TNF-α following LPS challenge124.  TRIAD3A (triad-domain containing protein 3 
variant A) and SOCS-1 (suppressor of cytokine signalling 1) are both intracellular 
proteins which inhibit the TLR4 signalling cascade at multiple points.  TRIAD3A over-
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expression promotes degradation of TLR4 and TRIF, as well as downregulation of NF-
κB activation125.  SOCS-1 promotes degradation of TIRAP and there is increased pro-
inflammatory cytokine secretion in LPS stimulated SOCS-1deficient macrophages126. 
 
LPS stimulation of B cells causes polyclonal proliferation and differentiation. LPS is not 
considered a good initiator of class switching or memory109.  B cells are distinct from 
macrophages and dendritic cells in their requirements for LPS stimulation.  Firstly, B 
cells are considered less sensitive than myelomonocytes to LPS stimulation.  Secondly, a 
novel set of receptor molecules, RP105/MD1, which are structurally similar to 
TLR4/MD2 but lacking TIR domains, are important for LPS responses.  B cells lacking 
RP105 are hyporesponsive to LPS in terms of proliferation and antibody production127.  
However, co-stimulator up-regulation is not impaired in the absence of RP105128.  
Although TLR4 and MD2 are expressed at extremely low levels on naïve B cells, in their 
absence, B cells do not respond to LPS at all.  RP105/MD1 is expressed elsewhere by the 
immune system and in contrast to the apparent stimulatory function on B cells, they serve 
to inhibit TLR4 signalling129.  It is clear from these studies that the molecular pathways 
of B cell activation by LPS are complex and there is potential for unique or aberrant 
signals by unusual Lipid A structures (such as C. jejuni) or rough versus smooth mutants. 
 
LPS causes polyclonal activation of B cells in an antigen independent manner through 
TLR4 signalling.  However, by linking the hapten 4-hydroxy-3, 5-dinitrophenyl (NNP) to 
LPS and measuring anti-NNP antibody production following in vitro stimulation of 
splenocytes with LPS-NNP, it was shown that antigen specific activation of B cells by 
LPS occurs at substantially lower concentrations than polyclonal activation130.  It is 
thought that in these circumstances the B cell receptor (BCR) can concentrate the LPS 
near the B cell surface which potentially allows cross-linking of the BCR and TLR4.  The 
BCR essentially substitutes for CD14, which is not expressed by B cells, in the function 
of concentrating LPS to the TLR4 complex. 
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LPS is frequently used as an in vitro B cell mitogen at concentrations of between 10 and 
30µg/ml.  Polyclonal activation begins at about 0.1µg/ml.  However, concentrations as 
low as 2ng/ml LPS-NNP are sufficient to stimulate NNP antigen specific B cells130.  The 
Marginal Zone (MZ) B cell subset is more sensitive to LPS than Follicular Origin (FO) B 
cells and responds at lower concentrations with more rapid kinetics131.  A serum LPS 
concentration of 10ng/ml is associated with an extremely high mortality in humans132.  It 
is clear that in vivo polyclonal activation of B cells by LPS is an uncommon event except 
in severe sepsis.  B cell sensitivity to LPS serves to select out antigen specific clones 
useful in the immune response against the LPS bearing pathogen.  This concept can 
explain the selection and emergence of ganglioside specific B cells in GBS without 
polyclonal activation (which is not a feature of GBS).  In addition, if unique or aberrant 
signalling occurs via C. jejuni LOS then it may be restricted to, or amplified on, 
ganglioside specific B cells due to the concentrating effect of the BCR.  Cross-talk 
between the B cell receptor and TLR4 has been shown to occur during LPS stimulation133 
indicating that both signalling pathways can be modulated by each other, or perhaps any 
additional signal, for example, if the ganglioside mimic is able to deliver a signal. 
 
1.7 Gangliosides in the immune system 
 
GBS-associated C. jejuni LOS mimics gangliosides which are glycolipid molecules 
expressed widely in the body including on immune cells.  Although their exact function 
remains enigmatic, they are associated with various immune-modulating functions134.  
 
Gangliosides exhibit immunomodulatory activity towards a number of different immune 
cell populations and, generally speaking, their effects tend to be inhibitory135-138.  The 
mechanisms by which exogenous, or tumour derived, gangliosides mediate receptor non-
specific effects are poorly understood.  Gangliosides have been shown to negatively 
regulate the transcription factor NF-κB by inhibiting its activation and nuclear 
translocation in macrophages138,139 and T cells140.  Certain gangliosides, including GM1 
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and GD1a, have been shown to reversibly inhibit activation of monocytes which were 
stimulated through a number of TLR receptors, including TLR4, and this inhibition 
coincided with upregulation of the inhibitory molecule IRAK-M (IL-1 receptor 
associated kinase-M)141.  In a separate study, it was shown that the carbohydrate moiety 
is necessary for the immunosuppressive activity of GD2 ganglioside.  However, it was 
the length of the acyl chains in the ceramide moiety that appeared to determine the 
strength of the effect142.  This is an important consideration as C. jejuni LOS only mimics 
the carbohydrate portion and not the ceramide portion of gangliosides.  It is thought that 
non-receptor specific ganglioside effects rely on insertion of gangliosides into lipid rafts. 
 
An alternative mechanism of ganglioside immune-modulation is via receptor specific 
interactions such as the sialic acid binding immunoglobulin like lectins (siglecs).  Siglecs 
are a family of receptors which bind sialylated glycoconjugates and are expressed 
differentially on various immune system cells143 (see Appendix 2 for siglec structure and 
cellular expression; see Appendix 3 for known siglec binding profiles).  Siglecs are 
divided into two categories on the basis of sequence similarity.  Sialoadhesin (Siglec 1), 
CD22 (Siglec 2), Myelin Associated Glycoprotein (Siglec 4) and Siglec 15 form one 
group while CD33 (Siglec 3), Siglec 5 to 11 and Siglec 14 make up the second group 
(termed the CD33 related siglecs)144.  The murine CD33 related siglecs comprise CD33, 
Siglec E, Siglec F, Siglec G and Siglec H while the non-CD33 related siglecs are named 
the same as for humans144.  Most of the CD33 related siglecs have two conserved 
cytoplasmic Immunoreceptor Tyrosine-Based Inhibitory Motifs (ITIMs) or ITIM-like 
motifs144.  Classically ITIMs function to inhibit signalling through Immunoreceptor 
Tyrosine-Based Activation Motifs (ITAMs) which form the signalling motifs of several 
types of activating receptors145.  There are significant variations in siglec receptors in 
their expression on haemopoietic cells, their sialic acid binding specificity and in their 
signalling motifs.  Some siglecs, for example Siglec 13, Siglec 14, Siglec 15, and Siglec 
H,  associate with adaptor proteins such as DAP12 which itself has an activating ITAM 
motif146, while other siglecs such as Sialoadhesin have no signaling motif, although the 
receptor appears to enhance phagocytosis while inhibiting dendritic cell antigen 
presentation147.  Numerous studies have demonstrated the immunomodulatory function of 
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siglecs and these effects include inhibiting proliferation and activation, promoting 
apoptosis and promoting pro-inflammatory cytokine secretion144.  Certain members of the 
siglec family are capable of binding gangliosides and in one instance binding to 
ganglioside mimicking LOS has been shown.  Siglec 7 (expressed on human NK cells 
and monocytes) mediates sialic acid dependent binding to LOS extracted from 
GM1/GT1a or GM3 mimicking strains of C. jejuni148.  The functional consequence of 
this remains to be investigated.   
 
The ganglioside GM1 is one of the few endogenous ligands known to be presented by the 
CD1 class of MHC I-like antigen presenting molecules.  CD1 presents glycolipid 
antigens to specific classes of T cells which are potent sources of immune polarising 
cytokines149.  However, there is no conclusive evidence to suggest that ganglioside 
mimicking LOS can substitute for gangliosides in the binding pocket of CD1 molecules. 
 
Rough and smooth O-antigen side chains alter the interaction of LPS with the 
TLR4/MD2 receptor complex123.  Few studies have addressed whether the side chain is 
capable of signalling independently, or co-operatively, with the Lipid A through 
interactions with non-TLR4 receptors.  However, it has been shown that LPS O-side 
chains bearing mannose are capable of mediating enhanced adjuvant activity through co-
operative signalling via the mannose receptor on myeloid cells150-152.  A possible direct 
link between gangliosides and TLR4 signalling has been revealed using Neu1 
(neuraminidase 1) deficient mice and neuraminidase inhibitors such as Tamiflu.  For full 
TLR4 signalling to occur, endogenous α2-3 linked sialic acid residues associated with the 
TLR4 must be cleaved, otherwise there is a deficiency in inflammatory cytokine 
production153,154.  LOS which mimics gangliosides GM1 and GD1a expresses α2-3 linked 
sialic acid residues.  It is theoretically possible that these can substitute for the 
endogenous sialic acid and affect TLR4 signalling. 
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There are clearly a number of ways in which gangliosides can alter immune function and 
it is possible that ganglioside mimicking LOS can substitute for gangliosides in these 
properties.  For example, they could deliver a second signal in addition to Lipid A/TLR4 
and also alter how the bacteria are taken up and processed by immune cells.  Either of 
these events might have a substantial effect on the immune response to ganglioside 
mimicking C. jejuni or the maintenance of self-tolerance by the responding cells. 
 
1.8 Immune responses to carbohydrate antigens 
 
Thymus independent (TI) antigens are molecules capable of directly stimulating B cell 
antibody responses without the requirement of conventional, MHCII restricted, T cell 
help155.  Although not an exclusive rule, generally speaking, carbohydrate and glycolipid 
molecules, such as LOS and gangliosides, tend to be TI antigens, while proteins and 
peptides tend to be thymus dependent (TD) antigens.  TI antigens are sub-classified into 
TI-1, which stimulate all sensitive B cells through innate receptor signalling such as 
TLR4, and are capable of causing polyclonal activation, and TI-2, which have repeating 
epitopes which cross link B cell receptors delivering an antigen specific signal which 
drives activation156.  LPS, and presumably C. jejuni LOS, signals through the innate LPS 
receptor TLR4 and are therefore TI-1 antigens.  Although gangliosides do not express 
multiple epitopes on the same molecule, they behave as TI-2 antigens157 presumably due 
to aggregates of molecules providing repeating epitopes, for example in micelles or cell 
membranes.  Ganglioside mimicking LOS might also be considered a TI-2 antigen, as 
well as a TI-1 antigen, for this same reason.  Immune responses to TI antigens are 
substantially different than responses to conventional TD antigens and involve specific 
sub-populations of B and T cells.  TI responses provide prompt and specific humoral 
responses to common bacterial products such as capsular polysaccharides and LPS156. 
 
There is no conclusive evidence that GBS represents a pure TI immune response or that 
C. jejuni LOS alone is sufficient to induce GBS.  Natural infection with C. jejuni results 
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in exposure to a range of antigens including proteins and bacterial DNA/RNA.  Models 
of GBS use adjuvants such as Freund’s and Keyhole Limpet Haemocyanin which 
introduce protein antigens and thus engage T cell help.  In addition, the pathogenic 
antibody isotypes often seen in GBS are considered to be “T dependent”.  However, the 
ganglioside target in GBS, like LOS, is a non-protein molecule and is not presented for T 
cell help by conventional means.  The immune response associated with GBS is often 
transient and no clear evidence of a lasting B cell memory has been shown.  These are 
features more in keeping with TI responses.  The lack of an MHC association with 
GBS72, which is virtually unique amongst auto-immune diseases, raises important 
questions about the exact role of T cells, or more specifically, protein antigens. 
 
The naïve murine B cell compartment consists of two broad subsets, B1 (comprising B1a 
and B1b) and B2 (comprising MZ and FO B cells).  Each subset shows distinct 
anatomical localisation.  B1 B cells are found primarily in the peritoneal and pleural 
cavities158 while the B2 subsets are located in secondary lymphoid organs such as the 
spleen and lymph nodes.  Within the secondary lymphoid organs, MZ B cells are located 
near the marginal sinus where they are able to interact with particulate blood borne 
antigens such as encapsulated bacteria131.  The traditional view is that B1 B cells and MZ 
B cells contribute to TI immune responses to glycolipid antigens and have a limited 
capacity for affinity maturation and class switch recombination131,158.  FO B cells 
participate in TD immune responses to protein antigens and produce highly specific 
affinity matured antibodies, with class switch recombination.  They are classically not 
thought to play a major role in TI responses.  However, the roles of B cell subsets are not 
as clearly delineated as this model suggests. 
 
B1 B cells are thought to bridge the gap between innate and adaptive immunity.  They are 
long lived cells with a BCR repertoire which is skewed towards polyreactivity with 
common bacterial and self antigens, particularly carbohydrate antigens.  Being 
exquisitely sensitive to LPS, they are believed to be important in TI-1 immune responses.  
B1 B cells, alongside MZ B cells, are considered to be the source of natural IgM.  B1 B 
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cells undergo class switch recombination to IgG3 and IgA although they do not usually 
undergo affinity maturation to any great extent158,159.  Animal and human studies of GBS 
indicate that isotype class switching and possibly affinity maturation are key events in 
pathogenesis.  Although B1 B cells are probably responsible for the natural anti-
ganglioside IgM (not usually associated with GBS), their restricted capacity for affinity 
maturation and class switch recombination makes them an unlikely candidate as the 
source of the high affinity IgG autoantibodies seen in GBS. 
 
MZ B cells are essential for TI-2 responses155.  MZ B cells (reviewed160) are highly 
enriched in the marginal zone of the spleen.  This region contains a number of specialised 
immune cells such as marginal dendritic cells and marginal zone metallophilic 
macrophages.  The latter population expresses siglec receptors and are postulated to play 
a role in capturing carbohydrate antigens to present to B cells161.  MZ B cells share 
properties with B1 B cells that make them important in TI responses162; they are highly 
sensitive to LPS (expressing higher levels of RP105/MD1 than FO B cells) and they 
respond rapidly following activation and produce large quantities of antibody158,163.  The 
preferred isotypes of murine MZ B cells are IgM and IgG3158 although they are capable 
of class switching to all IgG isotypes including those associated with GBS160,164.   
 
Marginal zone B cells participate in both TI and TD immune responses165.  When 
stimulated with TD antigens, MZ B cells are able to form early antibody secreting cells as 
well as later germinal centres with associated affinity maturation and class switch 
recombination166.  MZ B cells also selectively participate in extrafollicular immune 
responses to TI-2 antigens which do not involve germinal centres.  Although an initial 
interaction with T cells is seen, the plasmablasts depend on accessory help from a 
specialised population of CD11c+ dendritic cells which provide survival signals and 
promote isotype class switching in a T-independent manner.  Both class switch 
recombination and affinity maturation occur to a lesser degree than that found in 
germinal centres165,167.  MZ B cells, unlike FO B cells, are potent activators of naïve CD4 
T cells early in the immune response.  They express higher levels of MHCII, higher 
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levels of co-stimulatory molecules and are capable of polarising T cells towards a Th1 
phenotype168.  In addition, MZ B cells express the antigen presenting molecule CD1c 
which allows presentation of glycolipid antigens to specific subsets of T cells160,169.  
However, the transient nature of GBS and the lack of any evidence supporting the 
existence of B cell memory following GBS would suggest that T cells are not involved in 
the conventional sense. 
 
Models of GBS and other autoimmune diseases suggest that isotype class switching and 
affinity maturation are important events leading to pathogenesis.  The factors which 
control these during B cell responses to TI antigens are less well understood than to TD 
antigens.  This is made more complicated by the fact that substantial differences exist 
between human and mice in the generation of the MZ B cell pool.  For example, genetic 
studies of MZ B cells in humans before and after immunisation with polysaccharide 
antigens have shown that MZ B cells which participate in the response had already 
undergone somatic mutation prior to vaccination suggesting humans have a pre-
diversified repertoire.  Isotype switching however takes place during the evolution of the 
response160,170,171.  Whatever factors govern this pre-diversification may have a 
substantial bearing on GBS.  The factors that govern isotype class switching are also 
poorly understood.  The antigen itself appears to have some bearing on the nature of the 
response and the resulting IgG isotype.  For example, an antigen engineered to be 
expressed internally in E. coli triggered a TD response, while the same antigen expressed 
on the surface triggered a TI response172.  In addition, a polysaccharide antigen and a 
protein antigen which mimics the polysaccharide antigen (an idiotype antibody) both 
triggered TI type responses (IgM and IgG3)173-175, indicating the shape and not the 
chemistry of the antigen was important.  Other factors common to both TD and TI 
responses appear important in class switching to the highly pathogenic IgG2a isotype, for 
example co-operative signalling through complement receptors and IFN-γ.  IFN-γ may be 
derived from conventional T cells, innate lymphocytes (such as Natural Killer (NK) cells) 
or other accessory cells155. 
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T cells are able to recognise glycolipid molecules when they are presented on a novel 
family of MHC I like antigen presentation molecules termed CD1 (reviewed176).  
Humans express five CD1 molecules (CD1a to CD1e) on antigen presenting cells.  These 
are sub-classified into families.  CD1a to CD1c comprises one family and CD1d and 
CD1e comprises two additional families. Mice only express CD1d.  There is a degree of 
lipid binding specificity between CD1 molecules although some molecules, such as 
sulphatide, show promiscuity in being able to bind to several CD1 types.  
 
T cells capable of engaging CD1 fall into two broad categories: those that engage CD1a 
to CD1d, which behave in a similar manner to conventional peptide specific T cells, and 
those that engage CD1d alone.  The majority of this latter group (termed iNKT cells) 
have semi-invariant T cell receptors and behave in an innate manner in that they are 
capable of rapidly producing large quantities of cytokines including IL-4 and IFN-γ.   
 
There has been considerable progress made in the identification of ligands for CD1, and 
these include both pathogen and self molecules(reviewed176).  The majority of bacterial 
antigens are cell wall components, particularly those derived from Mycobacterium 
tuberculosis.  Bacterial lipopeptides have also been found to bind to CD1.  Intriguingly, 
gangliosides are prominent amongst the known self-ligands, particularly of CD1b.  
Ganglioside specific T cells have been isolated from multiple sclerosis patients.  In order 
to bind to CD1, the fatty tail of the ligand must conform to the hydrophobic binding 
pockets of the CD1 molecule while the carbohydrate portion must sit in, or extend from, 
the binding groove.  There is no evidence that LPS lipid A, and presumably LOS lipid A, 
is capable of binding to CD1. Binding would not be predicted by the nature of the acyl 
chains on the Lipid A tail.  Therefore it is unlikely that C. jejuni LOS, with its 
ganglioside mimic, can be presented directly to T cells (unless there is some, as yet 
unknown, processing pathway that substantially alters its Lipid A tail). 
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There are alternative routes by which LPS molecules might activate the T cell arm of the 
immune system.  Studies using Salmonella typhimurium LPS (rough mutant) have shown 
that dendritic cells activated by LPS secrete IL-12 which in turn activates iNKT cells.  
Surprisingly this was in a CD1d dependent manner, indicating that some sort of self 
antigen, or alteration of self antigen, was being sensed alongside the IL-12 (as LPS 
cannot itself be presented on CD1d).  In addition, there is evidence that iNKT cells can be 
activated directly by TLR ligands110. 
 
The role of T cells in GBS is largely unexplored although studies show no association 
with CD175 or MHC haplotypes.  In addition, a mouse model generating anti-ganglioside 
antibodies showed no role for the murine glycolipid antigen presenting molecule 
CD1d177.  However, this does not rule out non-antigen specific T cell help, as discussed 
above, in providing the cytokines necessary for pathogenic class switching. 
 
1.9 Tolerance to carbohydrate antigens 
 
Humoral tolerance to carbohydrate antigens probably follows similar mechanisms to 
tolerance to protein antigens.  A number of complex factors determine tolerance and 
some of the principal mechanisms are receptor editing or deletion during ontogeny, 
antigen ignorance, anergy and suppression. 
 
These processes may have specific differences when they relate to carbohydrate antigens 
and GBS.  For example, MZ B cells and B1 B cells which take part in anti-carbohydrate 
responses also contribute to the natural immune antibody repertoire which contains anti-
ganglioside specificities even in healthy people61,63.  Rather than negative selection of 
auto-reactive clones, the B cells which contribute to the natural repertoire are positively 
selected against self-antigen and possibly commensal flora in the gut178-181.  It appears 
that the affinity of the self-reactive BCR determines the fate of the B cell.  For example, 
mice have been genetically engineered to express an anti-αGal (carbohydrate) antibody.  
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In an αGal negative background, these B cells escape into the periphery and produce IgM 
antibodies of a sufficient affinity to reject αGal expressing grafts.  However, in an αGal 
expressing background, the anti-αGal (auto-reactive) B cells are located in the marginal 
zone (presumably becoming MZ B cells), but have edited their receptors to produce 
lower affinity, non-pathogenic, anti-αGal IgM antibodies182.  In genetically engineered 
anti-red blood cell autoantibody transgenic mice, the conventional B cells get clonally 
deleted but auto-reactive B1 B cells persist in the peritoneal cavity usually without 
causing disease.  Anaemia develops when the B1 B cells are activated by oral 
administration of LPS183 or injections of cytokines IL-10 or IL-5184.  
 
It is clear that the presence of anti-ganglioside antibodies is not in fact the mystery of 
GBS, but rather what activation events take place that allow them to become pathogenic.  
Animal models and human studies suggest isotype switching and affinity maturation 
(either one or both) are important events.  As low affinity anti-ganglioside specificities 
are already in place there are additional mechanisms of tolerance in these B cell 
populations which must be bypassed if they are to be responsible for the autoimmunity 
seen in GBS.  For example, cross linking of the BCR in B1 B cells does not lead to 
activation, as it does in conventional B cells, but instead induces apoptosis185.  Additional 
stimulation in the form of LPS or cytokines is also required183,186.  In addition, despite 
repeated immunisation, B1 cell anti-carbohydrate responses will only show limited 
isotypes (IgM, IgA and IgG3 in mice), no typical memory responses and limited or no 
affinity maturation187-190.  These combined factors will serve to protect the host from 
autoimmunity even when LPS type stimulation is present alongside ganglioside mimicry, 
such as with ganglioside mimicking LOS.  MZ B cells present a different problem as they 
are more like conventional FO B cells in their capabilities to class switch and affinity 
mature.  Previously described studies have demonstrated that MZ B cell receptors are 
edited to remove those with high affinity for self-antigens.  In addition, extensive cross 
linking of the BCR renders both immature and mature B cells anergic156 and therefore 
epitope density and presumably whether the antigen is soluble or particulate may be 
important in determining tolerance to TI-2 antigens.  Those MZ B cells that enter the 
germinal centre to participate in responses might be subject to the same T cell help and 
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regulatory mechanisms as FO B cells responding to conventional peptide antigens, while 
those MZ B cells that participate in extra-follicular responses show less affinity 
maturation and isotype switching167, presumably due to a lack of T cell help. 
 
Antigen ignorance may play an important role in GBS.  While gangliosides are expressed 
throughout the body, specific gangliosides are concentrated in certain regions.  For 
example, GM1 is concentrated in peripheral motor nerve myelin191 and GQ1b is 
concentrated in the occulomotor nerve192.  Antibodies to GM1 are associated with motor 
deficits and antibodies to GQ1b are associated with opthalmoplegia27.  Complexes of 
mixed gangliosides provide unique epitopes from single gangliosides36 and the nerves are 
partially protected from the immune system by a blood nerve barrier.  Therefore, due to 
localised expression levels, the unique configurations of complexes and the blood nerve 
barrier, it is possible that B cell receptors are not exposed to all of the possible 
arrangements of gangliosides during their development and so are not adequately 
tolerised.  In addition, it is possible that low levels of low affinity anti-ganglioside 
antibodies can safely exist due the protection afforded by the blood nerve barrier. 
 
Substantial differences exist between the human and murine immune systems.  Some of 
these may impact on responses to TI-1 and TI-2 antigens, such as LOS and gangliosides, 
in GBS.  Murine B1 B cells have been recognised for some time and their function and 
phenotype have been studied extensively188,193-195.  However, human B1 B cells remain a 
controversial entity whose existence is disputed, although B cells with an appropriate 
phenotype (CD5 positive) have been identified in human peritoneal washings196.  An 
additional important difference is that the LPS/LOS receptor TLR4 is expressed by 
murine, but not human, B cells107,108,127,197.  This difference in TLR4 expression is no 
doubt responsible for a major difference in function between human and murine MZ B 
cells, that is, murine MZ B cells respond to TI-1 antigens whilst human MZ B cells do 
not198.  However, there are more similarities than differences as both murine and human 
MZ B cells express high levels of CD21 and IgM.  In addition, both human and murine 
MZ B cells respond vigorously to TI-2 antigens, respond to TD antigens and are efficient 
 38 
antigen presenting cells198.  No such comparison can be made between human and murine 
B1 B cells as the principal murine B1 marker, CD5, is expressed on a wider range of B 
cell populations in humans.  While such differences can be related directly to GBS, there 
are many more general differences between human and murine immunity170.  This means 
that findings in murine models of GBS must always be taken in context and interpreted 
appropriately.  
 
1.10 Hypothesis  
 
The over-arching hypothesis is that ganglioside mimicking C. jejuni interact with the 
immune system in a unique way by virtue of their ganglioside mimicry, and this 
contributes to the events that lead to a break in tolerance.  More specifically, the aim of 
this study is to address the following hypotheses: 
 
1. LOS derived from a GBS associated strain of C. jejuni is able to bind to cellular 
or humoral ganglioside specific receptors through the ganglioside mimicking core 
sugars. 
2. Binding of LOS to these ganglioside specific receptors alters the potency or 
polarising properties of ganglioside mimicking LOS compared to non-mimicking 
LOS. 
3. Binding of ganglioside mimics to these ganglioside receptors alters trafficking of 
the C. jejuni within the immune system. 
 
In essence, it is possible that ganglioside mimicking LOS can deliver three signals.  First, 
the Lipid A can be sensed by TLR4; second, the ganglioside mimic can interact with 
ganglioside specific BCR; and third, putatively, the ganglioside mimic can interact with 
endogenous ganglioside specific receptors or can mediate cis interactions with 
endogenous gangliosides.  The importance of gangliosides goes beyond receptor specific 
 39 
interactions as they also play an important role in humoral immunity through interactions 
with natural antibody and complement components such as Factor H (fH)199-201.  GBS is a 
heterogeneous condition and it is clear that there is no single underlying aetiology.  
Therefore it is unlikely there is a single pathway that leads to breaking of tolerance and 
autoimmunity.   
 
If all, or some, of these hypotheses are proven correct it will alter our understanding of 
how GBS associated strains of C. jejuni interact with the immune system and might shed 
light on the events leading to pathogenesis.  In addition, if it can be established in 
principle that the ganglioside mimic is not simply a passive target of the BCR, but instead 
actively manipulates the immune system, this would provide an interesting new paradigm 
for any autoimmune disease in which molecular mimicry of a self signalling molecule 
can be shown to be a preceding event. 
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2 Materials and Methods (see Appendix 1 for buffers and 
media) 
 
2.1 Analysis software  
 
2.1.1 Statistical analysis 
 
Data were analysed using GraphPad Prism 4 (GraphPad Software Inc).  Figure 
illustrations follow the standard format (* = p<0.05, ** = p<0.01 and *** = p<0.001).  
Data were analysed using 1way ANOVA, 2way ANOVA with Bonferroni’s posttest or 
students T test where appropriate (detailed in text).  Graphs all show mean and standard 
error of the mean (SEM). 
 
2.1.2 Acquisition and analysis of FACS data 
 
FACS acquisition was done on a FACSCalibur machine (BD Biosciences) and analysis 
was done using FlowJo software (Treestar Inc)  
 
2.1.3 Analysis of immunohistology and immunocytology 
 
Immunohistology and immunocytology were visualised using an Apotome/Zeiss 
microscope or Laser Scanning Confocal microscope and the images analysed using 
AxioVision Rel 4.7 software with co-localisation module. 
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2.2 Preparation of Lipo-oligosaccharide (LOS) 
 
2.2.1 C. jejuni strains 
 
The strains of C. jejuni used were Penner serotype O:19 (HS O:19) in which the LOS 
structure mimics gangliosides GM1 and GD1a at 50:50 ratio 202; Penner serotype O:3 
(HS O:3) in which the LOS does not mimic gangliosides 203; C. jejuni strains GB2 and 
GB11 in which the LOS structure mimics gangliosides GM1 and GD1a at 50:50 ratio; 
and the isogenic sialyltransferase gene (CSTII) knock-out strains, GB2 CSTII knock out 
and GB11 CSTII knock out, in which the LOS does not mimic gangliosides due to the 
failure of addition of sialic acid to the carbohydrate side chain101.  GB19 LOS (GD1c 
mimic) and its CSTII knock out isogenic counterpart101 were also provided as pre-
purified LOS. The GB2, GB11 and GB19 strains and their CSTII knock out counterparts 
were kind gifts from B. Jacobs and M. Kuijf, Erasmus University, Netherlands. 
 
2.2.2 Growth and heat inactivation of C. jejuni 
 
For LOS purification C. jejuni were grown for 48 hours at 37oC in a microaerobic 
environment on Columbia Agar and Horse Blood plates (E & O Laboratories, Scotland. 
Container P090).  The bacteria were harvested into PBS (phosphate buffered saline) and 
heat inactivated at 60oC for 1 hour.  For siglec binding experiments bacteria were 
harvested into 8% formalin/PBS and left for 1 hour to inactivate. 
 
2.2.3 Crude hot phenol extraction of LOS 
 
Heat inactivated bacteria were centrifuged at 6000rpm for 10 minutes (Sorval 
ultracentrifuge, Rotor SS34) and the supernatant discarded.  The pellet was resuspended 
at 10g/ml in dH2O (distilled water) and blended to a paste, on ice, using an Ultra Turrax 
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homogeniser.  An equal volume of 85% liquid phenol (Sigma, UK) was added and the 
cells were blended on ice for 5 minutes.  The mix was placed in a water bath at 65oC and 
blended for 1 minute at 2 minute intervals for 10 minutes.  The mix was centrifuged at 
2500rpm for 20 minutes at < 10oC.  The aqueous (top) layer was removed and stored. An 
equal volume of dH2O was added to the remaining sample and blended for five minutes 
on ice repeating the procedure.  The combined aqueous layers were dialysed for 3 days at 
4oC against 5 litres of dH2O (whole volume changed twice daily) using 3.5 kDa MWCO 
(molecular weight cut-off) Snakeskin pleated dialysis tubing (Pierce Laboratories, UK).  
The crude LOS extract was lyophilised (Christ Alpha 1-2 LD lyophiliser). 
 
2.2.4  Quantification of LOS by dry weight 
 
LPS and LOS were lyophilised in pre-weighed conical flasks and the dry weight was 
determined using accurate scales (Ohous Explorer Pro). 
 
2.2.5 Purification of LOS 
 
The LOS was resuspended to 10mg/ml in dH2O.  200 µg/ml DNase I (Merck, UK) and 
50 µg/ml RNase A (Merck, UK) were added and incubated at 37oC for 2 hours. 1mg/ml 
of Proteinase K (Merck, UK) was added and the LOS was incubated for a further 3 hours 
at 65oC to allow auto-digestion of the Proteinase K.  The LOS was dialysed against 5 
litres dH2O for 48 hours (whole volume changed twice daily) at 4oC then lyophilised and 
resuspended to 2mg/ml in sterile dH2O. 
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2.2.6 Purification of commercially bought LPS 
 
Smooth mutant E. coli 0111:B4 LPS (Sigma, UK), rough mutant S. typhimurium LPS 
SL1181 (RE mutant) (Sigma, UK) and smooth mutant S. typhimurium LPS (RA mutant) 
(Sigma, UK) were subjected to the DNase, RNase and Proteinase K purification protocol 
to remove contaminants.  
 
2.2.7 Determination of LOS purity by silver stain 
 
SDS (sodium dodecyl sulphate) PAGE (Polyacrylamide Gel Electrophoresis) of LOS was 
carried out using a Novex 10-20% Tricine gel according to the manufacturer’s 
instructions.  Briefly, 5µg of LOS was added to 5µl Tricine SDS sample buffer and 1µl 
Nupage reducing agent (All Invitrogen, UK).  The sample was heated to 85oC for 2 
minutes and 10µl was then loaded into the wells.  The gel was run in Tricine SDS 
running buffer (Invitrogen, UK) at 125 V constant for 90 minutes.  A silver stain of the 
gel was performed using a SilverXpress silver stain kit (Invitrogen, UK) following the 
manufacturer’s instructions. 
 
2.2.8 Determination of LOS purity by spectrophotometry 
 
2mg/ml LOS was titrated with 4µM EDTA (ethylenediaminetetraacetic acid) /dH2O and 
1% triton X to disperse micelles and clarify the solution for spectrophotometry. DNA, 
RNA and protein content was determined by spectrophotometry (Eppendorf 
biophotometer AG 22337) (Fisherbrand semi-micro cuvettes). 
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2.2.9 Determination of LOS epitopes by Western blot 
 
LOS was subjected to SDS-PAGE and transferred onto an Invitralon PVDF 
(Polyvinylidene Fluoride) membrane (0.45µm pore size, Invitrogen, UK) following the 
manufacturer’s instructions. The PVDF membrane was either stained immediately or 
dried and stored overnight at 4oC then reactivated with methanol.  The membrane was 
blocked using 3% w/v Marvel (powdered milk)/PBS for 1 hour then washed three times 
for 5 minutes in PBS with 0.5% Tween 20.  The GM1 epitope was detected using cholera 
toxin conjugated to HRP (horse radish peroxidase) (Sigma, UK) diluted in a 1:7000 
solution in 0.2% Marvel/PBS while the GD1a epitope was detected using the MOG-35 
monoclonal antibody204 (159µl diluted in 10ml PBS with 0.5% Tween 20) used in 
conjunction with an anti-mouse IgG HRP conjugated antibody (Southern Biotech, USA) 
diluted 1:2000 in PBS with 0.5% Tween 20.  All incubation steps lasted 1 hour and the 
membrane was washed between steps three times in 0.5% PBS/Tween for 5 minutes.  
The membrane was developed using Super Signal West Pico (Pierce, USA) following the 
manufacturer’s instructions. 
 
2.2.10 Generation of GM1 mimicking LOS from GM1/GD1a mimicking 
LOS 
 
LOS was resuspended to 1mg/ml in dH2O and 0.3 units/mg of cholera neuraminidase 
(Calbiochem, UK) was added. Samples were incubated at 37oC for 2 hours.  Proteinase K 
was then added for 3 hours at 65oC to remove the neuraminidase and allow for auto-
digestion of the Proteinase K.  The LOS was dialysed, lyophilised and resuspended as 
before. 
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2.2.11 Determination of LOS purity by alcian blue stain 
 
A positive control for capsular polysaccharide was generated by lysing 200µl of heat 
inactivated C. jejuni (OD600 of 3.5) using 200µl of 200mg/ml Cell Lytic Express 
(Sigma, UK) according to the manufacturer’s instructions.  The sample was incubated for 
20 minutes then centrifuged at 16,000g for 15 minutes and the supernatant kept for 
analysis.  SDS-PAGE of LOS and the lysed bacteria supernatant was carried out. The gel 
was transferred to a PVDF membrane (Invitralon, 0.45µm, Invitrogen, UK) following the 
manufacturer’s instructions.  The PVDF membrane was dyed with 0.5% alcian blue in 
7% acetic acid for 2 minutes then washed in PBS until clean. 
 
2.2.12 Quantification of LOS by thiobarbituric acid assay 
 
A 3 deoxy-D-manno-oct-2-ulosonic acid (KDO) standard curve was generated from 0, 
0.5, 2.5, 5 and 7.5µl of 0.5mM KDO (Sigma, UK) dried overnight in eppendorf tubes.  
10µg of each LOS was also dried overnight.  250µl of pH4.4, 0.1M, sodium acetate 
(Sigma, UK) was added to each tube and the solution heated at 100oC for 1 hour.  125µl 
of 40mM periodic acid in 0.125M sulphuric acid (H2SO4) was added and the solution was 
vortexed briefly then left to stand for 30 minutes at room temperature.  250µl of 0.2M 
sodium arsenite (Sigma, UK)
 
in 0.5M hydrochloric acid was added and mixed 
thoroughly.  250µl of fresh 2-thiobarbituric acid (Sigma, UK) (60mg/10ml dH20) was 
added and the tubes heated to 100oC for 15 minutes.  500µl of DMSO was added into the 
hot tubes and mixed.  The optical density (OD) of the solution was determined at 549nm.  
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2.3 Binding of cellular receptors and humoral factors to C. jejuni and 
LOS 
 
2.3.1 Binding of Sialoadhesin, Siglec E and Siglec F to LOS and 
gangliosides 
 
Purified GB11 wild type, GB11 CSTII knock out, HS O:19 and HS O:3 LOS were 
adsorbed onto 96 well half area ELISA plates by dissolving in methanol at 5µg/ml and 
adding 50µl per well before allowing the methanol to evaporate in a fume hood.  The 
plates were washed twice with PBS then blocked with 100µl per well of 3% BSA (bovine 
serum albumin)/PBS for 1 hour.  The plates were washed once with PBS then specific 
siglecs were added to each well.  The siglec reagents were murine Siglec-human-Fc 
fusion proteins kindly supplied by Prof P. Crocker, University of Dundee (see Appendix 
4 for siglec-human-Fc fusion protein structures).  Sialoadhesin and Siglec F were made 
up at 1µg/ml in blocking buffer while Siglec E was used at 0.5µg/ml.  The siglecs were 
combined with 3 times the volume of anti-human IgG-HRP (Southern Biotech, USA) and 
left for 1 hour at room temperature to form complexes.  50µl of siglec, diluted in 
blocking buffer, was added per well and incubated for 1 hour.  The plates were washed 5 
times then developed using Sure Blue TMB solution (Insight Biotechnology, UK) and 
read at 450nm using a Labsystems Multiscan Ascent plate reader.  When siglec binding 
to gangliosides GM1 and GD1a (Sigma, UK) and O-side chain sugar molecules, asialo-
GM1, asialo-GM2 (both Sigma, UK) and lactosyl ceramide (Merck, UK) was assessed, 
the gangliosides were adsorbed onto the plate at 2µg/ml.  For complex ganglioside/O-side 
chain ELISAs (mixed ganglioside and sugar targets), the sugar molecules were dissolved 
together in methanol and sonicated for 5 minutes to generate micelles containing the 
different epitopes.  
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2.3.2 Binding of Sialoadhesin, Siglec E and Siglec F to C. jejuni 
 
C. jejuni were grown and harvested into 8% formalin/PBS and left for 1 hour at room 
temperature to inactivate.  The bacteria were washed 3 times in 20ml PBS by 
centrifugation at 12,000 g for 10 minutes (Beckman Coulter Allegra 64R, rotor F0630).  
They were then diluted in PBS to an OD600 of 1 and frozen at -80oC following the 
addition of glycerol to a final concentration of 10%. C. jejuni strains GB11 wild type, 
GB11 CSTII knock out, HS O:19 and HS O:3 were defrosted, centrifuged at 13,000g for 
1 minute and resuspended to an OD600 of 0.1 in PBS.  50µl of bacteria were put in each 
well of a 96 well half area ELISA plate (Costar, UK) and allowed to adsorb onto the 
surface overnight at 4oC.  The plate was washed twice with PBS and then blocked using 
100µl per well of 3% BSA/PBS for 1 hour.  The plate was washed once before the 
desired siglec was added at a diluting concentration (siglecs were made up as detailed 
earlier) and incubated for 1 hour. 50µl was added per well.  The plate was washed 5 times 
with PBS before being developed using 50µl of Sure Blue TMB substrate solution per 
well and stopped using 25µl 4N H2SO4.   
 
2.3.3 Visualisation of siglec binding to C. jejuni 
 
70µl of formalin fixed HS O:19 and HS O:3 C. jejuni with an OD600 of 0.5 were 
centrifuged onto a microscope slide (VWR Superfrost Plus) using a cytospin (600g, 5 
minutes).  The bacteria were labelled using Sialoadhesin, Siglec E and Siglec F adapting 
the above ELISA protocol except using a FITC labelled anti-human IgG (BD 
Biosciences, UK) instead of the HRP labelled antibody.  The slides were mounted using 
Vectashield DAPI containing mounting media (Vector, USA) and visualised using an 
Apotome/Zeiss microscope. 
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2.3.4 Binding of Sialoadhesin to C. jejuni following neuraminidase 
treatment 
 
Formalin fixed HS O:19 and HS O:3 were defrosted, centrifuged at 13,000g for 1 minute 
and resuspended to an OD600 of 0.1 in PBS.  50µl of bacteria were put in each well of a 
96 well half area ELISA plate (Costar, UK) and allowed to adsorb overnight at 4oC. The 
plate was washed twice with PBS. Selected wells were treated with 50µl of 0.004 U/ml of 
neuraminidase from vibrio cholerae (Merck) in HBSS (Hanks buffered salt solution) for 
1 hour at 37oC while control wells were incubated with HBSS alone.  The plate was 
washed twice with PBS and then blocked using 100µl per well of 3% BSA/PBS for 1 
hour.  The ELISA was carried out as before.  Increased GM1 expression was confirmed 
using the anti-GM1 mouse mAb DG2.  50µl of Ab (0.5mg/ml) diluted 1:200 in blocking 
buffer was added per well and incubated for 1 hour at room temperature.  This was 
washed three times and an anti-mouse IgG HRP secondary (southern biotech) was added 
(1mg/ml diluted 1 in 500) and incubated for 1 hour.  Following five washes the plate was 
developed with Sure Blue. 
 
2.3.5 Binding of purified human Factor H to C. jejuni by ELISA 
 
Formalin fixed C. jejuni were adsorbed onto ELISA plates, washed and blocked as 
before.  The wells were incubated with 60µg/ml of purified human Factor H (fH) (Sigma, 
UK) for 1 hour at 37oC.  The plate was washed twice with PBS and then incubated with a 
mouse monoclonal anti-human fH antibody (OX-23 clone, 1mg/ml, Serotec, UK) used at 
a 1:250 dilution.  Following two washes the plate was incubated with an anti-mouse IgG 
HRP secondary antibody (1:500 dilution)(Southern Biotech) to detect fH binding to the 
bacteria.  The plate was developed using Sure Blue substrate. 
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2.3.6 Binding of purified human Factor H to C. jejuni by FACS 
 
Heat inactivated C. jejuni were washed and resuspended to an OD600 of 3.6 in sterile 
filtered HBSS.  90µl of bacteria were incubated with 5µg of purified human fH in 10µl of 
PBS for 30 minutes at 37oC then washed with 400µl HBSS.  The bacteria were 
resuspended then incubated with 50µl of the anti-fH monoclonal antibody (1:100 
dilution) for 30 minutes.  After another wash they were incubated with 50µl of anti-
mouse IgG FITC (1:100 dilution) (Southern Biotech) for 30 minutes.  Following two 
final washes they were resuspended to 250µl in HBSS and acquired using a FACSCalibur 
FACS machine. 
 
2.3.7 Visualisation of Factor H binding to C. jejuni 
 
70µl of formalin fixed C. jejuni (OD600 of 0.5) were adsorbed onto a microscope slide 
by centrifugation (600g, 5 minutes), allowed to dry and marked using a pap pen.  The 
bacteria were incubated with 5µg of purified human fH in 30µl of HBSS for 30 minutes 
at 37oC.  Following a single wash the bacteria were incubated with the anti-fH mAb 
(30µl, 1:100 dilution) for 30 minutes.  The slides were washed and the bacteria incubated 
with anti-mouse IgG FITC (1:100 dilution) for 30 minutes.  The slides were washed and 
mounted with DAPI containing mounting media.  The slides were visualised using an 
Apotome/Zeiss microscope. 
 
2.3.8 Deposition of C3c and C9 on C. jejuni using ELISA 
 
Formalin inactivated C. jejuni were adsorbed onto ELISA plates as before.  The plates 
were blocked using 100µl of 3% BSA/PBS.  Human serum (donated by individuals self-
reporting no previous infection or exposure to C. jejuni) was diluted in PBS (dilutions 
detailed in results).  Following two washes, 50µl of the diluted sera was added per well 
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and the plates incubated at 37oC for 20 minutes.  The plates were washed 3 times after 
which 50µl of detection antibody was added: sheep anti-C3c or sheep anti-C9 (both 
Dako, Denmark) all diluted 1:500 in blocking buffer, and incubated for 1 hour.  
Following three washes anti-sheep IgG HRP (Santa Cruz Biotechnology, USA), diluted 
1:500 in blocking buffer, was added.  The plates were washed 5 times and developed 
using Sure Blue TMB solution. 
 
2.3.9 Binding of natural IgM and IgG to C. jejuni or LOS 
 
Formalin inactivated C. jejuni or LOS was adsorbed onto ELISA plates as before.  
Human sera was prepared as before and incubated for 1 hour at room temperature.  
Following 3 washes, IgM and IgG was detected using anti-human IgM HRP and anti-
human IgG HRP (Southern Biotech, USA) diluted 1:1000 in blocking buffer.  Following 
1 hour incubation and five washes, the plates were developed using Sure Blue TMB 
solution. 
 
2.4 Harvesting and labelling of cells for in vitro experiments 
 
2.4.1 Mouse strains 
 
Unless otherwise stated, the mice used were C57BL/6 wild type strains aged between 6 
and 14 weeks old taken from the in-house colony of Dr C Goodyear or Prof H Willison.  
C3H/HeJ and C3H/HeN mice were female, aged 8 to 12 weeks and purchased from 
Harlan (UK).  TLR2-/- mice were female, aged 14 weeks and kindly supplied by Dr C 
Michels, University of Glasgow, UK. 
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2.4.2 Harvesting of splenocytes 
 
Mice were sacrificed by suffocation with CO2 and the spleens removed and placed in 3ml 
sterile cRPMI (complete RPMI).  A cell strainer (Falcon, 70µm) was used to produce a 
single cell suspension of splenocytes which was washed in 10ml cRPMI by 
centrifugation at 500g for 5 minutes (Eppendorf Centrifuge 5408) with the supernatant 
being discarded. The pellet was resuspended in 2ml of ACK lysis buffer (BioWhittaker, 
UK) per spleen and gently mixed for 2 minutes before being washed with 10ml cRPMI 
and resuspended to 10ml in cRPMI.  Any cell debris was removed using a sterile pipette 
and the cell concentration was determined using a haemocytometer. The splenocytes 
were then resuspended to 1x107/ml in cRPMI and kept on ice.  For experiments involving 
overnight culture the cRPMI was supplemented with 500µl 2-mercaptoethanol and 5ml 
non-essential amino acids per 500ml of media.  
 
2.4.3 Purification of splenic B cells 
 
Spleens were harvested as above and B cells were purified by negative selection using the 
EasySep magnetic B cell negative selection kit (Stemcell Technologies, USA) according 
to the manufacturer’s instructions.  Purity was assessed by flow cytometry (BD, 
FACSCalibur).  Briefly, Fc receptors were blocked by incubating cells with Fc block 
(anti-mouse CD16/32, BD, UK), diluted 1:200 per million cells in 50µl FACS buffer for 
10 minutes at 4oC.  Cells were then stained with fluorophore labelled antibody (diluted 
1:200 per million cells) in 50µl FACS buffer and incubated for 15 minutes at 4oC.  The 
cells were washed in 500µl FACS buffer then resuspended in 250µl FACS buffer.  Purity 
was assessed by comparing the percentage of B220+ cells (anti-mouse B220 APC, 
Southern Biotech, USA) before and after purification and typically showed >90% B220+ 
cells (example FACS plot in results). 
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2.4.4 Carboxyfluorescein diacetate succinimidyl ester (CFSE) labelling of 
splenocytes and B cells 
 
Splenocytes, including erythrocytes, were harvested and resuspended to 1x107 nucleated 
cells/ml in RPMI (without added serum) at 37oC.  5mM stock CFSE (Invitrogen, UK) 
was diluted in RPMI so that 1µM CFSE was added to the cells.  This was incubated at 
37oC for 10 minutes with shaking.  The cells were washed four times with 10ml of ice 
cold cRPMI (with added serum to mop up free CFSE) by centrifuging at 500g for 5 
minutes.  The cells were then resuspended to the desired concentration.  For CFSE 
labelling of purified B cells the above protocol was followed with the exception of no 
erythrocytes being present. 
 
2.4.5 Generation of M-CSF containing supernatant 
 
L-929 cells are a murine fibrosarcoma cell line which secretes M-CSF (macrophage 
colony stimulating factor).  The conditioned supernatant can be used to induce 
macrophage differentiation in bone marrow derived cells205,206.  L-929 cells were grown 
to 90% confluence in cRPMI in T75 flasks before being split into T150 flasks and grown 
to confluence.  The cells were left for 3-4 days before the supernatant was collected by 
centrifugation (500g for 5 minutes).  Aliquots were frozen at -20oC and were sterile 
filtered (0.2µm Minisart filter, Sartorius) before use.   
 
2.4.6 Generation of GM-CSF containing supernatant 
 
X-63 cells are a fibroblast cell line transfected with the murine granulocyte-macrophage 
colony stimulating factor (GM-CSF) gene.  The conditioned supernatant can be used to 
generate bone marrow derived dendritic cells from bone marrow cells207.  X-63 cells were 
grown in 18ml ISCOVES Modified Medium (IMDM with 2mM L-glutamine, 10% foetal 
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bovine serum, 100 units/ml Penicillin and 100 units/ml Streptomycin) until confluent.  
The cells were then washed in IMDM and recultured in 18ml Iscoves Modified Medium 
with 1mg/ml G418 (Geneticin antibiotic, Promega, USA) for 4 days.  The cells were 
washed in RPMI 1640 and seeded into 25cm2 flasks and grown in complete IMDM.  
When the cells reached log growth they were transferred to 75cm2 flasks and grown until 
confluent.  The cells were harvested by centrifugation (500g for 5 minutes) and seeded 
into 150cm2 flasks in complete IMDM.  Once confluent and after 4-7 days the 
supernatant was collected and stored at -20oC. 
 
2.4.7 Harvesting of bone marrow 
 
Mice were sacrificed by CO2 suffocation and the hind limbs taken and stripped of flesh.  
The femurs and tibia were flushed with sterile PBS by inserting a 23 gauge needle into 
the marrow space and washing with PBS loaded into a 20ml syringe.  The cells were 
vortexed thoroughly to break up clumps and broken up by aspirating gently through a 21 
gauge needle if necessary.  The cells were centrifuged and resuspended in 10ml cRPMI. 
The cells were passed through a cell strainer to remove clumps and then counted using a 
haemocytometer and resuspended at 1x107/ml in cRPMI. 
 
2.4.8 Generation of bone marrow derived macrophages 
 
Bone marrow cells were plated out in 90mm Petri dishes (Sterlin, UK) at 5x106 cells in 
10ml cRPMI with 20% M-CSF (supernatant from the L-929 cell line) and incubated at 
37oC in 5% CO2.  After 4 days the cells were supplemented with 7ml of cRPMI with 20% 
M-CSF and then used on day 7.  Non-adherent cells were removed by aspirating the 
supernatant and gently washing with 5ml PBS.  Adherent cells were harvested by adding 
5ml ice cold PBS and scraping off with cell scrapers.  Purity was assessed by flow 
cytometry.  Fc receptors were blocked by incubating cells with Fc block (diluted 1:200 
per million cells) in 50µl FACS buffer for 10 minutes at 4oC.  Cells were then stained 
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with anti-mouse F4/80 biotin (Biolegend clone BM8, UK) diluted 1:200 per million cells 
in 50µl FACS buffer or the appropriate isotype control (Rat IgG2aκ biotin, Biolegend, 
UK) and incubated for 15 minutes at 4oC.  The cells were washed in 400µl FACS buffer.  
The cells were resuspended by flicking the tube and incubated in 50µl FACS buffer with 
streptavidin APC (Southern Biotech, USA) diluted 1:200 for 15 minutes at 4oC.  The 
cells were then washed twice in 400µl FACS buffer then resuspended in 250µl FACS 
buffer.  Purity was assessed by comparing the percentage of F4/80+ cells to the isotype 
control and was typically >90% F4/80+ (example FACS plots in results). 
 
2.4.9 Generation of bone marrow derived dendritic cells 
 
Bone marrow cells were plated out in 90mm petri dishes at 5x106 cells in 10ml cRPMI 
with 10% GM-CSF (supernatant from the X-63 cell line) and cultured at 37oC in 5% 
CO2.  The cells were supplemented after 4 days with 10ml cRPMI and 10% GM-CSF.  
The cells were used after 8 days with only the non-adherent cells being taken by gently 
swirling the plate and taking the supernatant. Purity was assessed using the same protocol 
as for macrophages (antibodies used were anti-mouse CD11c biotin (BD biosciences, 
UK), hamster IgG1 isotype control (BD Biosciences, UK) and streptavidin APC, all at a 
1:200 dilution per million cells in 50µl FACS buffer).  Purity was typically >70% 
CD11c+ as assessed by flow cytometry (example FACS plot in results). 
 
2.5 In vitro stimulation of splenocytes, B cells, dendritic cells and 
macrophages 
 
2.5.1 Stimulation of splenocytes and purified B cells 
 
CFSE labelled cells were prepared as above and resuspended to 1x107 cells/ml in cRPMI 
supplemented with 2-mercaptoethanol and non-essential amino acids.  The cells were 
divided into eppendorfs at 7x105 cells in 700µl of supplemented cRPMI and LOS was 
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added at the desired concentration before mixing. The cells were plated out in a 96 well 
round bottom plate (Corning, UK) at 2x105 cells per well at 1x106 cells per ml.  The cells 
were cultured at 37oC with 5% CO2 for 48 and 72 hours.  Following culture, the plates 
were centrifuged at 400g for 5 minutes and the supernatant collected and stored for 
further analysis.  The cells were resuspended in-situ in ice cold FACS buffer containing 
Fc block diluted 1 in 100 per million cells and incubated on ice for 10 minutes.  The cells 
were then transferred to FACS tubes for further labelling. 
 
2.5.2 Stimulation of bone marrow derived dendritic cells with LOS 
 
Bone marrow derived dendritic cells were generated from C57BL/6 mice.  Cells were 
resuspended to 1x107/ml in cRPMI then transferred to eppendorfs at 1x106/ml in cRPMI. 
LOS was added to the cells at the appropriate concentration, vortexed then plated out in a 
96 well flat bottomed plate (Corning, UK) with 3x105 cells in each well.  Cells were 
cultured for 12 hours at 37oC with 5% CO2.  The supernatant was harvested by 
centrifuging the plate at 300g for 5 minutes then carefully aspirating 200µl with a multi-
channel pipette.  The supernatant was either analysed immediately by ELISA or frozen at 
-20oC for later analysis.  FACS analysis of the cells was carried out by using gentle 
agitation (pumping the pipette up and down, followed by scraping the well with the tip) 
to resuspend the cells before transferring them to FACS tubes.  Fc receptors were blocked 
by incubating cells with Fc block (diluted 1:200 per million cells) in 50µl FACS buffer 
for 10 minutes at 4oC.  Cells were then stained with anti-mouse CD11c biotin and anti-
mouse CD40-PE (BD Biosciences, UK) diluted 1:200 per million cells in 50µl FACS 
buffer with the appropriate isotype controls (For CD40, Rat IgG2aκ Pe BD Biosciences, 
UK)  and incubated for 15 minutes at 4oC.  The cells were washed in 400µl FACS buffer.  
The cells were resuspended by flicking the tube and incubated in 50µl FACS buffer with 
streptavidin APC (Southern Biotech, USA) diluted 1:200 for 15 minutes at 4oC.  The 
cells were then washed in 400µl FACS buffer then resuspended in 250µl FACS buffer. 
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2.5.3 Quantification of bacteria 
 
C. jejuni were grown and harvested into PBS then heat inactivated.  The bacteria were 
dialysed against dH2O using 12-14kDa MWCO dialysis tubing.  The bacteria were then 
lyophilised and the dry weight recorded.  The lyophilised bacteria were resuspended to 
5mg/ml in PBS and a double dilution standard curve was generated comparing the dry 
weight to the OD600 to generate an equation linking dry weight and optical density at 
600nm.  For the purposes of estimating the number of bacteria it was assumed the mass 
of a single bacterium is approximately 1x10-12g (the estimated mass of an E. coli cell208) 
and this value was applied to all the strains being compared. 
 
2.5.4 Stimulation of bone marrow derived dendritic cells with whole C. 
jejuni 
 
Bone marrow derived dendritic cells were generated and prepared as before.  3x105 cells 
were pipetted in 100µl of cRPMI into sterile eppendorfs.  Heat inactivated C. jejuni were 
defrosted and washed as before.  Both strains were diluted to an OD600 of 0.6 in sterile 
PBS and the quantity of bacteria was estimated using the OD to dry weight formula 
established above.  The bacteria were diluted into cRPMI.  The desired ratios of bacteria 
to dendritic cell was 12:1, 6:1, 3:1 and 1.5:1 and the bacteria were diluted such that the 
desired number of bacteria for 3x105 dendritic cells was present in 200µl of cRPMI.  The 
C. jejuni were added to the dendritic cells at the diluting titration (200µl of bacteria 
containing cRPMI added to 100µl of dendritic cell containing cRPMI making the final 
concentration of dendritic cells 1x106/ml).  The cells were vortexed, then plated out for 
overnight culture in 96 well flat bottomed tissue culture plates.  The supernatant was 
harvested and stored as before. 
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2.5.5 Blocking of siglec receptors on bone marrow derived dendritic cells 
 
Bone marrow derived dendritic cells were generated as above.  3x105 cells were 
transferred into eppendorfs at 1x107cells/ml and siglec blocking antibodies (sheep anti-
mouse Siglec E, sheep anti-mouse Siglec F and rat anti-mouse Sialoadhesin clones 3D6 
and SER-4209) were added at 1µg per million cells. The cells were incubated for 15 
minutes on ice then diluted to 1x106cells/ml whereupon LOS was added at 10µg/ml.  The 
cells were incubated for 12 hours at 37oC with 5% CO2 and the supernatant collected for 
analysis. All blocking antibodies were kind gifts from Prof P Crocker, University of 
Dundee.   
 
2.5.6 Stimulation of bone marrow derived macrophages with LOS 
 
Bone marrow derived macrophages were generated from C57BL/6 mice as described 
previously.  Cells were resuspended to 1x107/ml in cRPMI then transferred to eppendorfs 
at 1x106/ml in cRPMI. LOS was added to the cells at the appropriate concentration.  The 
cells were vortexed then plated out in a 96 well flat bottomed plate with 3x105 cells in 
each well.  Cells were cultured for 12 hours at 37oC with 5% CO2 and the supernatant 
harvested as described for dendritic cells. 
 
2.5.7 Stimulation of bone marrow derived macrophages with whole C. 
jejuni 
 
Bone marrow derived macrophages were generated and prepared as before.  The same 
protocol was used for macrophages as for dendritic cell stimulation by whole bacteria 
only the bacteria to cell ratios for the diluting titration were 100:1, 50:1, 10:1 and 1:1.  
The supernatant was harvested and stored as before.  For analysis of CD40 upregulation, 
the macrophages were pulse stimulated with C. jejuni at 50:1 bacteria to cell ratio for 15 
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minutes in eppendorfs while incubated at 37oC with 5% CO2.  The cells were washed 
with 1.5ml cRPMI by twice centrifuging the tubes at 400g for 5 minutes.  The cells were 
then resuspended to 1x106 per ml and 3x105 were aliquoted into each well in a 96 well 
round bottom culture plate for overnight culture.  The cells were harvested and stained 
for CD40 upregulation using the same protocol detailed for dendritic cells above only 
anti-F4/80 antibody was used instead of anti-CD11c. 
 
2.5.8 Stimulation of bone marrow derived dendritic cells and 
macrophages with exogenous gangliosides and LOS 
 
Bone marrow derived dendritic cells and macrophages were generated from C57BL/6 
mice as described previously.  Cells were resuspended to 1x107/ml in cRPMI then 
transferred to eppendorfs at 1x106/ml in cRPMI.  The cells were stimulated with PBS, 
5µg/ml each of bovine brain derived gangliosides GM1 and GD1a (both from Sigma, 
UK), 10µg/ml of GB11 wild type LOS, 10µg/ml of GB11 knock out LOS or 10µg/ml of 
GB11 knock out LOS sonicated with 5µg/ml each of GM1 and GD1a for 5 minutes prior 
to addition to cells.  The gangliosides were prepared by taking 100µl each of GM1 and 
GD1a (stock was 1mg/ml in 50:50 methanol chloroform) and transferring this to a 15ml 
falcon tube.  The gangliosides were dried by blowing with nitrogen from a compressed 
gas cylinder (BOC, UK).  The gangliosides were then resuspended in 200µl sterile PBS 
(i.e. still at 1mg/ml) and sonicated and centrifuged repeatedly for 15 minutes.  They were 
then stored in a glass vial until the desired quantity was added to LOS or cells as 
described above.  The cells were vortexed then plated out in a 96 well flat bottomed plate 
with 3x105 cells in each well.  Cells were cultured for 12 hours at 37oC with 5% CO2 and 
the supernatant harvested as described for dendritic cells. 
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2.5.9 Quantification of dead cells by trypan blue exclusion assay 
 
Dendritic cells or macrophages were stimulated overnight with 10µg/ml LOS or PBS as 
described above.  After 200µl of supernatant had been aspirated (leaving 100µl), the plate 
was placed on ice at 4oC for 15 minutes following which the wells were scraped with a 
pipette tip to loosen off any adherent cells.  20µl was aspirated from the cells and added 
to 50µl cRPMI and stored on ice.  Shortly before counting, 10µl of trypan blue was added 
to the cells and a sample transferred to a haemocytometer where the live and dead cells 
were counted and the percentage of trypan blue positive cells (dead cells) was calculated. 
 
2.6 Analysis of stimulated cells 
 
2.6.1 Preparation and staining of B cells and splenocytes for FACS 
analysis 
 
Fc receptors were blocked by incubating cells with Fc block (diluted 1:200 per million 
cells) in 50µl FACS buffer for 10 minutes at 4oC.  Cells were then stained with primary 
fluorophore labelled or biotinylated antibody (diluted 1:200 per million cells) in 50µl 
FACS buffer and incubated for 15 minutes at 4oC. The cells were washed in 300µl FACS 
buffer (500g for 5 minutes) and resuspended in 50µl FACS buffer streptavidin 
conjugated fluorophore (diluted 1:200 per million cells) then incubated for 15 minutes at 
4oC.  The cells were washed a final time in 500µl FACS buffer then resuspended in 
250µl FACS buffer.  Immediately before acquisition, counting beads (Caltag 
laboratories) were added to the tubes according to the manufacturer’s instructions. The 
cells were acquired using a BD FACSCalibur. The data were analysed using FlowJo 
software (Treestar, USA).   
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2.6.2 IgG immunoglobulin ELISA 
 
Half area ELISA plates were coated overnight with 50µl of 5µg/ml anti-mouse IgG 
(Southern Biotech, USA) in sodium carbonate buffer (see appendix 1).  The plates were 
washed three times with 0.3% PBS/Tween then blocked for 1 hour with 100µl of 2% 
BSA/PBS at room temperature.  The plate was washed three times and mouse IgG 
standard (Bethyl laboratories, USA) was added at 50µl per well starting with 200ng/ml in 
0.1% BSA/PBS with doubling dilutions.  Supernatant from the splenocyte or B cell 
cultures was diluted 1:5, 1:10 and 1:20 in 0.1% BSA/PBS and 50µl added to each well.  
Samples were incubated for 1 hour at room temperature then the plates were washed 3 
times.  Detection antibody, anti-mouse IgG-HRP, was added (50µl per well, 1:4000 
dilution) and incubated for 1 hour.  The plate was washed 5 times and 50µl of developing 
solution was added per well.  (1 OPD tablet was added to 14ml Citric acid with 16ml of 
0.2M Na2HPO4 and 30ml of dH2O.  20µl of H2O2 was added immediately before use).  
The reaction was stopped using 25µl of 3N H2SO4 and the plate was read using a 
Labsystems Multiscan Ascent plate reader at 490nm within 15 minutes. 
 
2.6.3 IgM Immunoglobulin ELISA 
 
Half area ELISA plates were coated overnight with 50µl of 5µg/ml anti-mouse IgM 
(Southern Biotech, USA) in sodium carbonate buffer.  The plates were washed three 
times with 0.3% PBS/Tween then blocked for 1 hour with 2% BSA/PBS at room 
temperature.  The plate was washed three times and mouse IgM standard (Bethyl 
laboratories, USA) was added at 50µl per well starting with 100ng/ml in 0.1% BSA/PBS 
with 1:3 dilutions.  Supernatant from the splenocyte or B cell cultures was diluted 1:250, 
1:500 and 1:750 in 0.1% BSA/PBS and 50µl added to each well.  Samples were 
incubated for 1 hour at room temperature then the plates were washed 3 times.  Detection 
antibody, anti-mouse IgM-HRP, was added (50µl per well, 1:4000 dilution) and 
incubated for 1 hour.  The plate was washed 5 times and 50µl of developing solution was 
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added per well.  (1 OPD tablet was added to 14ml Citric acid with 16ml of 0.2M 
Na2HPO4 and 30ml of dH2O.  20µl of H2O2 was added immediately before use.) 
 
2.6.4 Interleukin-10 ELISA 
 
Supernatant from stimulation cultures was assayed using an OptEIA IL-10 ELISA kit 
(BD Biosciences, UK) as per the manufacturer’s instructions except the top standard was 
extended to 4000pg/ml.  The supernatant was either used neat or occasionally had to be 
diluted 1:2.  The plate was developed using Sure Blue TMB solution and read at 450nm 
in an Ascent Multiscan plate reader. 
 
2.6.5 Interferon Gamma (IFN-γ) ELISA 
 
Supernatant from stimulation cultures was assayed using an OptEIA IFN-γ ELISA kit 
(BD Biosciences) as per the manufacturer’s instructions.  Supernatants were used neat 
and developed as for the IL-10 ELISA. 
 
2.6.6 Interleukin-12 ELISA 
 
Supernatant from stimulation cultures was assayed using an OptEIA IL-12 p70 ELISA kit 
(BD Biosciences) as per the manufacturer’s instructions.  Supernatants were used neat 
and developed as for the IL-10 ELISA. 
 
2.6.7 Tumour Necrosis Factor Alpha (TNF-α) ELISA 
Supernatant from stimulation cultures was assayed using an OptEIA TNF-α mono/mono 
ELISA kit (BD Biosciences) as per the manufacturer’s instructions.  Supernatants were 
used neat, 1:10 or 1:20 dilutions, and developed as for the IL-10 ELISA. 
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2.7 Immunisation of mice with LOS 
 
2.7.1 Injection of mice with LOS 
 
Male C57BL/6 mice aged between 6 and 8 weeks were injected intra-peritoneally with 
50µg of GB2 wild type or GB2 CSTII knock out C. jejuni LOS in 200µl sterile PBS.  
Controls included PBS alone, smooth mutant S. typhimurium and rough mutant S. 
typhimurium LPS at the same concentration.  The mice were sacrificed 18 hours later.  
The spleens were taken and placed in a 5ml bijou where they were immersed in Cryo-M-
bed (Bright, UK) and transferred to a -80oC freezer. 
 
2.7.2 Immunohistochemical staining of spleen following LOS injection 
 
Spleens from the above mice were cut into 8µm frozen sections using a Bright cryostat 
(model OTF).  The sections were allowed to air dry for two hours and were then 
permeabilised in ice cold acetone for 10 minutes.  After drying, the sections were blocked 
with 100µl of 5% foetal bovine serum in PBS for 1 hour.  The sections were then washed 
3 times for 5 minutes in 0.3% PBS/Tween.  The sections were stained overnight with 
antibodies diluted 1:100, 100µl per section.  Antibodies used were anti-mouse B220 
AlexaFluor 647 (Biolegend, USA) and anti-mouse MOMA-1 FITC.  The sections were 
washed 5 times then mounted using CitiFluor (CitiFluor, UK).  Slides were analysed 
using a Laser Scanning Cytometer (Compucyte) microscope. 
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2.8 Harvesting and fluorophore labelling of C. jejuni  
 
2.8.1 CFSE labelling of bacteria 
 
C. jejuni were grown as before and harvested into sterile PBS.  The bacteria were 
centrifuged at 4500g for 15 minutes, the supernatant discarded and the pellet suspended 
in PBS.  The bacteria were diluted to an OD600 of 1.0 and divided into 10ml aliquots.  
Stock 5mM CFSE was diluted to 5µM in PBS.  An equal volume of the 5µM CFSE was 
added to the bacteria and incubated for 30 minutes at 37oC in the dark with regular 
mixing.  The labelled bacteria were transferred to a 65oC water bath and heat inactivated 
for 1 hour. They were then washed three times with 20ml of sterile PBS by centrifuging 
at 12,000g for 10 minutes.  The concentration of bacteria was standardised between 
strains using OD600 and then aliquoted to store at -80oC in 10% glycerol.  Before use, 
the aliquots were centrifuged at 13,000g for 5 minutes and the supernatant discarded.  
The pellet was resuspended and the concentration standardised by OD600. 
 
2.8.2 Quantification of the fluorescence of labelled bacteria 
 
20x106 labelled bacteria were added to 250µl FACS buffer and acquired using a BD 
FACSCalibur flow cytometer.  The data were analysed using FlowJo software and the 
MFI (mean fluorescence intensity) of the fluorophore labelled bacteria was determined.  
Only those batches where the ganglioside mimicking strain and the control strain 
exhibited an equal fluorescence were used in phagocytosis experiments.  In addition, 
20x106 bacteria were centrifuged onto a coated microscope slide using a cytospin 
(600rpm for 5 minutes) and the bacteria were visualised using a Carl Zeiss Apotome 
microscope to examine morphology and confirm the fluorescence. 
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2.8.3 Confirmation CFSE remains bound to bacteria 
 
20x106 CFSE labelled or unlabelled control bacteria were added to 1ml RPMI and 
incubated for 1 hour at 37oC.  The bacteria were removed by twice centrifuging the 
sample at 12,000g for 10 minutes and aspirating the supernatant.  1x106 mixed mouse 
splenocytes were then incubated with the supernatant for 30 minutes at 37oC.  The cells 
were centrifuged at 500g for 5 minutes and resuspended in 4% formalin for 10 minutes 
before being washed and resuspended in FACS buffer.  The splenocytes were acquired 
and the CFSE MFI determined to establish if CFSE had leaked from the labelled bacteria 
and been taken up by the splenocytes. 
 
2.9 Phagocytosis and cell association of intact bacteria 
 
2.9.1 Association of C. jejuni with splenic B cells in the presence or 
absence of fresh serum 
 
C57BL/6 mice were sacrificed by CO2 suffocation and a terminal bleed was carried out.  
The blood was centrifuged at 4000rpm and the serum collected and stored on ice.  The 
spleen was taken and digested using 1ml of cRPMI containing 100µl of DNase and 100µl 
collagenase (both 10mg/ml) and incubating for 10 minutes at 37oC.  A single cell 
suspension was made and the red cells lysed.  The splenocytes were washed and 
resuspended to 1x107cells/ml and kept on ice.  CFSE labelled GB11 strain C. jejuni were 
defrosted, centrifuged (13,000g for 1 minute) and resuspended in PBS with the OD600 of 
wild type and CSTII knock out strains matched.  The bacteria were then opsonised by 
adding the bacteria to cRPMI supplemented with 20% fresh homologous mouse serum 
(taken earlier) at a concentration of 40,000 bacteria per µl.  2x106 splenocytes were 
transferred into FACS tubes at 1x106/ml in cRPMI supplemented with 5mM NaAzide 
and 5mM EDTA, and opsonised or non-opsonised wild type or CSTII knock out bacteria 
were added to the cells at a ratio of 3:1.  The cells were vortexed then split into triplicate 
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tubes before being incubated for 15 minutes at 4oC.  The cells were then washed with 3ml 
of ice cold PBS and, following blocking of Fc receptors, stained for B cells using anti-
mouse CD19 APC (Southern Biotech, USA).  The cells were analysed using flow 
cytometry and the percentage of B cells with associated CFSE labelled C. jejuni was 
determined. 
 
Various controls were included to establish the role of complement.  The homologous 
mouse serum was heat inactivated (56oC for 30 minutes) and used for opsonisation and 
purified exogenous mouse complement (Sigma, UK) was reintroduced (20%) to the heat 
inactivated serum before opsonisation. 
 
2.9.2 Identification of Sialoadhesin receptor on bone marrow derived 
macrophages 
 
Bone marrow derived macrophages were grown and harvested as before.  The cells were 
fixed with 4% formalin/PBS then a cytospin was carried out (450g for 5 minutes).  Cells 
were blocked for 1 hour with 100µl 5% BSA/PBS and 1:100 Fc Block.  The slides were 
then washed once in 0.3% PBS/Tween followed by overnight staining at 1:100 dilution 
with anti-mouse F4/80 biotin (Biolegend) and anti-mouse MOMA-1 FITC (Serotec, UK).  
Slides were then washed 3 times before incubating the anti-F4/80 samples with 
streptavidin Alexa 647 (1:100 dilution) for 1 hour then washed a further 5 times.  The 
slides were mounted using DAPI containing Vectashield and analysed using a laser 
scanning confocal microscope. 
 
2.9.3 Bone marrow derived macrophage phagocytosis of C. jejuni 
 
Bone marrow derived macrophages were grown and harvested as before.  Complete 
RPMI supplemented with Ultra-low IgG foetal bovine serum (Invitrogen, UK) was used 
at all steps to exclude the possibility of natural Ig affecting phagocytosis.  FACS tubes 
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were labelled for each time point (0, 15, 30 and 60 minutes) and for cells cultured at 37oC 
and control tubes cultured at 4oC.  The cells were resuspended to 1x107 per ml and 
300,000 cells were transferred into the FACS tubes and kept on ice.  CFSE labelled 
GB11 wild type and CSTII knock out C. jejuni were defrosted, centrifuged and 
resuspended to remove bacterial debris.  The OD600 of both strains were matched.  C. 
jejuni were diluted in cRPMI then added to the macrophages at a 20:1 ratio so that the 
final concentration of macrophages was 1x106cells/ml.  The cRPMI used in the 4oC 
control tubes was supplemented with 5mM NaAzide.  All tubes were vortexed 
thoroughly. The 37oC tubes were transferred to an incubator and cultured at 37oC with 
5% CO2, with mixing every ten minutes, for the desired time before being washed with 
3ml ice cold PBS with 5mM NaAzide.  The cells were stained as for previous FACS 
analysis using anti-mouse F/480 biotin and streptavidin APC.  For analysis, F4/80+ cells 
were gated and the MFI of these cells (representing phagocytosed CFSE labelled 
bacteria) was determined. The MFI of the 4oC, NaAzide cultured controls was subtracted 
from the 37oC cultured cells for each time point. The residual sample following FACS 
analysis was deposited on slides (Superfrost plus, VWR) using a cytospin (450g for 5 
minutes) and visualised using an Apotome microscope to confirm the intracellular 
location of the bacteria. 
 
2.9.4 Inhibition of bone marrow derived macrophage phagocytosis 
 
Bone marrow derived macrophage phagocytosis of C. jejuni was carried out as above and 
cells were analysed at a single 40 minute time point.  Prior to addition of the bacteria, the 
macrophages were incubated with 0.3µg each of Sialoadhesin blocking antibodies SER-4 
and 3D6 per million cells for 15 minutes at 4oC.  CFSE labelled GB11 wild type and 
GB11 CSTII knock out C. jejuni were added to the cells at a 10:1 ratio and the amount of 
phagocytosis with and without Sialoadhesin blocking antibody was determined as before.  
In order to confirm that Sialoadhesin was the only receptor mediating enhanced uptake of 
the ganglioside mimicking C. jejuni strain, a titration of Sialoadhesin blocking antibodies 
was used ranging from 0 to 0.5µg of SER-4 and 3D6 per million macrophages.  In 
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addition, some cells were incubated with an isotype control antibody for the blocking 
antibodies at 1µg/million cells before the bacteria were added.   
 
2.9.5 Injection and tracking of labelled C. jejuni 
 
Age and sex matched C57BL/6 mice were injected i.v. with 200µl of heat inactivated, 
CFSE labelled, GB2 wild type and knock out C. jejuni diluted to an OD600 of 0.6 in 
PBS.  200µl of PBS i.v was used as a control.  The mice were sacrificed after 1 or 3 hours 
by CO2 anaesthesia and harvested for spleen, blood, lymph nodes and liver.  For 
Immunohistology studies, the tissues were transferred to filter paper and deposited on a 
drop of Cryo-M-bed media then placed in small metal containers and rapidly frozen using 
liquid nitrogen.  They were then stored at -80oC.  For FACS studies, the spleens were 
homogenised to a single cell suspension.  Briefly, cell strainers were first wet with 1ml 
PBS then the spleen tissue was mashed through using a syringe plunger before the 
strainer was washed with 4ml PBS.  The tissue was immediately lightly fixed using 1% 
paraformaldahyde for 15 minutes before labelling.  
 
2.9.6 Immunohistology of splenic sections 
 
Sections were cut to 8µm thickness using a cryostat and allowed to dry before being 
stored at -80oC.  Following defrosting, the sections were permeabilised with acetone for 
10 minutes, air dried and washed with PBS/tween for 10 minutes.  Sections were blocked 
with 10% normal goat serum in PBS/1%BSA for 1 hour.  For metallophilic macrophage 
staining supernatant from a clone producing MOMA1 antibody directed against the 
Sialoadhesin antigen was used. The MOMA1 clone is Rat IgG2a and the supernatant was 
kindly gifted by Dr P Leenen, Dept of Immunology, Erasmus MC, the Netherlands.  The 
supernatant was diluted 1:4 in PBS with 1% BSA and 300µl/slide was used for 1 hour at 
room temperature (control sections were incubated with 1%BSA/PBS alone).  Slides 
were washed for 1 minute then 10 minutes in PBS/tween.  The secondary antibody was 
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goat anti-rat IgG TRITC (Southern Biotech, USA) and was diluted 1:200 as before.  Each 
slide was incubated with 300µl for 1 hour at room temperature.  The slides were washed 
as before.  The sections were blocked with 1% normal rat serum before the anti-B220 
AlexaFluor 647 antibody was added diluted 1:75 in 1% normal mouse serum 
(250µl/slide).  Slides were washed as before then mounted using CitiFluor mounting 
medium.   
 
For marginal zone macrophage staining, supernatant from a hybridoma producing an ER 
TR-9 antibody was used.  The ER TR-9 antibody is rat IgM and is directed against the 
marginal zone macrophage marker SIGN R1.  The supernatant was a kind gift from Dr P 
Leenen, Dept of Immunology, Erasmus MC, the Netherlands.  The protocol was the same 
as above only the supernatant was used at a 1:2 dilution and the secondary antibody was 
goat anti-rat IgM TRITC (Southern Biotech), used at 1:200 dilution. 
 
Sections were analysed using an Apotome/Zeiss microscope and Axiovision software 
with the co-localisation module.  For co-localisation studies, two sections were cut from 
each spleen and three follicles in each section were analysed. 
 
2.9.7 FACS analysis of spleen following bacterial injections 
 
Age and sex matched C57BL/6 mice were separated into three groups of three and 
injected with bacteria as before.  After 1 hour the mice were sacrificed by CO2 
suffocation and the spleens were harvested.  A single cell suspension was made and the 
cells were briefly fixed in 1% paraformaldahyde for 15 minutes then kept at 4oC.  
Collagenase was not used and cells were fixed in paraformaldahyde because pilot studies 
had shown that the cells have to be analysed very rapidly following harvesting in order to 
detect the bacteria.  The cells were counted and resuspended to 10x106/ml in FACS 
buffer.  1 million cells were transferred to each FACS tube and the cells were blocked 
with 50µl of Fc block diluted 1:200.  To facilitate better compensation of fluorophores, 
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each cell population was studied in two colour flow cytometry, that is, C. jejuni in FL1 
and the cell identifying antibody in FL4.  F4/80 biotin, CD11c biotin, GR1 APC and their 
respective isotype controls were used at 50µl of 1:100 dilution.  CD19 APC (Southern 
Biotech, USA) was used at 1:200 dilution.  MOMA1 supernatant was used at 1:4 dilution 
(secondary antibody alone served as the isotype control for MOMA1).  Following a 45 
minute incubation the cells were washed and, where appropriate, 50µl of streptavidin 
APC was added at 1:200 dilution.  For the cells labelled with MOMA1, an anti-rat IgG2a 
biotin was added at 1:200 dilution.  After a half hour incubation, the cells were washed 
and resuspended to 250µl for analysis (a final staining step was carried out on the 
MOMA1 cells using streptavidin APC as before). 
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Figure 1: Structure of E. coli LPS and C. jejuni LOS. 
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Figure 1. Diagrammatic representation of A) E. coli LPS and B) C. jejuni LOS (mimicking ganglioside 
GM1).   KDO – 3-deoxy-D-manno-octulosonic acid; HGlcN3N - 2,3-diamino-2,3-dideoxy-D-glucose; Hep 
- L-glycero-D-manno heptose; Glc – glucose; PEA – phosphorylethanolamine; Gal – galactose; GalNac - 
N-acetylgalactosamine and  P – phosphate.  Numbers represent length of acyl chain. 
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3 Isolation and purification of C. jejuni LOS 
 
3.1 Introduction 
 
The aims of the experiments presented in this chapter are to purify LOS from C. jejuni, 
eliminate contamination, confirm ganglioside mimicry and accurately quantify the LOS.  
This will allows us to address one of the central hypotheses of the thesis; that the 
ganglioside mimicking epitopes found on the LOS molecules of GBS associated strains 
of C. jejuni alter the immunostimulatory properties of the LOS. 
 
Bacterial LPS is found in the outer membrane of gram negative bacteria102.  LPS is a 
glycolipid molecule that is classically considered as three covalently linked sections 
103,104: the hydrophobic Lipid A, the core oligosaccharide and the hydrophilic antigenic 
O-side chain.  The Lipid A usually consists of a diglucosamine backbone with attached 
fatty acyl chains which show inter- and intra-species variability in length and 
substitution.  Lipid A determines endotoxicity102,111,210,211.  The inner core 
oligosaccharide contains bacterial specific sugars such as 3-deoxy-D-mano-octulosonic 
acid (KDO), while the outer core contains hexoses and hexosamines.  The O-side chain 
consists of repeating saccharide units102.  GBS associated C. jejuni synthesise a truncated 
O-side chain. The resultant molecule, which is essentially Lipid A with attached core 
sugars, is termed lipo-oligosaccharide (LOS).  Figure 1(A) illustrates the structure of a 
“smooth” mutant E. coli LPS with an extended O-side chain and figure 1(B) shows a 
“rough” mutant C. jejuni LOS with a truncated O-side chain.  
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Figure 2: Structures of HS O:19 and HS O:3 C. jejuni LOS. 
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Figure 2.  Diagrammatic representation of the LOS structures of the ganglioside mimicking C. jejuni strain 
HS O:19 and non-mimicking strain HS O:3.  HS O:19 produces GM1 and GD1a mimicking LOS in 
equimolar amounts. KDO – 3-deoxy-D-manno-octulosonic acid; HGlcN3N - 2,3-diamino-2,3-dideoxy-D-
glucose; Hep - L-glycero-D-manno heptose; Glc – glucose; PEA – phosphorylethanolamine; Gal – 
galactose; GalNac - N-acetylgalactosamine,  P – phosphate, Cer – ceramide, GlcNAc – N-
acetylglucosamine and DdGlc – dideoxyglucose. 
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The initial experiments described in this chapter use two strains of C. jejuni from the 
clinical bacteriology departmental collection of C. jejuni at the Southern General 
Hospital, Glasgow.  HS O:19 is a GBS associated strain in which the LOS molecules 
mimic gangliosides GM1 and GD1a at a 50:50 ratio202 while HS O:3 is not associated 
with GBS and does not mimic gangliosides203.  Both LOS structures are illustrated in 
figure 2. 
 
For later experiments, through collaboration with Erasmus University, Rotterdam, 
additional useful strains of C. jejuni were used and were supplied as both the parent 
organism (GB11 and GB2 wild type and CSTII knock out) and as purified LOS (GB11, 
GB2 and GB19 wild type and CSTII knock out)101.  GB11 and GB2 both mimic 
gangliosides GM1 and GD1a in equimolar amounts.  Isogenic knock-out mutants were 
created lacking the sialyltransferase gene (CSTII) which attaches sialic acid to the core 
sugars.  These strains produce three asialo-sugars as part of their internal core sugar 
(structures illustrated in figures 3 (A) and 3 (B)) and do not mimic gangliosides. At least 
two of their core sugars mimic other self glycolipids.  Importantly, within the isogenic 
strains, all other structures in the bacteria and LOS (including Lipid A) are predicted to 
be identical.  GB19 (as distinct from HS O:19) mimics ganglioside GD1c and no 
information is available about the structure of the CSTII knock out mutant. 
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Figure 3(A): Structures of GB2 and GB11 wild type C. jejuni LOS. 
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Figure 3 (A).  Diagrammatic representation of the structures of the LOS molecules purified from the GB2 
and GB11 wild type strains of C. jejuni as well as the gangliosides that they mimic.  Each LOS molecule is 
produced by the bacteria in equimolar amounts (i.e. 50:50 ratio). KDO – 3-deoxy-D-manno-octulosonic 
acid; HGlcN3N - 2,3-diamino-2,3-dideoxy-D-glucose; Hep - L-glycero-D-manno heptose; Glc – glucose; 
PEA – phosphorylethanolamine; Gal – galactose; GalNac - N-acetylgalactosamine,  P – phosphate, Cer – 
ceramide.  
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Figure 3(B): Structures of GB2 and GB11 CSTII knock out C. jejuni LOS. 
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Figure 3 (B).  Diagrammatic representation of the structures of the LOS molecules purified from the GB2 
and GB11 CSTII knock out strains of C. jejuni as well as the asialo-sugars that they mimic.   Percentages 
indicate the proportion of each LOS molecule produced by the bacteria. KDO – 3-deoxy-D-manno-
octulosonic acid; HGlcN3N - 2,3-diamino-2,3-dideoxy-D-glucose; Hep - L-glycero-D-manno heptose; Glc 
– glucose; PEA – phosphorylethanolamine; Gal – galactose; GalNac - N-acetylgalactosamine,  P – 
phosphate, Cer – ceramide. 
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Figure 4: Silver stain analysis of hot phenol extracted LOS. 
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Figure 4.  SDS-PAGE and silver stain of hot phenol extracted LOS. (A) C. jejuni LOS. (B)  Smooth mutant 
E. coli LPS.  Each lane contained 5µg of LOS (the blank spacer lane contained dH2O). 
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3.2 Results 
 
3.2.1 Hot phenol extraction of C. Jejuni LOS and assessment of purity 
 
C. jejuni were grown for 48 hours at 37oC in a microaerobic environment on Columbia 
Agar and Horse Blood plates, harvested into PBS and heat inactivated at 60oC for 1 hour.  
These bacteria were used as a source for LOS which was extracted using the hot-phenol-
water technique.  The resultant product was analysed by SDS-PAGE and silver stain to 
assess purity and mass. 
 
Figure 4 (A) shows that there are distinct high molecular weight bands in the silver stain 
of the LOS which indicates contamination (the spacer lane with dH2O shows no such 
contamination).  This contamination is likely to be protein or nucleic acids212-214.  There 
is a distinct band at 4kDa which is the expected mass of LOS.  Figure 4 (B) shows a 
silver stain of smooth mutant E. coli LPS demonstrating the ladder pattern produced by 
LPS molecules with differing lengths of O-side chain which contrasts with the single 
mass of rough mutant LOS.  
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Figure 5: Photograph of LOS solution following enzyme treatment. 
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Figure 5.  Photographs of LOS purified in enzyme buffer using DNase, RNase, lysozyme and Proteinase K.    
(A) Photograph of the settled precipitate. (B) Photograph the opaque colloid solution after agitation.  
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3.2.2 Purification of hot phenol extracted LOS 
 
To obtain a purified sample of LOS it was necessary to remove the contaminating 
DNA/RNA, glycolipids and protein.  To do this hot phenol extracted LOS was treated 
with DNase, RNase, lysozyme and Proteinase K. 
 
LOS was resuspended in enzyme buffer (0.1M TrisHCL, 5mM CaCl2 and 5mM MgCl2. 
pH 7.5) and the enzymes added sequentially.  The enzyme buffer was derived from LPS 
purification protocols215 using suggested cation concentrations from the enzyme product 
data sheets.  Although the LOS solution was initially clear, the addition of lysozyme 
caused a precipitate to form which came out of suspension and settled in the universal.  
Figure 5 (A) and 5 (B) show photographs of the LOS solution containing the settled 
precipitate and the precipitate in a colloid suspension following vortexing. 
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Figure 6: Silver stain analysis of LOS precipitate. 
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Figure 6.  SDS-PAGE and silver stain of HS O:3 LOS precipitate and supernatant. The precipitate shows a 
continuous smear with no distinct bands.  The clear supernatant resolves into two distinct bands, one of 
which is double the mass of the other. 
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3.2.3 Assessment of purity and determination of the nature of the 
precipitate 
 
SDS-PAGE and silver staining was used to analyse the precipitate and the supernatant 
(5µg of each).  Figure 6 shows that the precipitate consists of a continuous smear of 
material with the staining characteristics of LOS and that there are no distinct bands of 
contamination like those seen in figure 4 (A).  The supernatant also contains LOS 
although it resolves into two bands, one at 8kDa and one at 4kDa. 
 
The two bands produced by the supernatant in lane 3 were interpreted to represent single 
LOS molecules (4kDa) and LOS “dimers” (8kDa).  These dimers probably consist of two 
LOS molecules held together, tail to tail, by hydrophobic interactions (illustrated in figure 
16 (B)).  
 
In order to test this hypothesis, HS O:19 LOS was subjected to SDS-PAGE and Western 
blotting.  HS O:19 produces two LOS molecules in equimolar amounts, one mimicking 
ganglioside GM1 and the other mimicking ganglioside GD1a.   The Western blot was 
labelled using cholera toxin (to identify GM1) and MOG35 monoclonal antibody (to 
identify GD1a). 
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Figure 7: Western blot analysis of ganglioside mimicking LOS epitopes. 
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Figure 7.  SDS-PAGE, Western blot and silver stain of HS O:19 and HS O:3 LOS demonstrating 
ganglioside epitopes. (A) Labelled with cholera toxin (binding GM1 epitope) and (B) Labelled with 
MOG35 mAb (binding GD1a epitope). (C) Loading control showing a silver stain of a gel run in parallel to 
(A) and (B). 
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The Western blot in Figure 7 shows that both epitopes (GM1 and GD1a) are present in 
both the 4kDa and 8kDa bands.  This is consistent with LOS dimers being responsible for 
the 8kDa band. In addition, the HS O:3 strain only produces a single LOS species and yet 
silver staining resolves into two bands (figure 6) consistent with an LOS homodimer. 
 
The continuous smear produced by the precipitate was interpreted to represent 
incompletely fragmented lamellar LOS macro-structures. Such structures form in solution 
as a consequence of the amphipathic nature of LOS. They are held together by lateral 
electrostatic interactions and bilayer hydrophobic interactions (illustrated in figure 16 
(A)).  The smear indicates that they were incompletely separated by the electrophoresis 
process.   
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Figure 8: Silver stain analysis of LOS following micelle dispersal. 
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Figure 8.  SDS-PAGE and silver stain of HS O:3 LOS or HS O:3 LOS treated with EDTA and Triton X 
detergent. (A) LOS prior to treatment.  (B) The same LOS sample after treatment.  
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3.2.4 Control of macro-molecular structures 
 
Macro-molecular structures, such as micelles and lamellar sheets, can potentially 
influence LPS activity and so it was decided to regulate their formation. 
 
Eliminating lysozyme from the protocol prevented the formation of the settled 
precipitate.  However, the LOS continued to from a stable opaque colloidal solution 
which resolved into double bands following SDS-PAGE and silver stain (figure 8 (A)).  
The opaque appearance of the solution and the dual band on silver stain were interpreted 
to represent continued aggregation into macro-molecular structures.   
 
LOS was subjected to treatment to disperse the macromolecular structures.  This was 
done by altering the pH (titration of NaOH), removing cations (addition of EDTA) or 
adding detergents.  A combination of treatments (EDTA with Triton X detergent) caused 
a visual dispersal of the colloid solution.  SDS-PAGE and silver stain of the treated LOS 
(figure 8, (B)) shows that it resolves into a single band of approximately 4kDa.  The LOS 
solution in figure 8 (A) was an opaque colloid solution while the solution in figure 8 (B) 
was clear. This confirms that double bands seen by silver stain correspond with macro-
molecular structures in the LOS and that these are visible as an opaque colloid solution.  
The clarification of the solution allowed spectrophotometry to be carried out on the LOS 
and no DNA, RNA or protein was detected.   
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Figure 9: Western blot analysis of LOS epitopes following neuraminidase treatment. 
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Figure 9.  SDS-PAGE, Western blot and silver stain of HS O19, HS O:3 and neuraminidase treated HS 
O:19 LOS demonstrating ganglioside mimicking epitopes.  (A) Shows all three strains incubated with 
cholera toxin (binds GM1 epitope). (B) Shows all three strains incubated with MOG35 mAb (binds GD1a 
epitope).  Cholera toxin labels HS O:19 and neuraminidase treated HS O:19 while MOG35 only labels HS 
O:19. (C)  Loading control showing a silver stain of a gel run in parallel to the gels used in (A) and (B). 
(These samples had not been pre-treated with detergent/EDTA). 
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3.2.5 Generation of a control strain of LOS and confirmation of 
ganglioside mimicking epitopes  
 
Intra-species differences in the structure of LOS Lipid A may alter LOS potency.  HS 
O:19 LOS was treated with cholera neuraminidase to remove sialic acid and provide a 
control strain with an identical Lipid A but without ganglioside mimicry.  
 
A Western blot was carried out, using cholera toxin and MOG35, in order to confirm the 
ganglioside mimicry of HS O:19, the non-mimicry of the neuraminidase treated HS O:19 
and the non-mimicry of HS O:3.  Figure 9 (A) and (B) confirms that HS O:19 LOS 
mimics ganglioside GM1 and GD1a respectively.  HS O:3 LOS does not mimic either of 
these gangliosides.  However, neuraminidase treated HS O:19 LOS continues to mimic 
GM1 (figure 9(A)) but no longer mimics GD1a (figure 9(B)).   
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Figure 10: Silver stain analysis of enzyme purified LOS. 
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Figure 10.  SDS-PAGE and silver stain of new strains of LOS, purified in Milli-Q. 5µg of LOS loaded per 
well.  
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3.2.6 Isolation and purification of GB11 wild type, GB11 CSTII knock 
out, GB2 wild type and GB2 CSTII knock out LOS 
 
New strains of C. jejuni were provided by collaborators as both the parent organism and 
as pre-purified LOS.  Isolation and purification was done using an identical protocol with 
the exception that Milli-Q distilled and deionised H2O was used at all steps of the 
procedure in place of enzyme buffer.  Silver stain was carried out on the LOS to establish 
if the new protocol successfully removed impurities.  Figure 10 shows that there is no 
evidence of impurities using silver stain, indicating that the purification enzymes 
remained active in the absence of calcium and magnesium.  In addition, the LOS formed 
a clear solution and resolved primarily into a single band.  All subsequent purifications 
used this protocol. 
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Figure 11: Alcian blue and silver stain analysis of purified LOS and whole cell lysate. 
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Figure 11.  SDS-PAGE with alcian blue and silver stain of a whole cell lysate of GB2 C. jejuni and purified 
GB2 LOS (5µg of each). (A) Shows alcian blue stain and (B) shows silver stain.   
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3.2.7 Detection of capsular polysaccharide contamination 
 
Capsular polysaccharide (CPS) is a glycolipid molecule with similar chemical properties 
to LOS and LPS.  Although steps were taken to eliminate nucleic acid and protein 
contamination, no precautions had been taken to eliminate CPS.  CPS can potentially 
signal through TLR2216 which would result in inaccurate measurements of LOS potency.  
LOS was tested for CPS contamination using an alcian blue stain.  A positive control was 
generated using whole cell C. jejuni lysate.  Figure 11(A) shows the alcian blue stain of 
the LOS and whole cell lysate and figure 11(B) shows the silver stain.  In the lanes 
containing cell lysate, there is a faint band of alcian blue staining at 45kDa which is the 
reported mass of C. jejuni CPS217.  There are additional bands at 65kDa (consistent with 
flagellum) and 4kDa (consistent with LOS).  In the lanes containing purified LOS there is 
a single LOS band at 4kDa.  No contaminating CPS is detected in the purified LOS. 
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Figure 12: Western blot analysis of gangliosides mimicry by GB11 and GB2 LOS. 
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Figure 12.  SDS-PAGE and Western blot of GB11 and GB2 strains of LOS demonstrating ganglioside 
mimicry. 5µg of LOS was used in each well. (A) shows membrane incubated with cholera toxin (specific 
for GM1 epitope) and (B) membrane incubated with MOG35 mAb (specific for GD1a epitope).   
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3.2.8 Confirmation of GM1 and GD1a epitopes on GB11 and GB2 wild 
type LOS. 
 
GB11 and GB2 wild type LOS are reported to mimic gangliosides GM1 and GD1a at a 
50:50 ratio.  SDS-PAGE and Western blot was carried out to confirm the ganglioside 
mimicry.  Figure 12 shows that GB11 and GB2 wild type LOS mimic gangliosides GM1 
and GD1a and that the CSTII knock out LOS strains do not mimic these gangliosides.  
GB19 LOS is reported to mimic GD1c and as expected does not label with cholera toxin 
or MOG35.  The Western blot also confirms that the LOS resolves primarily into a single 
4kDa band although very weak labelling was present at 8kDa. 
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Figure 13: LOS concentration determined by thiobarbituric acid assay. 
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Figure 13.  Concentration of LOS determined using the thiobarbituric acid assay.  There is a significant 
difference in LOS concentration (p<0.001) between GB11 wild type and knock out, and GB19 wild type 
and knock out.  Mean and SEM calculated from triplicate tubes with Students two tailed t test.  Experiment 
repeated twice. 
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3.2.9 Determination of LOS concentration by thiobarbituric acid assay 
 
In all experiments described above, LOS was quantified by dry weight following 
lyophilisation.  The thiobarbituric acid assay was used to confirm the concentration and 
ensure that wild type and CSTII knock out strains were equimolar.  The thiobarbituric 
acid assay measures the concentration of KDO, a core sugar unique to bacteria.  Figure 
13 shows the concentration of GB11, GB2 and GB19 wild type and CSTII knock out 
LOS.  There is a statistically significant difference (p<0.001) in the concentration of 
GB11 wild type and GB11 CSTII knock out strains as well as the GB19 wild type and 
GB19 CSTII knock out strains.  In both cases the sialylated strains are more concentrated.  
The GB2 wild type and CSTII knock out strains are equimolar. 
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Figure 14: Thiobarbituric acid assay of GM1 and sialic acid. 
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Figure 14.  Thiobarbituric acid assay of native GM1 and native sialic acid.  There is an increase in OD549 
for both molecules. Mean and SEM calculated from triplicate tubes.  Single experiment.  
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3.2.10 Assessment of the validity of the thiobarbituric acid assay 
 
A potential cause for the difference in molarity is interference in the assay.  Sialic acids 
are 2-keto-3-deoxy sugars which are similar in structure to KDO.  To test whether sialic 
acid in the ganglioside mimicking LOS is interfering with the thiobarbituric acid assay, 
native GM1 ganglioside and native sialic acid molecules were used as substrates in the 
assay.  Figure 14 shows that both GM1 and sialic acid cause an increase in absorbance at 
OD549 in the thiobarbituric acid assay.   
 
A second experiment was carried out to determine if sialic acid makes a significant 
contribution to the colour change when compared to KDO.  Native KDO molecules and 
native sialic acid molecules were used in the thiobarbituric acid assay.  Figure 15 (note 
that the graph x and y axes have been reversed) indicates that an approximately four 
times greater concentration, by molarity, of sialic acid is required to produce the same 
absorbance at OD549 as KDO.  Sialic acid and KDO exist in LOS at a 1.5:1 ratio in 
GB11 and GB2 LOS strains. 
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Figure 15: Thiobarbituric acid assay of KDO and sialic acid. 
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Figure 15.  Thiobarbituric acid assay of native KDO and native sialic acid comparing potency in inducing 
colour change at OD 549.  (Note that the graph x and y axes have been reversed).  Single experiment. 
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3.3 Discussion 
 
The principal concerns when isolating LOS were purity, ganglioside mimicry and 
accurate quantification.  The additional issue of secondary structures (how the LOS 
molecules associate with each other in solution) became apparent during the purification 
process. 
 
The technique of isolating LPS or LOS using hot phenol and water has been described 
previously218.  This involves disrupting bacterial cells in a hot water phenol mix and 
allowing the LOS to partition into the aqueous phase while cooling the mixture.  This 
method is not entirely specific as it relies solely on the relative solubility of the LOS for 
separation from other constituents.  Bacteria contain a number of immunostimulatory 
molecules such as proteins, glycolipids and DNA/RNA, all of which can be sources of 
contamination.  There are a number of variations of this technique optimised for different 
types of LPS.  My particular technique was chosen because the major studies on the 
structure on C. jejuni LOS have used the basic hot phenol technique to extract LOS202,203.  
 
My initial studies show that hot phenol extraction of LOS does not yield a pure product.  
The use of DNase, RNase and Proteinase K in an appropriate enzyme buffer to remove 
contamination is an established technique219 and this was employed to improve purity.  
SilverXpresstm staining is exquisitely sensitive for proteins (detecting sub-nanogram 
quantities) and DNA (detecting nanogram quantities).  SilverXpresstm staining detected 
no evidence of contamination in LOS purified using the final protocol.  In support of this, 
after LOS solutions had been clarified using detergent and EDTA, biophotometry 
detected no evidence of DNA, RNA or protein.   
 
Lysozyme was initially used to remove CPS.  However, lysozyme caused a precipitate to 
form which was interpreted as the formation of LOS lamellar macro-structures.  Studies 
have shown that lysozyme interacts electrostatically with phosphate groups on the Lipid 
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A in Re (rough mutant) LOS causing increased rigidity of the acyl chains which affects 
the LOS aggregate structures220.  This is a likely explanation for my observations of 
precipitate formation, although changes in the pH or ionic concentration of the solution 
might also account for this.  For this reason it was decided to eliminate lysozyme from 
the protocol.  Capsular polysaccharide produced by C. jejuni is detectable using alcian 
blue staining217.  LOS purified without lysozyme was tested by this method. No evidence 
of CPS is seen in the LOS while a band at the expected molecular mass was visible in the 
whole cell lysate positive control.  Based on these findings it was concluded that CPS is 
either absent or present at levels below the limits of the alcian blue assay sensitivity. 
 
The structures of LOS molecules produced by HS O:19, HS O:3, GB11 wild type, GB2 
wild type, GB11 CSTII knock out and GB2 CSTII knock out have been 
established101,202,203.  Western blot analysis using reagents directed against gangliosides 
GM1 and GD1a confirms the expected ganglioside mimicry and shows no evidence of 
such mimicry in the control strains.  An attempt was made to produce an additional 
control strain for HS O:19 by treating the LOS with cholera neuraminidase.  However, 
this resulted in the GD1a epitopes being converted to GM1 which can be explained by 
the fact that cholera neuraminidase is only active against external sialic acids221,222.  
Additional neuraminidase enzymes capable of cleaving internal sialic acids, such as 
Arthrobacter ureafaciens sialidase223, could have been used alongside cholera 
neuraminidase to completely remove all sialic acid residues. 
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Figure 16: Diagram of LOS macromolecular structures. 
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Figure 16.  Diagrammatic representation illustrating potential macro-molecular LOS structures.  (A) 
represents a lamellar bilayer.  (B) shows a “dimer” structure comprising GM1 and GD1a mimicking LOS 
molecules linked by hydrophobic bonds. (C) shows a monolayer micelle. 
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LPS is an amphipathic molecule consisting of a hydrophobic tail and hydrophilic head.  
In aqueous solutions LPS spontaneously forms a variety of macro-molecular structures224-
226
. These include lamellar bilayers, micelle bilayers, single layer micelles and dimer 
structures102 (illustrated in figure 16).  The precise nature of these macro-molecular 
structures depends on a variety of factors including LPS concentration, ionic 
concentration, pH and temperature.  LOS is more hydrophobic than LPS and has a greater 
tendency to form these structures.  Divalent cations, required for activity of the DNase227, 
RNase228 and Proteinase K229, increase the tendency for such structures to form.  A 
number of different purification protocols were tested to try and prevent colloid 
formation and these included varying the pH and cation concentrations. 
 
Macromolecular structures are a concern because several studies report aggregated LPS 
to be more potent than monodisperse LPS230-232 and aggregate dependent differences in 
mAb binding to LPS have been demonstrated232.  This means that important epitopes 
might be hidden by secondary structures, for example ganglioside availability for 
antibody binding can be influenced by neighbouring gangliosides233.  To allow a 
comparison of potency of the ganglioside mimicking versus non-mimicking strains 
without the confounding influence of aggregate effects, it was decided to regulate the 
micelle structures.  Micelles could be dispersed by treating the colloidal LOS with EDTA 
and detergent and dispersal was confirmed by changes in the silver staining properties.  
However, EDTA and detergent proved difficult to remove by dialysis. 
 
New strains of C. jejuni and LOS were provided by a collaborating group.  In addition to 
eliminating potential differences in the Lipid A, the GB2, GB11 and GB19 strains of 
LOS were purified using a procedure that omitted divalent cations and minimised micelle 
formation.  Tests of LOS purity under these alternative conditions confirmed that the 
DNase, RNase and proteinase remained effective in removing contamination.  
Presumably residual cations chelated by the LOS were available to activate the enzymes.  
The visual appearance of the LOS and the resolution of the LOS into a mainly single 
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band by SDS-PAGE and silver stain indicate that the omission of divalent cations at all 
stages of purification provides a simple solution to colloidal aggregate formation. 
 
It was noted that the bands formed by silver staining of these LOS strains showed 
variations in size and intensity.  It is thought that silver staining binds to the carbohydrate 
rather than the lipid portion of LPS/LOS234,235.  Therefore differences in staining intensity 
are probably due to differences in the carbohydrate structure of wild type and knock out 
LOS rather than differences in concentration. 
 
The LOS was quantified using a combination of dry weight and the thiobarbituric acid 
assay.  This chemical assay relies on the cleavage of a diol grouping in 3 deoxy-D-
manno-oct-2-ulosonic acid (KDO) which is a unique sugar found in the LOS/LPS core 
region.  This releases a derivative which reacts with thiobarbituric acid to produce a 
chromophore236.  LOS concentration is determined by comparing to a known 
concentration of KDO.  The initial assay shows that wild type and knock out strains of 
LOS are not equimolar.  There are a number of potential explanations including 
inaccuracy in the dry weight, differences in molecular mass and inaccuracy of the KDO 
assay. 
 
Variants of the thiobarbituric acid assay are used to measure sialic acid.  Due to 
differences in the chemical structure of these molecules, sialic acid requires harsher acid 
treatment in order to contribute to colour change in this assay236.  Several variations of 
this assay were tested and the least harsh protocol was employed to measure the LOS.  
However, both free sialic acid and GM1 causes a colour change using my protocol, 
confirming inaccuracy in the KDO assay. 
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A further attempt at quantification was done using the Limulus Ameobocyte Assay 
although due to its exquisite sensitivity it was found to be impractical.  Quantification 
was therefore done using dry weight alone as this was considered the most convenient 
and reliable method of quantification.  It is recognised that this does not take into account 
differences in molecular mass. 
 
In conclusion, I have purified LOS to such a degree that no contamination can be 
demonstrated using standard detection techniques.  I have verified that my LOS strains 
either mimic or do not mimic gangliosides as predicted.  In addition, I have shown that 
the thiobarbituric acid assay is unreliable for quantifying sialylated LOS and concluded 
that dry weight is the most suitable alternative.  There is no evidence of differences in 
macromolecular structures between the wild type and knock out strains although I have 
not shown this definitively.  Overall, I judge the LOS to be suitable for testing my 
hypotheses. 
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4 Interaction of ganglioside mimicking LOS and whole C. 
jejuni with ganglioside specific cellular receptors and 
complement components 
 
4.1 Introduction 
 
The aim of the experiments presented in this chapter is to establish if the ganglioside 
mimicking side chain of LOS can act as a ligand for cellular receptors and complement 
proteins which are believed to bind to endogenous gangliosides. 
 
The pathophysiology of GBS is thought to involve the generation of LOS specific 
antibodies that cross react with gangliosides on self-cells resulting in autoimmune 
damage40,237.  This model of pathogenesis relies on gangliosides substituting for 
ganglioside mimicking LOS as a target for antibodies and this cross-reactivity has been 
confirmed238,239.  I wish to establish if ganglioside mimicking LOS can substitute for 
gangliosides as a ligand for immune system receptors. 
 
A number of ganglioside binding cellular receptors are known. The best characterised 
family of receptors are siglecs (sialic acid binding immunoglobulin like lectins)144,146,240. 
The precise specificities and physiological roles of these receptors are still being 
investigated.  It has been shown that Siglec 7 binds to GT1a/GM1 mimicking C. jejuni 
and its purified LOS148.  The myeloid expressed mouse siglecs, Sialoadhesin, Siglec E 
and Siglec F, are predicted to bind to GD1a/GM1 mimicking C. jejuni and its LOS 
although this has not yet been confirmed experimentally.  (See Appendix 3 and 4 for 
siglec structure, cellular expression and binding profiles). 
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The complement regulatory protein Factor H has a sialic acid binding site241,242.  Factor H 
inhibits the alternative complement pathway and this protects self-cells from aberrant 
complement activation241.  Non-campylobacter pathogens are thought to use sialylation 
and fH binding to enhance complement resistance243-245.  It has not been established if 
ganglioside mimicry by C. jejuni facilitates fH binding or if this affects complement 
activation on GBS associated strains. 
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Figure 17: Sialoadhesin binding to whole C. jejuni. 
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Figure  17.  Sialoadhesin-Fc fusion protein binding to whole C. jejuni.  (A) whole GB11 wild type and 
GB11 knock out C. jejuni and (B) whole HS O:19 and HS O:3 C. jejuni. There is statistically significant 
binding of Sialoadhesin to ganglioside mimicking strains of C. jejuni (GB11 wild type and HS O:19) 
compared to their control strains (GB11 knock out and HS O:3) at each concentration of Sialoadhesin 
tested (A and B).  Mean and SEM calculated from triplicate wells.  Significance compares binding to 
ganglioside mimicking and control strain at each Sialoadhesin concentration using 2way ANOVA with 
Bonferroni’s post tests (*=p <0.05, ***p= <0.001). Graphs representative of 3 experiments.   
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4.2 Results 
 
4.2.1 Sialoadhesin binding to C. jejuni.  
 
Murine Sialoadhesin-human-Fc fusion protein binding to whole, formalin fixed, C. jejuni, 
pre-adsorbed onto ELISA plates, was measured.  Figures 17 (A) and (B) show that 
Sialoadhesin binds to both of the ganglioside mimicking strains (GB11 wild type (A) and 
HS O:19 (B)).  Sialoadhesin does not bind to the non-mimicking control strains (GB11 
knock out (A) and HS O:3 (B)).  The difference in binding between ganglioside 
mimicking strains and control strains is statistically significant (GB11 wild type v knock 
out: p<0.001 at 1µg/ml and 0.5µg/ml, p<0.05 at 0.25µg/ml.  HS O:19 v HS O:3: p<0.001 
at 1, 0.5 and 0.25µg/ml).  
 
Sialoadhesin is predicted to bind GD1a and GT1b.  Sialoadhesin binding to gangliosides 
and ganglioside mimicking LOS was assessed using ELISA.  The target gangliosides 
tested were GM1, GD1a and GT1b, and the asialo-glycolipids were asialo-GM1, asialo-
GM2 and lactosyl ceramide (the core components of GB11 knock out C. jejuni LOS).  
Sialoadhesin binding to GB11 wild type and knock out LOS, and HS O:19 and HS O:3 
LOS was also assessed.  No Sialoadhesin binding was detected to any of these targets 
(data not shown). 
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Figure 18: Immunocytometry of Sialoadhesin binding to C. jejuni. 
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Figure 18.  Immunocytometry of Sialoadhesin binding to C. jejuni.  (A) DAPI labelled HS O:19.  (B) HS 
O:19 labelled with Sialoadhesin-Fc fusion protein and anti-human IgG FITC.  (C) Merge of (A) and (B).  
Inset is digital magnification of (C); arrow shows punctate staining of the bacteria.  (D)  Control 1 – 
merged image of DAPI labelled HS O:19 and anti-human IgG FITC (secondary Ab only). (E) Control 2 – 
merged image of DAPI labelled HS O:3 with Sialoadhesin-Fc fusion protein and anti-human IgG FITC.  
Single experiment. 
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4.2.2 Visualisation of Sialoadhesin binding to C .jejuni 
 
Sialoadhesin was found to bind whole bacteria but not the LOS or native ganglioside.  It 
was decided to confirm the binding specificity by using Sialoadhesin to fluorescently 
label the bacteria.  Formalin fixed C. jejuni were adsorbed onto slides and labelled with 
Sialoadhesin-Fc fusion protein pre-complexed with anti-human IgG FITC labelled 
antibodies.  The DNA binding fluorophore DAPI was used to localise the bacteria.  Two 
test strains were chosen, HS O:19 and HS O:3, both of which are wild type strains of C. 
jejuni which mimic and do not mimic gangliosides respectively.  Figure 18 (A) shows 
DAPI labelled HS O:19 C. jejuni.  Figure 18 (B) shows Sialoadhesin labelled HS O:19 C. 
jejuni. Figure 18 (C) shows the merged and digitally magnified image which confirms 
that the Sialoadhesin binding is associated specifically with the bacteria.  Interestingly, 
the Sialoadhesin appears to show a punctuate pattern of staining (white arrow) which is 
often localised to one or both poles of the bacterium.  In addition, not all of the bacteria 
were labelled with Sialoadhesin.  Figures 18 (D) and (E) show the secondary antibody 
alone and Sialoadhesin labelling of the HS O:3 strain respectively.  These show no 
detectable binding.  These controls confirm the specificity of Sialoadhesin binding. 
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Figure 19: Sialoadhesin binding to C. jejuni following neuraminidase treatment. 
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Figure 19.  Effect of removal of GD1a on Sialoadhesin binding.  (A) ELISA showing GM1 specific mAb 
DG2 binding to C. jejuni.  There is a statistically significant increase in binding to HS O:19 C. jejuni 
following neuraminidase treatment.  (B) ELISA showing Sialoadhesin binding to neuraminidase treated C. 
jejuni.  Sialoadhesin binding to HS O:19 is completely obliterated by neuraminidase treatment.  Mean and 
SEM calculated from triplicate wells and analysed using students 2 tailed t test (***=p<0.001).  Single 
experiment. 
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4.2.3 Confirmation of Sialoadhesin binding to the GD1a epitope 
 
In order to confirm that Sialoadhesin was binding to the GD1a epitope, HS O:19 and HS 
O:3 whole C. jejuni were treated with cholera neuraminidase.  The experiment in chapter 
3.2.5 (figure 9) demonstrates that cholera neuraminidase cleaves the external sialic acid 
on LOS and converts GD1a to GM1.  The prediction is that neuraminidase treatment will 
result in an increase in GM1 epitopes on the surface of HS O:19 bacteria and a decrease 
in GD1a with a subsequent decrease in Sialoadhesin binding.  Figure 19 (A) shows 
binding of the GM1 specific mAb DG2 to HS O:19 and HS O:3 before and after 
neuraminidase treatment.  As expected, there is a significant (p<0.001) increase in DG2 
binding following neuraminidase treatment of HS O:19, which is consistent with an 
increase in GM1 epitopes.  There is no DG2 binding to HS O:3.  Figure 19 (B) shows 
Sialoadhesin binding to HS O:19 and HS O:3 before and after neuraminidase treatment.  
Neuraminidase treatment completely abrogates Sialoadhesin binding to HS O:19 
(p<0.001)  consistent with a loss of the GD1a epitope.  There is no binding to the HS O:3 
control strain.  This experiment confirms that GD1a mimicry is necessary for 
Sialoadhesin binding.  
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Figure 20: Siglec F binding to gangliosides, LOS and C. jejuni. 
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Figure 20.  ELISAs measuring Siglec F-Fc fusion protein binding to (A) glycolipids (Siglec F used at 
1µg/ml); (B) LOS from GB11 wild type and knock out strains of C. jejuni; (C) LOS from HS O:19 and HS 
O:3 strains of C. jejuni; (D) whole GB11 wild type and GB11 knock out C. jejuni and (E) whole HS O:19 
and HS O:3 C. jejuni. Siglec F shows statistically greater binding to gangliosides GD1a and GT1b when 
compared to ganglioside GM1 and the asialo-sugars (A).  Siglec F shows significantly greater binding to 
ganglioside mimicking LOS (GB11 wild type and HS O:19) when compared to the non-mimicking 
counterparts (GB11 knock out and HS O:3) (B and C) . In addition, there is significantly greater binding of 
Siglec F to ganglioside mimicking strains of whole C. jejuni compared to their control strains at each 
concentration of Siglec F tested (D and E). Mean and SEM calculated from triplicate wells.  Significance 
compares Siglec F binding to GD1a and GT1b compared to each other glycolipid using 1way ANOVA and 
Bonferroni’s multiple comparison post test (A). Significance compares binding to ganglioside mimicking 
and control strain at each Siglec F concentration using 2way ANOVA with Bonferroni’s post tests (B to E) 
(*=p<0.05, ***=p<0.001).  Graphs representative of 3 experiments. 
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4.2.4 Siglec F binding to gangliosides, LOS and C. jejuni  
 
Siglec F binding to glycolipids was assessed by ELISA.  In contrast to Sialoadhesin, 
figure 20 (A) demonstrates that Siglec F (used at 1µg/ml) can bind to native gangliosides.  
Comparing GD1a and GT1b to the other glycolipids, the difference in binding is 
statistically significant (p<0.001) with no difference between GD1a and GT1b 
themselves.  Siglec F binding to GD1a mimicking LOS was tested by comparing 
ganglioside mimicking LOS to control strains.  Figures 20 (B) and (C) show significantly 
greater binding of Siglec F to the ganglioside mimicking strains GB11 wild type and HS 
O:19 respectively compared to the control strains GB11 knock out and HS O:3 (p<0.001 
at 1µg/ml and 0.5µg/ml, p<0.05 at 0.1µg/ml).  This dose dependent effect indicates 
specific binding.  Finally, Siglec F binding to whole, formalin fixed, C. jejuni was 
assessed.  Figures 20 (D) and (E) show statistically greater binding of Siglec F to 
ganglioside mimicking strains (GB11 wild type and HS O:19 respectively) than to their 
relevant control strains (p<0.001 over the complete range of concentrations). 
 115 
Figure 21: Immunocytometry of Siglec F binding to C. jejuni. 
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Figure 21.  Immunocytometry of Siglec F binding to C. jejuni.  (A) DAPI labelled HS O:19.  (B) HS O:19 
labelled with Siglec F-Fc fusion protein and anti-human IgG FITC.  (C) Merge of (A) and (B).  Inset digital 
magnification of (C).  (D)  Control 1 – merged image of DAPI labelled HS O:19 and anti-human IgG FITC 
(secondary Ab only). (E) Control 2 – merged image of DAPI labelled HS O:3 with Siglec F-Fc fusion 
protein and anti-human IgG FITC.  Single experiment. 
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4.2.5 Visualisation of Siglec F binding to C. jejuni 
 
Siglec F binding to formalin fixed HS O:19 and HS O:3 C. jejuni was visualised using 
the same method as for Sialoadhesin. 
 
Figures 21 (A) and (B) show DAPI labelled HS O:19 and Siglec F-Fc anti human IgG 
FITC labelled HS O:19.  Figure 21 (C) shows the merged and digitally magnified image.  
These show specific Siglec F labelling of HS O:19 and they also reveal a punctate 
staining pattern similar to that of Sialoadhesin.  Figures 21 (D) and (E) show secondary 
antibody alone and Siglec F labelling of the HS O:3 strain respectively and confirm that 
Siglec F binds specifically to the ganglioside mimicking HS O:19 strain. 
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Figure 22: Siglec E binding to gangliosides, LOS and C. jejuni. 
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Figure  22.  ELISAs measuring Siglec E-Fc fusion protein binding to (A) glycolipids (Siglec E used at 
0.5µg/ml); (B) LOS from GB11 wild type and knock out strains of C. jejuni; (C) LOS from HS O:19 and 
HS O:3 strains of C. jejuni; (D) whole GB11 wild type and GB11 knock out C. jejuni and (E) whole HS 
O:19 and HS O:3 C. jejuni. Siglec E shows significantly greater binding to gangliosides GD1a and GT1b 
when compared to ganglioside GM1 and the asialo-sugars (A) (analysis by 1way ANOVA and 
Bonferroni’s multiple comparison posttest.). Siglec E shows statistically greater binding to non-ganglioside 
mimicking LOS (GB11 knock out and HS O:3) when compared to the mimicking counterparts (GB11 wild 
type and HS O:19) at higher concentrations of Siglec E (B and C).  Siglec E binding to whole C. jejuni 
showed significantly increased binding to GB11 knock out compared to GB11 wild type at a single 
concentration and significantly increased binding to HS O:19 over HS O:3 at a single concentration.  Mean 
and SEM calculated from triplicate wells.  Significance was calculated using 2way ANOVA with 
Bonferroni’s posttest analysis. (*=p<0.05, **=p<0.01, ***=p<0.001).  Graphs representative of 3 
experiments.  
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4.2.6 Siglec E binding to gangliosides, LOS and C. jejuni 
 
Siglec E binding to selected gangliosides and asialo-glycolipids was assessed as before 
(Siglec E used at 0.5µg/ml).  Figure 22 (A) shows significantly greater binding of Siglec 
E to GD1a (p<0.001) than any other glycolipid and to GT1b compared to GM1 and the 
asialo-glycolipids (p<0.01).  Figures 22 (B) and (C), which show Siglec E binding to 
LOS, reveal unexpected findings.  Siglec E shows statistically greater binding at higher 
concentrations to the non-ganglioside mimicking strains, GB11 knock out (B) and HS 
O:3 (C), than the ganglioside mimicking strains (GB11 wild type v knock out: p<0.001 at 
0.5 and 0.1µg/ml.  HS O:19 v HS O:3: p<0.001 at 0.5µg/ml).  Figures 22 (D) and (E) 
show Siglec E binding to both ganglioside mimicking and non-mimicking strains of C. 
jejuni.  Siglec E does not show any clear trend as there is greater binding to GB11 knock 
out than wild type (p<0.05 at 0.25µg/ml) and greater binding to HS O:19 than HS O:3 
(p<0.05 at 0.5µg/ml) at a single concentration point in each titration.   
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Figure 23: Immunocytometry of Siglec E binding to C. jejuni. 
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Figure 23. Immunocytometry of Siglec E binding to C. jejuni.  (A) DAPI labeled HS O:19.  (B) HS O:19 
labeled with Siglec E-Fc fusion protein and anti-human IgG FITC.  (C) Merge of (A) and (B).  Inset digital 
magnification of (C).  (D)  Control 1 – merged image of DAPI labelled HS O:19 and anti-human IgG FITC 
(secondary Ab only). (E) Control 2 – merged image of DAPI labelled HS O:3 with Siglec E-Fc fusion 
protein and anti-human IgG FITC.  Arrows in (C) show non-specific background binding of Siglec E-Fc 
fusion protein in the HS O:19 strains which is also present in HS O:3. 
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4.2.7 Visualisation of Siglec E binding to C. jejuni 
 
In order to further understand this unexpected finding, Siglec E binding to formalin fixed 
C. jejuni was visualised as before.  Figures 23 (A) and (B) show DAPI labelled HS O:19 
and Siglec E-Fc anti-human IgG FITC labelled HS O:19 respectively.  Figure 23 (C) 
shows the merged and digitally magnified images.  Figure 23 (D) shows secondary 
antibody alone.  Figure 23 (E) shows merged DAPI and Siglec E-Fc anti-human IgG 
FITC labelled HS O:3 C. jejuni.  Figures 23 (C) and (E) show that some Siglec E is 
associated with both strains of bacteria.  However, intense non-specific staining (white 
arrows in (D)) and speckled background staining is also present.  These results show that 
Siglec E is binding non-specifically to the background material and not specifically to 
either strain of bacteria. 
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Figure 24: Siglec E binding to LOS, gangliosides and complexed gangliosides. 
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Figure 24.  Siglec E binding to LOS, gangliosides and complexed gangliosides using ELISA. (A) Siglec E 
binding to LOS compared to gangliosides and complexed gangliosides.  The strongest binding observed 
was to GB11 knock out LOS which reached saturation (p<0.001 compared to all other targets). There was 
strong and equal binding to HS O:3 LOS, GD1a and GD1a/GM1 complexes (p<0.001 compared to other 
targets but not to each other).  There was no statistical difference between GB11 wild type LOS and HS 
O:19 LOS but both of these showed greater binding than GM1 and all the asialo-sugars (p<0.001). There 
was no difference between GM1 and all of the asialo-sugars.  (B) Siglec E binding to C. jejuni LOS was 
compared to binding to S. typhimurium LOS.  Similar to (A), GB11 knock out LOS shows greater binding 
than all the other targets (p<0.001) and HS O:3 shows greater binding than the two ganglioside mimicking 
strains (p<0.001).  There is no difference between GB11 wild type and HS O:19.  There is significantly less 
binding to S. typhimurium LOS (p<0.001) than any of the C. jejuni LOS strains. Only the key statistical 
differences have been marked for clarity.  Mean and SEM calculated from triplicate tubes.  Statistical 
analysis was by 1way ANOVA and Bonferroni’s posttests. (***=p<0.001).  Single experiment. 
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4.2.8 Siglec E binding to LOS, gangliosides and ganglioside complexes 
 
In order to investigate the specificity of the binding of the Siglec E reagent it was decided 
to directly compare LOS to ganglioside binding, and to include complexes of mixed 
gangliosides and asialo-sugars.  Ganglioside complexes were included as LOS consists of 
mixed GM1 and GD1a mimics and such complexes might be important in altering 
epitopes.  Figure 24 (A) shows Siglec E binding to gangliosides and to LOS.  Siglec E 
binding to GB11 knock out LOS is significantly greater than any other LOS or, 
surprisingly, the asialo-sugars (asialo-GM1, asialo-GM2 and lactosyl ceramide) which 
constitute the core sugars of the GB11 knock out LOS itself (p<0.001).  There is no 
statistical difference in binding to HS O:3 LOS, native GD1a alone and GD1a/GM1 
complexes.  Binding to these three glycolipids is greater than to the other glycolipids 
tested (p<0.001) other than GB11 knock out LOS.  Interestingly, binding to GM1 and 
GD1a targets is significantly greater (p<0.001) than binding to the LOS strains that 
mimic these gangliosides.   
 
There is an inconsistency between Siglec E binding to LOS and the native sugars found 
in the LOS core.  This is seen in both the ganglioside mimicking strains and the non-
mimicking GB11 knock out strain.  This raises the question of whether the Siglec E target 
is the external core sugars or another part of the molecule such as Lipid A.  To address 
this, a rough mutant LOS from S. typhimurium was used as a target to provide an 
independent Lipid A i.e. not from C. jejuni.  Figure 24 (B) shows binding of Siglec E to 
C. jejuni LOS and S. typhimurium LOS.  There was significantly less binding to S. 
typhimurium LOS than to any of the C. jejuni strains (p<0.001).  
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Figure 25: Factor H binding to C. jejuni. 
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Figure 25.  Purified human fH binding to whole C. jejuni using ELISA. Mean and SEM calculated from 
triplicate wells.  Graph representative of 3 experiments. 
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4.2.9 Purified human complement Factor H binding to C. jejuni 
 
Purified human fH binding to formalin fixed C. jejuni was assessed using an ELISA 
technique.  Bacteria were adsorbed onto an ELISA plate and incubated with purified fH 
for 1 hour at 37oC.  Binding was assessed using a monoclonal anti-human fH antibody.  
Figure 25 shows that no fH binding, above the limits of sensitivity, to either ganglioside 
mimicking or non-mimicking strains could be detected.  In order to confirm this finding, 
fH binding to heat killed bacteria was measured using FACS analysis (figure 26).  C. 
jejuni were incubated with 10µg purified fH for 30 minutes at 37oC and a mouse anti-fH 
mAb with anti mouse Ig-FITC were used for detection.  There is no evidence of fH 
binding to ganglioside mimicking or non-mimicking strains of C. jejuni.  Binding to 
formalin fixed bacteria was assessed using immunocytometry (figure 27).  None of the 
methods employed showed evidence of purified fH binding to either sialylated or non-
sialylated strains whether heat inactivated of formalin fixed.  Although no suitable 
positive control was available to test the purified fH reagent, subsequent experiments, 
detailed below, indicate that the anti-fH mAb works.  In addition, the FACS analysis 
protocol works as I have used this technique to demonstrate cholera toxin-FITC binding 
to ganglioside mimicking strains of C. jejuni in other projects233 (data shown in figure 26 
(B)). 
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Figure 26: FACS of Factor H binding to C. jejuni. 
A(i)
B(i) B(ii)
A(ii)
 
Figure 26 . Purified human fH binding to heat inactivated GB11 wild type or GB11 knock out C. jejuni 
using FACS analysis.  Dot plot (A)(i) shows bacteria gate. (A)(ii) Shows histograms of bacteria showing 
the FITC MFI as a measure of fH binding.  Anti-mouse Ig-FITC only (secondary) was used as a control.  
(B) Shows a separate experiment in which HS O:19 and HS O:3 bacteria were labelled with cholera toxin 
FITC which binds to GM1. (B)(ii) shows binding of cholera toxin to O:19 but not O:3 confirming that 
labelled bacteria can be detected by FACS analysis with this protocol.  Representative of triplicate tubes. 
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Figure 27: Immunocytometry of Factor H binding to C. jejuni. 
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Figure 27.  Immunocytometry of purified human fH binding to HS O:19 and HS O:3 C. jejuni.  (A) and (C) 
show mAb anti-fH and anti-mouse IgG FITC only (negative control).  (B) and (D) shows C. jejuni 
incubated with 5µg purified human fH followed by anti-fH mAb and anti-mouse IgG FITC.  Experiment 
repeated twice. 
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Figure 28: Factor H binding following incubation with serum. 
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Figure 28.  Serum fH binding to whole C .jejuni following incubation with active naïve human serum using 
ELISA.  (A) Shows fH binding to GB11 wild type and knock out C .jejuni.  (B) Shows binding to HS O:19 
and HS O:3 C. jejuni.   There are statistically significant differences in binding with increased fH binding 
to the non-sialylated strains.  Mean and SEM calculated from triplicate wells.  Statistical analysis was done 
using a 2way ANOVA with Bonferroni’s posttests. (*=p<0.05, **=p<0.01, ***=p<0.001).  Graphs 
representative of three donors. 
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Factor H has a binding site for C3b and activated complement provides binding sites for 
fH by depositing C3b on target structures.  In order to test if activated serum provides 
binding sites for fH, and to confirm that the anti-fH mAb works, formalin fixed C. jejuni 
were adsorbed onto an ELISA plate and incubated with naïve human serum for 20 
minutes at 37oC.  Serum fH binding was assayed as before using the monoclonal anti-fH 
antibody.  Figures 28 (A) and (B) show significantly greater binding of serum fH to non-
sialylated strains of C. jejuni compared to sialylated strains (GB11 wild type v knock out: 
p<0.001 at 20% and 10% serum, p<0.005 at 5% serum.  HS O:19 v HS O:3: p<0.001 at 
20%, p<0.005 at 10% and p<0.05 at 5% serum).  
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Figure 29: Complement C3c and C9 deposition on C. jejuni. 
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Figure  29.  C3c and C9 deposition on whole C. jejuni after incubation with naïve human serum for 20 
minutes using ELISA.  (A) and (B)  show human C3c deposition on GB11 wild type v knock out and HS 
O:19 v HS O:3 respectively.  (C) and (D) show human C9 deposition on GB11 wild type v knock out and 
HS O:19 v HS O:3 respectively. Deposition was measured using rabbit anti-C3 or anti-C9 with an anti-
rabbit Ig-HRP detection antibody.  All graphs show greater C3 and C9 deposition on the non-ganglioside 
mimicking C. jejuni strains. Mean and SEM calculated from triplicate wells.  Significance measured using 
two way ANOVA with Bonferroni’s posttests (***=p<0.001). Graphs representative of 3 naïve donors. 
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4.2.10 Human C3c and C9 complement deposition on C. jejuni 
 
Purified fH alone shows no binding to sialylated C. jejuni.  The previous results show 
enhanced serum fH binding to non-sialylated C. jejuni that had been incubated with 
active serum.  As complement activation provides fH binding sites, this suggests there is 
greater complement activation on the surface of non-ganglioside mimicking strains.  To 
test this hypothesis, deposition of C3c and C9 (the main component of membrane attack 
complex) on C. jejuni was measured following incubation with naïve human serum.  
Figures 29 (A) and (B) show binding of complement C3c to whole formalin fixed C. 
jejuni following incubation with human serum for 20 minutes at 37oC.  Although C3c is 
deposited on all the C. jejuni strains, there is significantly greater C3c deposited on the 
non-sialylated strains, GB11 knock out (B) and HS O:3 (C), than the corresponding 
sialylated strains (p<0.001 over the range of serum concentrations).  Figures 29 (C) and 
(D) show significantly increased Complement C9 deposition on the non-ganglioside 
mimicking C. jejuni strains when compared to the ganglioside mimicking strains under 
the same conditions (p<0.001 over the range of serum concentrations).  Serum from three 
naïve individuals showed the same pattern of C3c and C9 deposition. 
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Figure 30: Anti-LOS natural IgM and IgG antibody. 
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Figure 30.  IgM and IgG binding to LOS following incubation with naïve human serum for 1 hour using 
ELISA.   (A) IgM binding to GB11 wild type and knock out LOS; (B) IgM binding to HS O:19 and HS O:3  
LOS; (C) IgG binding to GB11 wild type and knock out LOS and (D) IgG binding to HS O:19 and HS O:3 
LOS.  There is significantly greater IgM and IgG specific for non-ganglioside mimicking strains of LOS. 
Mean and SEM calculated from triplicate wells.  Significance was calculated using 2way ANOVA with 
Bonferroni’s posttest analysis (*=p<0.05, **=p<0.01, ***=p<0.001).  Graphs representative of 3 naïve 
donors. 
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4.2.11 Natural IgM and IgG binding to C. jejuni LOS 
 
A potential explanation for increased complement deposition on non-sialylated strains is 
the presence of pre-existing “natural” antibodies which can activate the classical 
pathway.  Self-tolerance predicts that there will be less natural antibody specific for 
ganglioside mimicking strains of LOS.  To test this hypothesis, relative levels of IgM or 
IgG to ganglioside mimicking and non-mimicking LOS were compared using sera from 
three naïve human donors (each donor serum was tested individually).  Figures 30 (A) 
and (B) show significantly greater levels of IgM to the non-ganglioside mimicking LOS 
compared to the relevant ganglioside mimicking LOS (GB11 wild type v knock out: 
p<0.001 at 10%, 5% and 2.5% serum.  HS O:19 v HS O:3: p<0.001 at 10% serum and 
p<0.05 at 5 % serum).  Figures 30 (C) and (D) show significantly greater levels of IgG to 
the non-ganglioside mimicking LOS compared to the relevant ganglioside mimicking 
LOS (GB11 wild type v knock out: p<0.01 at 10% and 2.5% serum, p<0.001 at 5% 
serum.  HS O:19 v HS O:3: p<0.01 at 10 and 5% serum).  
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Figure 31: Anti-C. jejuni natural IgM and IgG. 
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Figure 31.  IgM and IgG to whole C. jejuni in naïve human serum using ELISA.  (A) IgM binding to GB11 
wild type and knock out C. jejuni; (B) IgM binding to HS O:19 and HS O:3 C. jejuni; (C) IgG binding to 
GB11 wild type and knock out C. jejuni (D) IgG binding to HS O:19 and HS O:3 C. jejuni.  There are 
significantly more natural antibodies (IgM and IgG) to non-sialylated strains of C. jejuni. Mean and SEM 
calculated from triplicate wells.  Significance was calculated using 2way ANOVA with Bonferroni’s post 
test analysis  (***=p<0.001).  Graphs representative of 3 naïve donors. 
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4.2.12 Natural IgM and IgG binding to whole C. jejuni 
 
Having demonstrated that there are fewer natural antibodies specific for purified 
ganglioside mimicking LOS than non-mimicking LOS it was hypothesised that there will 
be less natural antibodies specific for whole C. jejuni in ganglioside mimicking strains.  
Whole formalin fixed bacteria were adsorbed onto an ELISA plate and incubated with 
naïve human serum following which the C. jejuni specific antibodies were measured.  
Figures 31 (A) and (B) show IgM binding to ganglioside mimicking and non-mimicking 
strains.  Figures 31 (C) and (D) show IgG binding.  There is statistically more IgM 
(GB11 wild type v knock out: p<0.001 over the whole titration.  HS O:19 v HS O:3: 
p<0.001 over the whole titration) and IgG (GB11wild type v knock out: p<0.001 over the 
whole titration.  HS O:19 v HS O:3: p<0.001 at 5 and 2.5% serum) to the non-ganglioside 
mimicking strains of C. jejuni when compared to the relevant ganglioside mimicking 
strains.  Serum from three separate naïve individuals was tested and showed the same 
trend. 
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4.3 Discussion 
 
Sialoadhesin (Siglec-1 or CD169) is a type 1 membrane protein with 17 extracellular 
immunoglobulin like domains246.  Purified sialoadhesin is approximately 40nm247 in 
length and it is the largest member of the siglec family. In contrast to most siglecs, 
Sialoadhesin lacks tyrosine based signalling motifs.  Sialoadhesin is constitutively 
expressed at high levels on specific subpopulations of macrophage including the 
metallophilic macrophages of the spleen and subcapsular sinus macrophages in the lymph 
node. It is also expressed at lower levels by tissue resident macrophage populations of the 
bone marrow and liver209,248.  Sialoadhesin expression can be modulated by a number of 
factors, for example IL4 inhibits Sialoadhesin expression249 while type 1 interferons and 
specific TLR agonists can increase expression250.  Sialoadhesin has affinity for the 
terminal oligosaccharide sequence Neu5Acα23Galβ13GalNac and has been shown 
to bind the ganglioside GD1a.  It does not bind to GM1247.  The function of Sialoadhesin 
is still being explored.  It has been postulated as a lymphocyte adhesion molecule251 and 
is believed to inhibit the function of regulatory T cells252.  Sialoadhesin knock out mice 
have reduced inflammation in experimental autoimmune uveoretinitis suggesting a 
possible pro-inflammatory role for Sialoadhesin253.  In addition, knock out mice have 
subtle changes in B and T cell populations and reduced levels of IgM suggesting 
Sialoadhesin may have a role in antibody or B cell population regulation254.  Sialoadhesin 
has also been shown to bind sialylated N. meningitidis resulting in enhanced 
phagocytosis255.  
 
Due to its affinity for Neu5Acα23Galβ13GalNac it was predicted that the 
Sialoadhesin-Fc fusion proteins would bind to GD1a and GD1a mimicking LOS.  
However, in my assays I found no evidence of binding.  Contrary to this, I found that 
Sialoadhesin binds to GD1a mimicking whole C. jejuni.  GD1a mimicking LOS, in-situ, 
was confirmed as the target on the native bacterium.  The isogenic control strain, which 
differs only in its lack of ganglioside mimicry by the LOS, was unable to interact with 
Sialoadhesin.  Direct visualisation of the binding and the loss of binding after specific 
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removal of the GD1a epitope further confirmed that Sialoadhesin is binding to GD1a on 
the bacteria. 
 
A number of possible explanations for the lack of binding to LOS and native gangliosides 
were addressed by varying the protocol.  Epitope density of the GD1a and LOS was 
increased by increasing the target concentration.  The effects of secondary micelle 
structures were addressed by altering the buffer.  Low Sialoadhesin avidity was addressed 
by pre-complexing it with biotin labelled anti-Fc and streptavidin-HRP.  None of the 
changes to the protocol resulted in Sialoadhesin binding to gangliosides or ganglioside 
mimicking LOS.  The Sialoadhesin-Fc reagent is composed of a truncated Sialoadhesin 
molecule (comprising the four N-terminal Ig domains – see Appendix 4 for structure) and 
it may therefore have a reduced capacity to bind its ligand.  My results reflect the 
complexity of carbohydrate ligand binding in which repetitive epitopes and three 
dimensional structures can be essential for increasing avidity and this might explain why 
the Sialoadhesin reagent binds whole bacteria but not the LOS.   
 
An additional unexpected finding is that Sialoadhesin does not bind to all of the GD1a 
mimicking C. jejuni and the binding tends to be localised to one or both poles of the 
bacterium.  Manual counting of three fields found that 34% (ranging from 26% to 39%) 
of the ganglioside mimicking bacteria are labelled with Sialoadhesin and that 16% 
(ranging from 11% to 21%) are labelled at both poles.  There are a number of possible 
explanations for this.  Phase variation within the population might alter LOS expression 
and the two types of ganglioside mimicking LOS (GM1 and GD1a) might not be evenly 
dispersed across the surface of the bacterium.  The C. jejuni polysaccharide capsule217,256 
might be limiting access of the Siglec-Fc complexes to the poles of the organism where 
the flagellum penetrates the capsule.  In addition, it is known in standard 
immunohistochemistry that formalin fixation can alter epitope expression by allowing 
soluble epitopes to diffuse off the target. 
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Siglec F has four extracellular immunoglobulin-like domains with an immunoreceptor 
tyrosine-based inhibitory motif on its cytoplasmic tail257.  It has specificity for α2-3 
linked sialic acids and its constitutive expression is restricted to precursor cells of 
myeloid lineages257 and mature eosinophils258.  Siglec F is also expressed by a subset of 
CD4+ T cells following induction of allergic lung inflammation259.  As well as signalling, 
Siglec F has endocytic properties, delivering ligands to lysosomes260.  The human 
homologue, Siglec 8, is restricted to eosinophils and basophils.  Cross-linking Siglec F 
induces apoptosis in eosinophils and it has been postulated that upregulation of Siglec F 
ligands during allergic inflammation may contribute to a negative feedback loop, limiting 
disease259. 
 
My assay shows Siglec F binding to GD1a and GT1b.  Consistent with this affinity for 
GD1a, for the first time, Siglec F binding to ganglioside mimicking LOS and whole C. 
jejuni is shown.  When visualised, the binding pattern was similar to Sialoadhesin 
although it appeared that more of the ganglioside mimicking bacteria were labelled.  
Manual counting of three fields found that 87% (ranging from 86% to 89%) of 
ganglioside mimicking bacteria labelled for Siglec F.  In addition, 22% of these (ranging 
from 17% to 30%) had distinct labelling at both poles.  However, subjectively, the Siglec 
F binding was more diffuse around the edge of the bacteria instead of the distinct 
punctate staining seen with Sialoadhesin.  Siglec F binds native ganglioside, LOS and 
whole bacteria, therefore the different binding pattern might reflect it being a better 
reagent than Sialoadhesin.  Alternatively, it might bind to a more conserved part of GD1a 
or, being a smaller siglec than Sialoadhesin, it might gain easier access to its target 
epitopes.  Further studies could be carried out using FACS analysis to gain an objective 
measure of siglec binding and ideally heat inactivated or live bacteria should be used to 
exclude fixation artefact. 
 
Siglec E has three extracellular immunoglobulin-like domains while its intracellular 
domain contains two immunoreceptor tyrosine based inhibitory motifs261.  It appears to 
be a functional orthologue of human siglecs 7 and 9.  Siglec E shows differing affinity for 
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a number of sialic acid arrangements in the order α2,8 disialic acid>α2,3 
sialylactose>α2,6 sialylactose258.  Siglec E is expressed on neutrophils, peritoneal 
macrophages, splenic myeloid dendritic cells and subsets of NK cells258.  Weak Siglec E 
expression is also found on peritoneal B1a B cells as well as splenic T2 and MZ B 
cells258. 
 
Siglec E shows strongest binding to ganglioside GD1a with less binding to GT1b.  There 
was weak binding to the asialo-glycolipids, which are mimicked by the GB11 knock out 
strain.  However, in contrast to these findings, Siglec E shows very high affinity for the 
GB11 knock out LOS (significantly greater than the wild type strain) with greater binding 
to HS O:3 LOS compared to HS O:19 at high concentrations.  Binding to the whole C. 
jejuni shows a mixed profile. 
 
Binding to GB11 knock out LOS and its respective asialo-glycolipids was compared 
directly at matching concentrations.  Binding to LOS was significantly greater than to the 
respective asialo-sugars suggesting that the epitope is not the core sugars of the LOS.  
Using complexed asialo-glycolipid molecules (i.e. asialo-GM1, asialo-GM2 and lactosyl 
ceramide together) did not replicate the LOS binding.  Further, an additional species of 
LOS (salmonella) was compared to establish if the lipid A or internal core sugars might 
provide a conserved epitope unique to LOS but not found in asialo-glycolipids. There 
was no evidence that this is the case. 
 
Direct visualisation of Siglec E binding to whole C. jejuni reveals high levels of non-
specific background staining.  One possibility is that epitopes are shed from whole killed 
C. jejuni perhaps during the freeze/thaw process.  However, the bacteria were formalin 
fixed specifically to preserve their structural integrity and there is no evidence of this 
problem with either Sialoadhesin or Siglec F.  The binding buffer (methanol) and 
blocking buffer (3% BSA) were also tested for Siglec E binding and, while the 
 139 
background was higher than for other siglecs, this did not account for the strong GB11 
knock out LOS binding.   
 
Siglec E is known to have a wider specificity than the other siglecs tested and the α2,3 
sialylactose epitope found on LOS is not its preferred epitope. However, this does not 
provide an explanation for the observed binding.  No satisfactory conclusion could be 
drawn as to the epitope in GB11 knock out LOS that Siglec E binds to.  The visualisation 
studies suggest the reagent is sticky and non-specific.  This further confirms the 
complexity and difficulty of studying carbohydrate epitopes. 
 
The siglec binding results confirm one of the central hypotheses; that ganglioside 
mimicking LOS and whole ganglioside mimicking C. jejuni can bind to cellular receptors 
via their ganglioside mimics.  Only three receptors, out of many potential ganglioside 
receptors, were tested and their binding specificities were very idiosyncratic.  Although 
the function of siglecs is poorly understood, in principle this could result in additional 
LOS signalling events (in combination with TLR4) or altered trafficking of bacteria.  
Experiments designed to test these hypotheses are reported later in the thesis. 
 
Complement is a conserved component of the innate immune system which consists of 
~40 serum and cell associated proteins.  Complement functions to opsonise and lyse 
bacteria; link the innate and adaptive immune systems and remove immune complexes 
and apoptotic cells before they trigger unwanted inflammation.  There are three pathways 
of complement activation: the classical pathway, the alternative pathway and the 
mannose-binding lectin pathway.  The alternative pathway is continuously activated at a 
low level by the hydrolysis of C3.  Self-damage and amplification is kept in check by a 
number of complement regulatory proteins.  The classical pathway is activated by C1q 
binding to antibody bound to the surface of a target.  The classical and alternative 
complement cascades converge at the level of C3 convertase.  The final common 
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pathway involves the formation of a Membrane Attack Complex pore on the surface of 
the target by polymerisation of C9262. 
 
Factor H is 150kDa glycoprotein consisting of 20 short consensus repeats263.  It is 
synthesised predominantly in the liver and is part of a structurally related family of 
proteins.  Factor H functions as a complement regulatory protein that inhibits the classical 
and alternate complement cascades by interfering with C3 convertase199,200.  Factor H 
competes with Factor B and inhibits convertase formation264, it facilitates the dissociation 
of the convertase265 and fH is a cofactor for Factor I mediated cleavage of C3b265.  Factor 
H binds to a number of ligands including C3b, C3d, heparin, self-glycosaminoglycans 
and bacterial virulence factors266,267.  Sialic acid is an important target for fH binding on 
self-cells and this protects against complement activation268,269.  However, sialylation is 
also used by pathogens where it is believed to increase their resistance to complement 
mediated lysis242 
 
Using a variety of techniques, my assays showed no evidence of purified fH binding to 
either sialylated or non-sialylated strains of C. jejuni.  This was unexpected given the 
known binding site for sialic acid present on fH.  Previous publications have shown that 
fH binds to GM1 ganglioside and inhibits Complement activation on liposomes270.  
Factor H binding to sialylated N. gonorrhoeae242 has also been demonstrated.  However, 
it has become clear that the gonococcal porin Por1B is responsible for fH binding to N. 
gonorrhoeae245 while N. meningitidis produces a Factor H Binding Protein capable of 
mimicking charged carbohydrates and binding fH271.  In support of my negative results, 
some sialylated strains of N. gonorrhoeae do not bind fH242.  The contribution of 
sialylation to complement resistance in these species is not clear and it appears that sialic 
acid is neither necessary nor sufficient for fH binding.  I could not show fH binding to 
sialylated C. jejuni and this may be due to complexities in the role of sialic acid in fH 
binding, due to a problem with the purified fH reagent or due to alterations of the sialic 
acid fH binding sites on the heat killed or fixed bacteria. 
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Following incubation with active human serum, fH was detected at higher levels on the 
non-sialylated strains.  I believe this is due to deposition of C3b on the C. jejuni 
providing a binding site for fH.  Alternatively, this may be due to the anti-fH mAb 
binding to the Factor H Related Proteins which are present in serum and share a similar 
structure to fH.  In support of the former hypothesis, I showed greater C3 and C9 
complement deposition on the non-sialylated strains.  C3c is a breakdown product of C3b 
under the influence of Factor I and Factor H. Anti-C3c antibodies are not able to 
distinguish between C3c and the C3c portion of native C3 or C3b. However measuring 
C3c has the advantage of not being sensitive to complement consumption as it gives a 
total measure of recent complement activation (i.e. native C3b and metabolised C3b). 
 
It was hypothesised that the difference in complement activation is due to enhanced 
classical pathway activation through the action of natural antibody and it was expected 
that there are less natural antibodies specific for the sialylated strains of LOS because of 
self-tolerance.  This was investigated by measuring IgM and IgG specific for the 
ganglioside mimicking or non-mimicking LOS.  In addition, I show that there are less 
natural antibodies to the ganglioside mimicking whole bacteria when compared to the 
non-mimicking control strains.  The complement and antibody experiments used sera of 
three naïve humans (that is, subjects who self-reported no known previous exposure to C. 
jejuni).  However, this is too small a number to draw definitive conclusions and further 
studies using pooled human serum from many donors are necessary.  
 
Further experiments are required to support these hypotheses.  For example, measuring 
complement deposition in the absence of immunoglobulin (purified human complement) 
would confirm or refute the role of natural antibody.  My findings that all of the serum 
components tested (fH, C3, C9 and Ab) bound more to non-sialylated bacteria could be 
due to an experimental flaw.  For example, my method of quantifying the bacteria might 
be inaccurate (if one strain is stickier than the other it might clump and affect the OD600 
reading).  The strong negative charge of sialic acid might reduce binding of these strains 
to the ELISA plate or it might repel complement and antibodies in a non-specific manner.  
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My studies could be made more relevant by measuring serum resistance, that is, the 
ability of live bacteria to survive incubation with human serum.  The differences I 
measured in complement and antibody binding are relatively small therefore such studies 
would give a better idea of the physiological importance of these findings.  This could not 
be done in my laboratory due to restrictions on the use of live pathogens. 
 
In conclusion, by demonstrating Sialoadhesin binding to GD1a mimicking C. jejuni and 
Siglec F binding to ganglioside mimicking LOS and C. jejuni I have confirmed my 
hypothesis that the ganglioside mimics on GBS associated strains of C. jejuni can interact 
with endogenous immune system receptors.  Siglec E did not show specific binding.  In 
addition, and in contrast to my initial expectations, I found no evidence of fH binding to 
sialylated C. jejuni.  However, C. jejuni ganglioside mimicry results in less complement 
activation which may be related to my finding of lower natural antibody levels against 
these strains.  These findings require further clarification. 
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5 Immunostimulatory effects and potency of purified C. jejuni 
LOS 
 
5.1 Introduction 
 
The aim of the experiments presented in this chapter is to investigate the 
immunostimulatory properties of C. jejuni LOS and to establish if ganglioside mimicry 
has an effect on potency. 
 
Ganglioside mimicking C. jejuni LOS can be conceptually divided into two portions; the 
Lipid A tail and the ganglioside mimicking external core.  Lipid A is the “endotoxic 
principal” of lipopolysaccharides111,210-212,272 and mediates a plethora of 
immunostimulatory effects via signalling through the LPS receptor complex, TLR4-
MD2, in conjunction with co-receptor CD14116,119.  The primary responder cells to LPS 
are those of the myeloid lineage; monocytes, macrophages, dendritic cells and 
neutrophils, which constitutively express CD14 and TLR4105-108.  B cells are also 
sensitive to LPS although the receptors employed are less well characterised.  While 
TLR4 is not expressed on human B cells108,197 a structurally related complex, RP105-
MD1, appears to confer sensitivity to LPS273.  In mouse models, the absence of either 
RP105 or MD1 results in B cell hyporesponsiveness, although absence of TLR4 or MD2 
results in a complete loss of sensitivity127,274-276.  This illustrates potential murine-human 
disparities and the complexity of the LPS sensing system. 
 
Myeloid cells respond to LPS stimulation at picomolar concentrations.  LPS has a 
panoply of effects, principal amongst them being secretion of acute phase cytokines; 
TNF-α, IL-1 and IL-6, as well as immunomodulatory cytokines such as IL-12 and IL-
10277-282.  LPS has important adjuvant effects which include maturation of antigen 
presenting cells coinciding with increased co-receptor expression and enhanced antigen 
presentation283-286. 
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The B cell compartment is broadly divided into two subsets.  The B1 subset comprises 
B1a and B1b B cells and the B2 subset comprises MZ and FO B cells.  B1 B cells are 
located primarily in the peritoneal and pleural cavities158 while MZ B cells are located in 
close proximity to the marginal zone and Sialoadhesin expressing metallophilic 
macrophage populations near the marginal sinuses of the spleen131.  Both B1 B cells and 
MZ B cells are important in T-independent antibody responses, have a tendency towards 
polyreactivity and autoreactivity, and produce natural antibodies against carbohydrate 
antigens131,158.  In addition, and in contrast to FO B cells, they are highly responsive to 
LPS stimulation which results in proliferation, maturation and antibody secretion109.  
Marginal zone B cells are mobilised by LPS and play a role in transporting antigen into 
the follicle287-290 where they can function as potent antigen presenting cells168.  In 
addition, following LPS stimulation, they are an important source of the cytokine IL-
10291.  LPS is a Type I TI antigen which is capable of directly triggering polyclonal B cell 
activation and proliferation292.   
 
Bacteria exhibit substantial inter-species differences in LPS structure102.  LPS and LPS 
analogues, derived from diverse bacterial species, in addition to causing TLR4-MD2 
homodimerisation, appear capable of interacting with different receptor clusters, 
recruiting unique combinations of signalling proteins and stimulating different cellular 
responses293-296.  While differences in LPS potency clearly exist, such studies are 
inevitably complicated by impurities present in the LPS preparation and must be 
interpreted with caution. 
 
C. jejuni LOS, while structurally similar to related species, has a number of unique 
differences.  A glucosamine residue of the Lipid A backbone is replaced with a related 
sugar, 2,3-diamino-2,3-dideoxy-D-glucose, and the inner core contains a unique 
tetrasaccharide (Glc–Hep–Hep–Kdo)102,112.  In addition, the acyl chains are particularly 
long which, combined with the absence of an O-side chain, makes the molecule highly 
hydrophobic.   
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GBS associated C. jejuni LOS are exclusively rough mutant.  Substantial differences are 
thought to exist between sensing and signalling of smooth mutant LPS (S-form) and 
rough mutant LPS (R-form).  While S-form LPS requires LBP and CD14 in order to 
signal, R-form LPS can bind to TLR4/MD-2 directly99,123 and cells lacking CD14 (such 
as mast cells and B cells) can recognise R-form LPS without the CD14 and LBP 
accessory molecules99.  In addition, signalling by R-form LPS, in the absence of LBP and 
CD14, results in signal transduction via the MyD88 dependent pathway with only weak 
signalling via the TRIF dependent pathway99,123,297. 
 
Gangliosides have long been recognised as immune system modulators134.  Incubation of 
human dendritic cells with purified GD1a ganglioside causes inhibition of IL-12 
production and enhanced IL-10 production, although subsequent co-culture with naïve T 
cells results in a blunting of both Th1 and Th2 differentiation298.  Pre-incubation of 
dendritic cells with GD1a also inhibits subsequent co-stimulator upregulation and 
cytokine production following LPS stimulation299.  T cells incubated with GD1b, GT1c 
or GQ1b show enhanced Th1 cytokine production when stimulated with PHA 
(phytohaemagglutanin)300 while human B cells incubated with GM2 or GM3 show 
inhibited immunoglobulin production and reduced thymidine uptake (GM1 and GD1a 
have no effect)301.  Although gangliosides are generally considered immunosuppressive, 
there is no clear consensus on their specific effects or the mechanisms by which they 
produce these effects.  The complexity of the ganglioside repertoire complicates such 
studies.  Gangliosides, and ganglioside mimicking LOS, are capable of engaging immune 
system receptors such as siglecs (demonstrated previously in 4.2.4 and 4.2.5).  In 
addition, gangliosides are important self ligands for presentation in the CD1 family of 
glycolipid antigen presentation molecules and this allows them to interact with specific 
subsets of T cells302-304.  Due to the ubiquitous nature of gangliosides, and their co-
localisation on plasma membrane lipid rafts with a wide array of signalling molecules in 
lymphocytes305,306, there is potential for exogenous gangliosides, or ganglioside mimics, 
to insert into membranes and disrupt signalling. 
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One of my central hypotheses is that ganglioside mimicry alters the potency of LOS.  In 
the experiments in this chapter I compare ganglioside mimicking LOS to LOS derived 
from isogenic, non-mimicking, control strains in their ability to stimulate those cell types 
most likely responsible for the effector stage (B cells) and induction stage (myeloid cells) 
of GBS.  This hypothesis is not without precedent.  I have demonstrated ganglioside 
mimicking LOS engaging siglec receptors through the O-side chain and this may alter 
adjuvant activity in a similar manner to E. coli and Klebsiella LPS strains which contain 
mannose in the carbohydrate O-side chain and which show enhanced adjuvant activity 
through binding to the mannose receptor on myeloid cells150-152,307-309. 
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Figure 32: In vivo mobilisation of marginal zone B cells by LPS. 
A) PBS injected
MOMA1 FITC
B220 Alexa 647
B) S. typhimurium LPS injected
MOMA1 FITC
B220 Alexa 647
D) GB2 Knock out LOS injected
MOMA1 FITC
B220 Alexa 647
C) GB2 Wild type LOS injected
MOMA1 FITC
B220 Alexa 647
 
Figure 32. Immunohistology of murine spleens following LOS injection.  Metallophilic macrophages 
(MOMA1 positive, green) mark the edge of the follicles.  B cells, including MZ B cells, are labelled with 
B220 (red).  (A) PBS injected. White arrows show B cells outwith the metallophilic macrophages. (B) 
Smooth mutant S. typhimurium LPS injected mouse spleen.  (C) GB2 wild type C. jejuni LOS injected 
spleen.  (D) GB2 knock out C. jejuni LOS injected spleen.  (B, C, D) White arrows show absence of B cells 
in the marginal zone following LPS or LOS injection.  Images representative of three experiments. 
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5.2 Results 
 
5.2.1 In vivo mobilisation of Marginal Zone B cells  
 
Marginal zone B cells are potentially important in GBS because they are a source of 
antibodies directed against carbohydrate antigens131,158, they are responsive to LPS109 and 
they are believed to contain auto-reactive specificities within their repertoire.  Marginal 
zone B cells are also potent antigen presenting cells168 and have been shown to migrate 
and carry antigen from the marginal zone of splenic follicles into the follicle287,289,290.  
This mobilisation occurs rapidly in response to LPS stimulation and the aim of my initial 
experiments was to test whether or not C. jejuni LOS could do the same. 
 
Mice were injected intra-peritoneally with 50µg of GB2 wild type LOS, GB2 knock out 
LOS, S. typhimurium LPS (smooth mutant) and PBS (the latter two being positive and 
negative controls respectively).  After 18 hours, spleens were harvested and frozen.  
Frozen sections were stained with the mAb MOMA1, which is specific for the 
metallophilic macrophage marker Sialoadhesin and distinguishes the edge of the follicle, 
and a mAb specific for the B cell marker B220.  Figure 32 shows immunohistology of 
splenic sections.  Figure 32 (A) shows a section from a mouse injected with PBS.  The 
white arrows indicate the position of B220 positive marginal zone B cells (red) outwith 
the MOMA1 positive metallophilic macrophage population (green).  Follicular B cells 
also stain positive for B220 and are present within the follicle which is surrounded by the 
MOMA1 positive macrophage population.  Figures 32 (B), (C) and (D) show sections 
following injection with S. typhimurium LPS, GB2 wild type LOS and GB2 knock out 
LOS respectively.  B cells are no longer present in the marginal zone (white arrows) 
indicating that LOS is capable of mobilising MZ B cells.  Ganglioside mimicry does not 
affect this property. 
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Figure 33: Example FACS plots of labelled B cells. 
A (i) A(ii) A(iii)
B(i) B(ii) B(iii)
C(i) C(ii) C(iii)
 
Figure 33. Example FACS plots of (A) B cell selection, (B) tracking B cell division using CFSE and (C) B 
cell subpopulations.  B cells were purified from mixed splenocytes using the EasySep B cell negative 
selection kit. (A) FACS analysis showing B cell purity before and after magnetic bead negative selection. 
(A) (i) Parent lymphocyte gate on forward and side scatter, (A) (ii) Pre-selection purity  (51.24% B220+).  
(A) (iii)  Post selection purity (>91% B220+).  (B) FACS analysis of cell division. (B) (i) Forward v side 
scatter of mixed splenocytes including the parent lymphocyte gate and the Caltag counting beads (R1).  (B) 
(ii) Dot plot showing CFSE v B220.  Each gate is a B cell population in a particular round of division 72 
hours after E. coli LPS stimulation.  B(iii) as before except C. jejuni LOS stimulation.  (C) Examples of 
gates used to determine the size of each population (C) (i) B220+ B cell population (parent population to C 
(ii) and (iii)). C (ii) CD138 positive B cell population.  C (iii) IgG positive B cell population. 
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5.2.2 B cell activation by ganglioside mimicking and non-mimicking C. 
jejuni LOS in a purified B cell culture  
 
To test the B cell stimulatory potency of C. jejuni LOS in a pure B cell culture, B cells 
were purified using negative selection from a mixed splenocyte population.  The EasySep 
B cell negative selection kit uses a panel of antibodies, directed against non-B cells, 
magnetic nanoparticles and a magnetic sleeve to remove unwanted cells without 
antibodies binding to the B cells.  Figure 33 (A) shows B cell purity before and after 
negative selection by labelling with the B cell marker B220 (all experiments resulted in 
purity of >90%).  To assess mitogenic potency, cells were labelled with the cell tracking 
fluorophore CFSE310,311.  CFSE forms covalent bonds with intracellular molecules and 
the fluorescence of the cell halves with each round of mitosis.  Cell division can be 
tracked using flow cytometry and Figure 33 (B) shows example FACS plots of E. coli 
LPS and C. jejuni LOS stimulated B cells co-labelled with the B cell marker B220.  Each 
gate is a B cell population in the same round of division.  The concentration of cells was 
derived from the FACS data using Caltag counting beads, a known concentration of 
which was added to the samples prior to analysis and from which the cell concentration 
can be mathematically derived (according to the manufacturers lot specific instructions).  
B cells were stimulated with 20µg/ml ganglioside mimicking (GB2 wild type) or non-
mimicking (GB2 CSTII knock out) C. jejuni LOS or E. coli LPS as a control.  Plasma 
cell differentiation was measured by co-labelling with the plasma cell differentiation 
marker CD138312 (Syndecan1) and IgG isotype switching measured by co-labelling with 
anti-IgG (example FACS plots shown in figure 33 (C)). 
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Figure 34: B cell responses to C. jejuni LOS in a purified B cell population. 
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Figure 34.  Purified B cells responses to LOS/LPS stimulation measured by FACS analysis.  The cells were 
harvested and labelled for the B cell marker B220, the plasma cell marker CD138 and surface IgG 
expression.  Cells were enumerated using Caltag counting beads.  (A) concentration of B cells (B220 
positive).  (B) concentration of B cells in each round of division.  (C) concentration of CD138 positive 
cells. (D) Concentration of CD138 positive cells in each round of division.  (E) Concentration of IgG 
positive B cells.  (F)  Concentration of IgG positive B cells in each round of division.  Mean and SEM 
calculated from triplicate tubes.  Representative of two experiments. Bar graphs analysed using  1way 
ANOVA with Bonferroni’s multiple comparison test, Line graphs analysed using 2way ANOVA with 
Bonferroni’s posttests (*=p<0.05, **=p<0.005, ***=p<0.001).   
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Figure 34 (A) shows the total B cell concentration at 72 hours after stimulation with 
20µg/ml wild type LOS, knock out LOS or E. coli LPS.  There is no statistical difference 
between either of the C. jejuni LOS strains.  However, twice as many B cells are present 
following E. coli LPS stimulation (p<0.001).  Figure 34 (B) shows the concentration of B 
cells in each round of division.  C. jejuni LOS and E. coli LPS both induced B cell 
division.  However, there are significantly more B cells in rounds 0, 1, 2, 3 and 4 of 
division following E. coli LPS stimulation (p<0.001) compared to C. jejuni LOS 
stimulation.  There is no statistical difference between the C. jejuni LOS strains.  These 
results suggest E. coli LPS is more potent at stimulating B cell mitosis in a pure B cell 
culture than C. jejuni LOS and that ganglioside mimicry has no effect on LOS potency. 
 
The ability of C. jejuni LOS to stimulate plasma cell differentiation in a purified B cell 
culture was assessed by co-staining the B cells with the plasma cell differentiation marker 
CD138.  Figure 34 (C) shows the concentration of CD138 positive cells present after 72 
hours.  There is no statistical difference between the C. jejuni LOS strains.  However, the 
E. coli LPS has stimulated greater CD138 positive cell differentiation (p<0.01).  Figure 
34 (D) shows the concentration of CD138 positive cells in each round of division.  A 
greater number of CD138 positive cells did not divide (remaining in round 0) following 
C. jejuni LOS stimulation compared to E. coli LPS stimulation (p<0.05).  A greater 
number of CD138 positive cells were in each subsequent round of division (except round 
5) following E. coli LPS stimulation (Round 1 p<0.01, rounds 2 to 4 p<0.001). There was 
no difference in potency at generating CD138 positive cells between the C. jejuni LOS 
strains.   
 
To assess the capacity of C. jejuni LOS to stimulate isotype switching to IgG, B cells 
were co-stained with an IgG specific antibody. Figure 34 (E) shows the concentration of 
IgG positive B cells after 72 hours of stimulation.  There is no statistical difference 
between the ganglioside mimicking and non-mimicking C. jejuni LOS strains.  However, 
E. coli LPS stimulation resulted in more than twice as many IgG positive B cells 
(p<0.001).  Figure 34 (F) shows the concentration of IgG positive B cells in each round 
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of division.  There are no differences between either LOS strains.  E. coli LPS stimulation 
resulted in more IgG positive B cells in all rounds of division except round 6 (p<0.001).  
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Figure 35: B cell responses to C. jejuni LOS in a mixed splenocyte population. 
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Figure 35.  Mixed splenocyte response to LOS/LPS stimulation measured by FACS analysis.  The cells 
were harvested and labelled for the B cell marker B220, the plasma cell marker CD138 and IgG expression.  
The number of cells was enumerated using Caltag counting beads.  (A) Concentration of B cells (B220 
positive)  (B) Concentration of B cells in each round of division.  (C) Concentration of CD138 positive 
cells. (D) Concentration of CD138 positive cells in each round of division.  (E) Concentration of IgG 
positive B cells.  (F)  Concentration of IgG positive B cells in each round of division.  Mean and SEM 
calculated from triplicate tubes.  Representative of two experiments.  Bar graphs analysed using  1way 
ANOVA with Bonferroni’s multiple comparison Test, Line graphs analysed using 2way ANOVA with 
Bonferroni’s posttests (*=p<0.05, **=p<0.01, ***=p<0.001). 
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5.2.3 B cell activation by ganglioside mimicking and non-mimicking LOS 
in a mixed splenocyte culture 
 
Myeloid lineage cells can act as accessory cells for B cell activation and survivial313 and 
are sensitive to LPS.  It was decided to compare the B cell activating potency of 
ganglioside mimicking and non-mimicking LOS in a mixed splenocyte culture (i.e. 
including accessory cells).  The methods used were the same as before. 
 
Figure 35 (A) shows the total B cell concentration in a mixed splenocyte culture.  There 
are more remaining B cells after 72 hours following E. coli LPS stimulation than C. 
jejuni wild type or knock out LOS (p<0.001).  There is no statistical difference between 
either of the C. jejuni LOS strains.  Figure 35 (B) shows the concentration of B cells in 
each round of division.  LOS and LPS have both stimulated B cell mitosis although there 
are significantly more B cells in rounds 1 (p<0.05), 2 (p<0.001), 3 (p<0.001), and 4 
(p<0.001) of division following E. coli LPS stimulation.  There is no statistical difference 
between the C. jejuni LOS strains.  These results confirm E. coli LPS is more potent at 
stimulating B cell mitosis than C. jejuni LOS.  Ganglioside mimicry has no effect on 
LOS induced B cell mitogenicity. 
 
Figure 35 (C) shows the concentration of CD138 positive cells present after 72 hours.  
There is no statistical difference between either of the C. jejuni LOS strains or the E. coli 
LPS.  Figure 35 (D) shows the concentration of CD138 positive cells in each round of 
division.  There are more CD138 positive cells in round 3 of division following E. coli 
LPS stimulation (p<0.001).  There are no statistical differences between the wild type of 
knock out LOS strains. 
 
Figure 35 (E) shows the concentration of IgG positive B cells.  E. coli LPS stimulation 
results in more IgG positive B cells after 72 hours (p<0.01), while there is no difference 
between the C. jejuni LOS strains.  Figure 35 (F) shows the concentration of IgG positive 
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B cells in each round of division.  There are more IgG positive B cells in rounds 1, 2, 3 
and 4 (p<0.001) following E. coli LPS stimulation compared to C. jejuni LOS 
stimulation.  There is no difference between either of the C. jejuni strains.   
 
Combined, these results show E. coli LPS to be more potent than C. jejuni LOS.  
Ganglioside mimicry does not appear to enhance C. jejuni LOS potency. 
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Figure 36: Immunoglobulin production by LOS stimulated B cells and splenocytes. 
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Figure 36.  Purified B cells or mixed splenocytes were stimulated with 10 µg/ml of GB2 or GB19 strains of 
C. jejuni LOS or E. coli LPS for 72 hours and immunoglobulin secretion was measured in the supernatant 
using ELISA.  (A) Shows IgM production by purified B cells. (B) Shows IgM production by mixed 
splenocytes.  (C) Shows IgG production by purified B cells.  (D) Shows IgG production by mixed 
splenocytes.  Mean and SEM calculated from triplicate wells. Analysed using 1way ANOVA with 
Bonferroni’s multiple comparisons test (**=p<0.01, ***=p<0.001).    Representative of three experiments. 
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5.2.4 Comparison of LOS potency at stimulating antibody secretion 
 
Having compared the potency of ganglioside mimicking and non-mimicking LOS at 
stimulating B cell mitosis and CD138 positive cell differentiation it was decided to 
compare immunoglobulin secretion as another measure of potency. 
 
Purified B cells or mixed splenocytes were cultured for 72 hours with 10µg/ml LOS and 
antibody secretion into the supernatant was measured using an ELISA.  An additional 
ganglioside mimicking LOS, GB19 wild type mimicking GD1c, and the CSTII knock out 
control was included in the assay.  Figure 36 (A) shows IgM production by a purified B 
cell population.  There is no difference in IgM production between wild type and knock 
out LOS in both the GB2 and GB19 strains.  There is also no statistical difference 
between both GB2 and both GB19 strains.  E. coli LPS is more potent than both GB2 
(p<0.001) and both GB19 (p<0.01) strains. 
 
Figure 36 (B) shows IgM production by a mixed splenocyte population.  There is no 
difference in IgM production between wild type and knock out LOS in both the GB2 and 
GB19 strains.  However, both GB19 LOS strains are more potent than both GB2 LOS 
strains (p<0.01) and E. coli LPS is more potent than both GB2 strains (p<0.001) and both 
GB19 strains (p<0.01). 
 
Figure 36 (C) shows IgG production by a purified B cell population.  Very low quantities 
of IgG were produced in the absence of accessory cells (compare to figure 36 (D)).  
There was no statistical difference in IgG production between any of the strains of LOS 
or LPS.  Figure 36 (D) shows IgG production by a mixed splenocyte population.  There is 
no difference in IgG production between wild type and knock out LOS in both the GB2 
and GB19 strains.  Both GB19 strains are more potent than both GB2 strains (p<0.01) 
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and E. coli LPS is more potent than both GB2 strains (WT p<0.001, KO p<0.01) but is 
not statistically different from either GB19 strain. 
 
These results show that ganglioside mimicry does not affect the potency of C. jejuni LOS 
at stimulating IgM or IgG secretion from purified B cells or mixed splenocytes.  They 
highlight intra-species differences, as both GB19 LOS strains appear more potent than 
both GB2 LOS strains.  Inter-species differences are also apparent as E. coli LPS is 
generally more potent than either C. jejuni strain. 
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Figure 37: Cytokine production by LOS stimulated B cells and splenocytes. 
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Figure 37.  Purified B cells or mixed splenocytes were stimulated with 10µg/ml C jejuni LOS or E. coli 
LPS and cytokine secretion was measured using ELISA after 72 hours.  (A) IL-10 production by purified B 
cells following GB2 wild type and knock out LOS or E. coli LPS stimulation.  (B) IL-10 production by 
mixed splenocytes following GB2 wild type and knock out LOS or E. coli LPS stimulation.  (C) IL-10 
production by purified B cells following GB19 wild type and knock out LOS or E. coli LPS stimulation. 
(D) IL-10 production by mixed splenocytes following GB19 wild type and knock out LOS or E. coli LPS 
stimulation. (E) IFN-γ production by mixed splenocytes following 10µg/ml LOS or E. coli LPS 
stimulation.  (F) IL-12 production by mixed splenocytes following 10µg/ml LOS or E. coli LPS 
stimulation.  Mean and SEM calculated from triplicate wells.  Analysed using 1way ANOVA with 
Bonferroni’s multiple comparison test (*=p<0.05, ***=p<0.001). Representative of four experiments. 
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5.2.5 Comparison of LOS potency at stimulating cytokine secretion 
 
A further functional measure of LOS potency is cytokine secretion.  Purified B cells or 
mixed splenocytes were stimulated with ganglioside mimicking or non-mimicking LOS, 
and E. coli LPS.  Cytokine secretion was measured after 72 hours.  Figure 37 (A) shows 
IL-10 production in a purified B cell culture and figure 37 (B) shows IL-10 production in 
a mixed splenocyte culture, following GB2 wild type and knock out LOS stimulation.  In 
both cases, there is no difference between ganglioside mimicking and non-mimicking 
strains.  However, E. coli LPS is more potent than either of the C. jejuni LOS strains in 
both cases (p<0.001).  Figures 37 (C) and (D) show similar experiments as before only 
using GB19 strains of LOS.  Again, there is no difference between the ganglioside 
mimicking and non-mimicking variants of LOS.  E. coli is more potent (p<0.05) than 
GB19 wild type C. jejuni LOS (with no statistical advantage over knock out LOS) in the 
mixed splenocyte culture, but not the pure B cell culture. 
 
IFN-γ production was measured in a mixed splenocyte culture (figure 37(E)).  None of 
the C. jejuni LOS strains induced detectable IFN-γ secretion although the E. coli LPS 
stimulated large quantities of IFN-γ.  In addition, no IL-12 could be detected from mixed 
splenocytes following LPS or LOS stimulation (figure 37 (F)). 
 
 162 
Figure 38: Cytokine production by rough v smooth LPS stimulated mixed splenocytes. 
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Figure 38.  Mixed splenocytes were stimulated with a titrating dose of smooth (Ra) and rough (Re) mutant 
S. typhimurium LPS and GB2 C. jejuni LOS following which IFN-γ and IL-10 secretion into the 
supernatant was measured by ELISA.  (A) IFN-γ production following stimulation.  (B) IL-10 production 
following stimulation. Mean and SEM calculated from triplicate wells.  Analysed using 2way ANOVA 
with Bonferroni’s post tests (**=p<0.01, ***=p<0.001).   
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To test if an inability to stimulate IFN-γ production is a property unique to C. jejuni LOS 
or a general property of rough mutant LPS, a number of additional strains of LPS were 
tested.  Re (deep rough mutant) and Ra (smooth mutant) S. typhimurium LPS strains were 
used in an IFN-γ, mixed splenocyte assay (figure 38 (A)).  The smooth mutant S. 
typhimurium LPS induces more IFN-γ over a range of concentrations (10µg/ml, 1µg/ml 
and 0.1µg/ml (p<0.001)) than any of the rough mutant strains, including the rough S. 
typhimurium LPS.  C. jejuni LOS does not induce IFN-γ.  Figure 38 (B) shows IL-10 
production in the same experiment.  Smooth S. typhimurium LPS is statistically more 
potent than the rough mutant strains (greater than C. jejuni LOS at 10µg/ml, 1µg/ml and 
0.1µg/ml (p<.001) and greater than rough S. typhimurium LPS at 10µg/ml and 1µg/ml 
(p<0.001)).  Rough S. typhimurium LPS is more potent than C. jejuni LOS at 1µg/ml and 
0.1µg/ml (p<0.001).  There is no difference between the ganglioside mimicking and non-
mimicking C. jejuni GB2 LOS strains 
 
These cytokine experiments showed a small degree inter-experiment variability.  In two 
IL-10 repeats the GB2 knock out C. jejuni LOS induced slightly more IL-10 from mixed 
splenocytes (p<0.05) than the wild type strains while in two experiments there was no 
difference.  Where a difference was present it could be attributed to a single outlier.  
Although the rough S. typhimurium resulted in detectable IFN-γ (including statistically 
more than C. jejuni LOS at 0.01µg/ml (p<0.01)), a number of subsequent repeats (data 
not shown) using single concentration points (2µg/ml, 5µg/ml and 20µg/ml) resulted in 
no detectable IFN-γ following rough S. typhimurium stimulation.  The balance of results 
suggests that rough mutant LPS/LOS from either S. typhimurium or C. jejuni do not 
induce significant amounts of IFN-γ from mixed splenocytes.  These results also 
demonstrate no difference in potency between ganglioside mimicking and non-
mimicking LOS in stimulating IL-10 secretion from purified B cells or mixed 
splenocytes. 
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Figure 39: Bone marrow derived dendritic cell and macrophage purity assessed by FACS. 
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Figure 39.  Bone marrow derived dendritic cell and bone marrow derived macrophage purity assessed using 
FACS analysis (monoclonal antibody to CD11c (dendritic cells) or F4/80 (macrophages)). (A)(i) Forward v 
side scatter of BMDC parent cells.  (A)(ii) histogram showing CD11c positive cells (blue, 70%) against 
isotype control (black).  (B)(i) forward v side scatter of BM macrophage parent cells.  (B)(ii) histogram 
showing F4/80 positive cells (blue, 96%) against isotype control (black). 
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5.2.6 Potency of ganglioside mimicking and non-ganglioside mimicking 
LOS at stimulating myeloid antigen presenting cells 
 
Bone marrow derived dendritic cells (BMDC) and bone marrow derived macrophages are 
innate immune cells of myeloid lineage.  Myeloid cells express numerous pathogen 
recognition receptors such as TLRs (including TLR4) and also express members of the 
siglec family of ganglioside receptors.  Bone marrow derived dendritic cells and 
macrophages were stimulated with LOS in order to test if ganglioside mimicry alters the 
potency of LOS. 
 
Bone marrow derived dendritic cells were differentiated from bone marrow cells using 
GM-CSF containing supernatant from the X-63 cell line.  Before use, cells were 
harvested and labelled with the dendritic cell marker CD11c in order to establish purity.  
Figure 39 (A) shows harvested cells labelled with anti-CD11c and the isotype control.  
Dendritic cell purity was greater than 70%.  Bone marrow derived macrophages were 
differentiated from bone marrow using M-CSF containing supernatant from the L-929 
cell line and purity was confirmed by labelling with the macrophage marker F4/80.  
Figure 39(B) shows F4/80 positive cells against isotype control.  Macrophage purity was 
greater than 90%. 
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Figure 40: Cytokine production by LOS stimulated dendritic cells and macrophages. 
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Figure 40.  Dendritic cell or macrophage responses to wild type or knock out C. jejuni GB11 LOS.  The 
supernatants were harvested and analysed for cytokine production using OptEIA ELISA kits. (A) BMDC 
IL-10 production following overnight stimulation with GB11 wild type or knock out LOS.  (B)  BM 
macrophage IL-10 production following overnight stimulation with GB11 wild type or knock out LOS.  (C) 
BMDC TNF-α production following overnight stimulation with GB11 wild type or knock out LOS.  (D) 
BM macrophage TNF-α production following overnight stimulation with GB11 wild type or knock out 
LOS.  (E) BMDC IL-12 production following overnight stimulation with GB11 wild type or knock out 
LOS. Mean and SEM calculated from triplicate wells. Analysed using 2way ANOVA with Bonferroni’s 
posttests (**=p<0.01, ***=p<0.001).  Representative of three titration experiments. 
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Bone marrow derived dendritic cells or macrophages were stimulated with a titrating 
dose of wild type or knock out GB11 C. jejuni LOS and the supernatants were harvested 
after overnight incubation.  Cytokine production was assayed using cytokine ELISAs.  
Figures 40(A) and (B) shows IL-10 production by dendritic cells and macrophages 
respectively.  Dendritic cells produce double the amount of IL-10 (1433 pg/ml v 665 
pg/ml) following stimulation with 10µg/ml knock out LOS than compared to wild type 
LOS (p<0.001) and almost 50% more (509 pg/ml v 354 pg/ml) when stimulated with 
1µg/ml (p<0.001).  1µg/ml of knock out LOS has potency comparable to 10µg/ml of wild 
type LOS.  Macrophages produce one third more IL-10 when stimulated with 10µg/ml 
knock out LOS as compared to wild type LOS (p<0.01) although no difference in 
potency is apparent at lower concentrations. 
 
Figures 40(C) and (D) show dendritic cell and macrophage TNF-α production under the 
same conditions.  There is no statistical difference in dendritic cell TNF-α secretion 
following GB11 knock out LOS or GB11 wild type LOS stimulation.  There is greater 
TNF-α production by macrophages at 10µg/ml and 1µg/ml (p<0.01) with knock out LOS 
having approximately double the potency of wild type LOS at each concentration. 
 
Figure 40 (E) shows bone marrow derived dendritic cell IL-12 production.  GB11 knock 
out LOS is more potent at 0.1µg/ml and 10µg/ml (p<0.001) than wild type LOS 
producing just under twice as much IL-12 at each concentration. 
 
The differences in dendritic cell IL-10 production were reliably reproduced each time it 
was tested (over eight separate repeats) with similar levels of cytokines, high levels of 
statistical significance and consistent dose response curves.  However, the other 
cytokines showed marked inter-experiment variability with inconsistent dose response 
curves.  Small differences in macrophage IL-10 production at high concentrations 
(10µg/ml) of LOS were generally consistent while macrophage TNF-α production 
showed fluctuations in the dose response curves with knock out LOS being more potent 
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at higher concentrations.  Dendritic cell IL-12 responses were extremely variable over a 
number of repeats making it difficult to draw definite conclusions.  
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Figure 41: Dendritic cell IL10 production in response to alternative C. jejuni LOS strains. 
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Figure 41.  IL-10 production by bone marrow derived dendritic cells following overnight stimulation with 
10µg/ml of wild type or knock out GB2 or GB19 C. jejuni LOS assayed using an OptEIA ELISA kit. Mean 
and SEM calculated from triplicate wells. Analysed using 1way ANOVA with Bonferroni’s multiple 
comparison test. (**=p<0.01, ***=p<0.001).  Single experiment. 
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In order to confirm that the difference in dendritic cell IL-10 production could be reliably 
related to the presence of ganglioside mimicry, dendritic cells were stimulated with an 
additional two strains of ganglioside mimicking LOS and their non-mimicking control 
strains (GB2 and GB19 wild type and knock out).  Figure 41 shows IL-10 production and 
confirms a similar trend to the previous results with knock out strains being more potent 
(GB19 p<0.01, GB2 p<0.001) than the wild type strains although the magnitude of the 
difference is less marked than with GB11 strains. 
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Figure 42: Whole C. jejuni stimulation of dendritic cells and macrophages. 
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Figure 42.  Bone marrow derived dendritic cells or macrophages were stimulated overnight with a titrating 
dose of whole heat inactivated GB11 wild type or knock out C. jejuni. Cytokine production was measured 
using ELISA.  (A)  BMDC IL-10 production following stimulation with whole C. jejuni. (B) BM 
macrophage IL-10 production following stimulation with whole C. jejuni. (C) BMDC TNF-α production 
following stimulation with whole C. jejuni  (D) BM macrophage TNF-α production following stimulation 
with whole C. jejuni. (E) BMDC IL-12 production following stimulation with whole C. jejuni. Mean and 
SEM calculated from triplicate wells. Analysed using 2way ANOVA with Bonferroni’s posttests 
(*=p<0.05).  Representative of three experiments. 
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5.2.7 Potency of whole C. jejuni at stimulating myeloid antigen presenting 
cells 
 
To investigate the role of ganglioside mimicry in differences in potency, dendritic cells 
and macrophages were stimulated with whole ganglioside mimicking or non-mimicking 
bacteria.  The cells were stimulated overnight with whole heat killed C. jejuni.  Figures 
42(A) and (B) show dendritic cell and macrophage IL-10 production following 
stimulation.  There is no difference in potency between the wild type and knock out 
strains in stimulating either cell type.  Figures 42(C) and (D) show TNF-α production.  
Although there is a small statistical difference in dendritic cell responses at a bacteria to 
cell ratio of 1.5:1 (p<0.05) there is no substantial difference in potency between the GB11 
wild type and knock out strains.  Figure 42 (E) shows dendritic cell IL-12 production 
following whole bacteria stimulation and there is no difference in potency between 
ganglioside mimicking and non-mimicking strains. 
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Figure 43: LOS and ganglioside stimulation of dendritic cells and macrophages. 
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Figure 43. Bone marrow derived dendritic cells or macrophages were incubated with 10 µg/ml gangliosides 
GD1a and GM1 alone, GB11 wild type LOS, knock out LOS, and knock out LOS which had been 
sonicated with 10 µg/ml GD1a and GM1. The cells were incubated overnight and cytokine production was 
measured in the supernatant using ELISA.  (A) BMDC IL-10 production (B) BM macrophage IL-10 
production. (C) BMDC TNF-α production (D) BM macrophage TNF-α production. (E) BMDC IL-12 
production.  Mean and SEM calculated from triplicate wells.  Analysed using 1way ANOVA with 
Bonferroni’s multiple comparison test (*=p<0.05, **=p<0.01, ***=p<0.001).  Representative of three 
experiments. 
 174 
5.2.8 Effect of exogenous gangliosides on knock out LOS potency 
 
Exogenous gangliosides have been shown to alter activation of immune cells.  To 
establish if the measured differences in potency between ganglioside mimicking and non-
mimicking LOS are due to the ganglioside mimic, and to gain an insight into the 
mechanism, myeloid cells were stimulated with knock out LOS in the presence of 
exogenous gangliosides.  The cells were stimulated with 10µg/ml non-ganglioside 
mimicking LOS which was first sonicated in solution with 5µg/ml each of gangliosides 
GM1 and GD1a.  The cells were also stimulated with PBS, ganglioside alone or wild type 
LOS.  Contrary to expectations, rather than reduce the potency of knock out LOS to that 
of wild type LOS, the general trend was for GM1 and GD1a to slightly increase the 
potency of knock out LOS (although this was subject to inter-experiment variability and 
was usually not statistically significant).  Figures 43(A) and (B) show dendritic cell and 
macrophage IL-10 secretion.  Addition of exogenous gangliosides slightly increased the 
potency of knock out LOS (p<0.05) at stimulating IL-10 from dendritic cells although it 
had no effect on macrophages.  Figures 43 (C) and (D) show dendritic cell and 
macrophage TNF-α secretion.  There was no statistical difference in TNF-α production 
for either population when gangliosides were added to knock out LOS.  Figure 43 (E) 
shows dendritic cell IL-12 secretion.  Addition of gangliosides to knock out LOS had no 
effect on the LOS potency.  Gangliosides alone had no effect on the dendritic cells or 
macrophages. 
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Figure 44: IL10 production by dendritic cells following blocking of siglec receptors. 
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Figure 44.  Bone marrow derived dendritic cell IL10 production following Sialoadhesin, Siglec E or Siglec 
F blockade and LOS stimulation.  The supernatants were harvested and assayed for IL10 production using 
an ELISA.  Mean calculated from triplicate wells.  Analysed using 2way ANOVA with Bonferroni’s 
posttests  (***=p<0.001).  Representative of three experiments. 
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5.2.9 Effect of siglec blockade on LOS potency 
 
The greatest and most reproducible difference in LOS potency was observed with 
dendritic cell IL-10 secretion following 10µg/ml of GB11 LOS stimulation.  It was 
hypothesised that wild type LOS is less potent than knock out LOS because of inhibitory 
signalling through a siglec receptor.  A restricted set of blocking antibodies against 
candidate myeloid expressed siglec receptors was used to block potential signals 
mediated by the ganglioside mimicking LOS.  Figure 44 shows IL-10 secretion by 
dendritic cells following LOS stimulation in combination with blocking anti-Sialoadhesin 
(3D6 and SER-4209), anti-Siglec F258 or anti-Siglec E258 antibodies (1µg/million cells).  
The cells were incubated with blocking antibody at 4oC for 15 minutes before 10µg/ml 
LOS was added, and then cultured overnight.  The addition of siglec blocking antibodies 
has no effect on wild type LOS potency which remained less potent than knock out LOS 
under all the conditions (p<0.001).  Surprisingly, addition of siglec blocking antibody to 
knock out LOS had a trend of increasing potency although not with statistical 
significance. 
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Figure 45: Upregulation of co-stimulator CD40 by LOS and whole C. jejuni stimulated 
dendritic cells and macrophages. 
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Figure 45. (A) (i)  Bone marrow derived dendritic cells were stimulated with 10µg/ml GB11 wild type or 
knock out LOS and incubated overnight.  CD40 upregulation was measured by FACS analysis (increase in 
CD40-PE MFI shown in histogram). (A)(ii) Graphical representation.  (B)(i) Bone marrow derived 
macrophages were pulsed with heat inactivated whole GB11 C. jejuni for 15 minutes, washed, and then 
incubated overnight.  Upregulation of CD40 was measured by increased MFI.  (B)(ii) Graphical 
representation. Mean and SEM calculated from triplicate tubes.  Analysed using 1way ANOVA with 
bonferroni’s multiple comparisons test.  Representative of three experiments.  
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5.2.10 Upregulation of co-stimulatory molecule CD40 following LOS 
stimulation 
 
CD40 is a co-stimulatory molecule expressed on a number of cells of the immune system 
including dendritic cells and macrophages.  CD40 is up-regulated on dendritic cells 
following stimulation via TLRs and is a useful marker of dendritic cell maturation as 
ligation of CD40 leads to increased expression of other co-stimulators such as CD80 and 
CD86 as well as pro-inflammatory cytokine production314.  CD40 plays a similar role in 
macrophages315. 
 
Having established differences in the potency of ganglioside mimicking and non-
mimicking LOS at inducing cytokines, it was decided to test if there were differences in 
the up-regulation of the co-stimulatory molecule CD40.  Dendritic cells were stimulated 
with ganglioside mimicking or non-mimicking LOS while macrophages were pulse 
stimulated with ganglioside mimicking or non-mimicking whole C. jejuni.  The cells 
were stained with anti-CD11c mAb and F4/80 respectively and co-stained for CD40.  
Example FACS histograms are shown in Figure 45(A)(i) and (B)(i) (an isotype control 
antibody for CD40 showed no increase beyond PBS stimulated cells).  Upregulation was 
measured using the change in the MFI.  Figures 45 (A)(ii) shows the change in dendritic 
cell CD40 expression and indicates no difference between wild type and knock out LOS.  
(B)(ii) shows macrophage CD40 upregulation and no difference is noted between wild 
type and knock out whole C. jejuni.  
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Figure 46: Dendritic cell and macrophage death following LOS stimulation. 
PB
S
Wi
ld 
Ty
pe
 
LO
S
Kn
oc
k O
ut 
LO
S
0
10
20
30
Stimulation
%
 D
ea
d 
ce
lls
PB
S
Wi
ld 
Ty
pe
 
LO
S
Kn
oc
k O
ut 
LO
S
0
10
20
30
40
50 *
Stimulation
%
 
De
ad
 
ce
lls
B
A
 
Figure 46.  Percentage of dead cells determined by trypan blue exclusion assay.  (A) Bone marrow derived 
dendritic cells, (B) bone marrow derived macrophages.  Each population was stimulated with 10µg/ml wild 
type or knock out GB11 C. jejuni LOS and incubated overnight.  Mean and SEM calculated from triplicate 
wells.  Analysed using 1way ANOVA with bonferroni’s multiple comparisons test  (*=p<0.05).  
Representative of three experiments. 
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5.2.11 Effect of LOS on cell death 
 
The inter-experimental variation in cytokine production could be due to cell death 
because of the high concentrations of LOS being used.  Dendritic cells and macrophages 
were stimulated overnight with 10µg/ml wild type or knock out LOS and cell death was 
assayed using a trypan blue exclusion assay.  Figure 46 (A) shows the percentage of dead 
dendritic cells.  There is no statistical difference in dead cells when stimulated with wild 
type LOS, knock out LOS or PBS.  Figure 46(B) shows the percentage of dead 
macrophages.  There is no statistical difference between wild type and knock out LOS 
although knock out LOS caused more cell death than PBS alone (p<0.05).  The trend for 
increased cell death associated with knock out strains of LOS (GB11, GB2 and GB19) 
was seen in a number of dendritic cell and macrophage experiments, although the trend 
was not statistically significant.  To confirm these findings a single experiment was done 
using the 7AAD viability probe in conjunction with FACS analysis.  This confirmed the 
trend but was not statistically significant. 
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Figure 47: C3H/HeJ and TLR2-/- dendritic cell IL10 production following LOS 
stimulation. 
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Figure 47.  Bone marrow derived dendritic cells from (A) C3H/HeJ and C3H/HeN and (B) TLR2 Knock 
Out and C57BL/6 mice were stimulated with 10µg/ml wild type or knock out LOS and IL-10 was 
measured by ELISA in the supernatant after overnight culture.  There is no statistical difference between 
PBS and LOS stimulation of C3H/HeJ cells.  There is no statistical difference between wild type and knock 
out LOS in TLR2-/- cells.  Mean and SEM calculated from triplicate wells.  Analysed using 2way ANOVA 
with Bonferroni’s posttest (nd=no statistical difference, ***=p<0.001).  Single experiment. 
 182 
5.2.12 LOS stimulation of dendritic cells from C3H/HeJ LPS 
hyporesponsive mice and TLR2-/- mice 
 
Capsular polysaccharide is a frequent and tenacious contaminant of LPS preparations.  It 
is sensed by immune cells using TLR2216.  In order to test for contamination, bone 
marrow derived dendritic cells from the LPS hyporesponsive mouse strain, C3H/HeJ, and 
the normo-responsive control strain, C3H/HeN, as well as a TLR2-/- strain and the 
C57BL/6 background strain, were stimulated overnight with C. jejuni LOS and the 
supernatant assayed for IL-10 production.  Figure 47(A) shows that C3H/HeN dendritic 
cells, consistent with previous results for C57BL/6 derived cells, produce IL-10 and that 
knock out is more potent than wild type LOS (p<0.001 for knock out v wild type LOS 
and for both types of LOS v PBS alone).  The C3H/HeJ dendritic cells do not respond to 
LOS, consistent with their LPS hyporesponsive phenotype (no statistical difference 
between either LOS and PBS). 
 
Figure 47(B) shows that C57BL/6 dendritic cells respond as before with knock out LOS 
generating more IL-10 than wild type LOS (and both being greater than PBS) (p<0.001).  
The dendritic cells from TLR2-/- mice produce IL-10 at low levels but both were 
significantly greater than PBS (wild type p<0.01, knock out p<0.001).  However, in 
contrast to the C57BL/6 derived control cells, there is no statistical difference between 
the wild type and knock out LOS at inducing IL-10. 
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5.3 Discussion 
 
The aim of these experiments was to investigate the immunostimulatory properties of C. 
jejuni LOS and any potential effect of ganglioside mimicry.  There are a number of ways 
ganglioside mimicry can potentially modulate the subsequent immune activation 
following TLR4/Lipid A interactions.  Firstly, as shown in chapter 4, the ganglioside 
mimic can act as ligand for siglec receptors.  Secondly, sialic acid plays a direct role in 
TLR4 signalling which has been demonstrated in Neu1 (neuraminidase 1) deficient mice 
and with the use of pharmacological neuraminidase inhibitors such as Tamiflu.  Neu1 is 
expressed by macrophages and it associates with TLR4 where it specifically cleaves α2-3 
linked sialic acid residues, such as those found on gangliosides GM1 and GD1a, linked to 
β−galactoside of TLR4.  When Neu1 activity is blocked or absent there is a reduction in 
the ability of TLR4 to signal with significant reductions in inflammatory cytokine 
production such as IL-6 and TNF-α153,154.  If the α2-3 linked sialic acids on ganglioside 
mimicking LOS can substitute for the α2-3 linked sialic acid residues on β−galactoside of 
TLR4 then this may alter signalling. 
 
LPS mobilises MZ B cells causing them to migrate into the follicle where they deliver 
antigen to FO B cells287-290.  Marginal Zone B cells are important effector cells in the 
response to carbohydrate antigens and are believed to harbour auto-reactive specificities 
131,158
, making them potentially important in GBS.  Results presented in this chapter 
provide evidence for the first time that C. jejuni LOS is capable of mobilising MZ B cells 
in vivo and the results also show that ganglioside mimicry has no effect on this.  
However, an alternative explanation for my observations is that LOS kills all of the MZ B 
cells.  My methodology, which does not differentiate between B cell subsets, does not 
exclude this.  My original intention was to label FO and MZ B cells separately using anti-
IgD and anti-IgM, but for technical reasons related to reagents, this did not work. 
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A number of immune cell populations were stimulated with wild type and knock out LOS 
in order to test for the effects of ganglioside mimicry.  B cells were chosen as they are the 
effector cells responsible for producing auto-reactive antibodies in GBS.  Both purified B 
cells and B cells as part of a mixed splenocyte population were used in order to examine 
direct ganglioside effects on B cells as well as more complex multiple cell lineage 
interactions.  My results show that C. jejuni LOS triggers B cell division and CD138 
positive cell differentiation and that a number of the cells which divided were, or became, 
IgG positive.  However, this probably does not represent de-novo class switching as 72 
hours is too early for this to occur.  There is no difference in potency between ganglioside 
mimicking and non-mimicking LOS strains in this assay.  Interestingly, E. coli LPS 
stimulation results in statistically greater division, CD138 positive cell differentiation and 
class switching than either C. jejuni LOS strain.   
 
In addition to cell division and maturation, IgM and IgG antibody production was 
measured.  Consistent with the previous results, no difference is observed between 
ganglioside mimicking and non-mimicking C. jejuni LOS, although E. coli LPS is more 
potent at stimulating purified B cell and mixed splenocyte IgM production.  In addition, 
there is an inter-strain difference in mixed splenocyte IgM production with the GB19 
strains (both wild type and knock out) inducing more IgM than the GB2 strains (wild 
type and knock out).  There is a similar trend in IgM production from purified B cells.  
This suggests that the specific strain of C. jejuni from which the LOS is derived is more 
important at determining potency than ganglioside mimicry.  This in turn suggests that 
the Lipid A portion is the only important part of the molecule in determining B cell 
stimulating potency.  A similar trend is seen for IgG production by purified B cells, 
although it is not statistically significant.  The GB19 strains of C. jejuni LOS and E. coli 
LPS are equally potent and both are more potent than GB2 strains of C. jejuni LOS at 
stimulating IgG production by mixed splenocytes.  
 
An additional measure of potency is cytokine secretion and IL-10 was chosen as it is an 
important immune modulating cytokine secreted by both B cells and myeloid cells291.  
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My results show no difference in IL-10 production by B cells or mixed splenocytes when 
stimulated with LOS from ganglioside mimicking or non-mimicking strains of C. jejuni, 
and this was seen with both GB2 and GB19 strains.  Consistent with previous findings, E. 
coli LPS is more potent than GB2 strains of C. jejuni LOS and have a trend for greater 
potency than GB19 C. jejuni LOS.   
 
Previous studies of C. jejuni LOS show that it is 50% less toxic to galactosamine 
sensitised mice, 30 to 50 fold less pyrogenic in rabbits and induces 100 fold less TNF-α 
from peritoneal macrophages than LPS from salmonella species316.  The studies presented 
here demonstrate for the first time the potency of C. jejuni LOS in stimulating purified 
murine B cells and B cells as part of a mixed splenocyte population.  They show that C. 
jejuni LOS shares similar immunostimulatory properties as other types of LPS.  
However, consistent with previous publications, they show C. jejuni LOS to be generally 
less potent than other species of LPS (in this case E. coli LPS).  Some authors have 
suggested that the low potency is linked to a higher phase transition (lower fluidity) of C. 
jejuni LOS and the unique diaminoglucose structure in the Lipid A316.  This evidence of 
low potency is reinforced when the molarity of my LOS is considered.  S-form LPS can 
have up to 100 times the mass of R-form LPS (LOS) which means that the C. jejuni LOS 
was used at significantly higher molar concentrations than the E. coli LPS.  S-form LPS 
is heterogeneous in size, so there is no definitive mass with which to calculate molarity 
and make a direct comparison to the C. jejuni LOS.   
 
No difference in B cell stimulation is obvious between the wild type and knock out 
strains.  Given that LPS is one of the most potent immune stimulators known, it is 
possible that any additional signal from a ganglioside receptor is overwhelmed by the 
TLR4 signal or that ganglioside specific receptors are unable to engage soluble LOS.  To 
address this possibility some assays were done with LOS pre-adsorbed onto the tissue 
culture plate, but this had no effect.  Siglec receptors are known to be held in cis 
interactions and require “liberating” from these bonds before they can engage in trans 
binding with external gangliosides.  Further experiments could address this issue by pre-
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treating the cells with a neuraminidase to release any siglec receptors from cis bonds 
prior to exposing them to LOS. 
 
IFN-γ secretion by mixed splenocytes was tested to establish if ganglioside mimicry 
affects production of polarising cytokines.  Intriguingly, no IFN-γ is secreted when 
splenocytes are stimulated with C. jejuni LOS, while E. coli LPS stimulates ample IFN-γ 
production.  No IL-12 production is detected from splenocytes following stimulation with 
any of the LPS/LOS types and this might be due to consumption of the cytokine by the 
cells themselves. 
 
To test if a lack of IFN-γ was unique to C. jejuni LOS, or a general property of R-form 
LPS, splenocytes were stimulated with a titration of C. jejuni LOS, R-form S. 
typhimurium LPS and S-form S. typhimurium LPS.  The data presented shows large 
quantities of IFN-γ production by splenocytes stimulated with S-form S. typhimurium 
LPS with significantly lower quantities from R-form S. typhimurium LPS and none from 
C. jejuni LOS.  In a number of subsequent repeats at varying concentrations, no IFN-γ 
could be detected following R-form S. typhimurium LPS stimulation.  These results 
indicate that R-form LPS, and especially C. jejuni LOS, does not stimulate IFN-γ 
secretion by mixed splenocytes.  This has not been reported before.  Analysis of the same 
supernatant shows that IL-10 secretion remains intact and confirms that S-form S. 
typhimurium LPS is more potent than R-forms of LPS.  10µg/ml is considered a very 
high concentration for LPS stimulation so it is unlikely the lack of IFN-γ is due to the 
LPS concentration being too low. 
 
The mechanisms underlying these differences have not been investigated.  It is possible 
that IL-10 is inhibiting the IL-12/IL-18 – IFN-γ axis.  However, S-form LPS induces 
more IL-10 than R-form LPS and yet continues to induce IFN-γ.  R-form LPS signals 
principally through the MyD88 dependent pathway in the absence of CD14 and this 
might skew the resultant cytokine response towards Th2 and away from Th1  For 
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example, Mast cells are TLR4 positive/CD14 negative and are a potent source of 
cytokines such as IL-5, IL-13 and IL-10.  The antibody isotypes commonly (but not 
exclusively) associated with GBS are IgG1 and IgG3 and this is classically thought to be 
a manifestation of a Th1 dominated response.  Therefore, confirming that C. jejuni LOS 
polarises towards Th2 under normal circumstances would be an important discovery. 
 
These results must be interpreted with caution.  Although all of the LPS types were 
treated with enzymes to improve purity, the two S. typhimurium strains were purified 
using different methods (the S-form by hot phenol extraction and the R-form by the 
phenol-chloroform-petroleum ether method) and both S. typhimurium strains were bought 
commercially.  It is possible that they contain different quantities of contaminating 
bacterial immune stimulators, such as capsular polysaccharide, from each other, or the C. 
jejuni LOS.  The observed phenomena can only be adequately investigated using sources 
of ultra-pure LPS and TLR-/- mouse strains to exclude confounding effects. 
 
Myeloid cells, such as dendritic cells and macrophages, play an important early role in 
shaping the immune response.  LPS stimulates maturation of dendritic cells and 
macrophages into potent antigen presenting cells whereupon they can secrete cytokines 
such as IL-10, IL-12 and TNF-α277-286.  In order to compare the potency of ganglioside 
mimicking and non-mimicking C. jejuni LOS, and to establish if there is any difference 
in the production of polarising cytokines, bone marrow derived dendritic cells and bone 
marrow derived macrophages were stimulated with LOS and the resultant production of 
TNF-α (an acute phase inflammatory cytokine), IL-10 (a cytokine generally considered to 
be anti-inflammatory/Th2) and IL-12 (a Th1 cytokine) was measured.   
 
Dendritic cells stimulated with GB11 knock out LOS produce approximately twice as 
much IL-10 as wild type LOS at 10µg/ml stimulation.  This difference is consistent, 
entirely reproducible (being present in at least eight separate repeats), always highly 
statistically significant and is considered a good candidate for biological significance due 
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to the magnitude of the difference.  Importantly, this effect follows a dose response curve 
although the difference in potency only becomes significant above 1µg/ml.  In addition, 
the increased IL-10 production seen with knock out LOS (or reduced IL-10 production 
seen with wild type LOS) is also present when GB2 and GB19 strains (mimicking 
GM1/GD1a and GD1c respectively) of LOS are used.  This too is consistent and 
reproducible.  However, the magnitudes of the differences for these strains of LOS are 
not as great as for GB11.  
 
The experiments measuring IL-12 and TNF-α suffered from a degree of inter-
experimental variation and the results presented offer a fair reflection of the general 
trends of the experiments.  While the GB11 knock out LOS appears to be generally more 
potent at inducing cytokines from both dendritic cells and macrophages, the differences 
between knock out and wild type strains for TNF-α and IL-12 production is variable, not 
always statistically significant and therefore of questionable biological significance. 
Further experiments studying an alternative marker of dendritic cell activation, 
upregulation of the co-stimulator molecule CD40, show no difference between wild type 
and knock out strains of LOS confirming differences in potency is largely specific to the 
cytokine IL-10.  
 
In order to further investigate the role of ganglioside mimicry and its affect on potency, 
dendritic cells and macrophages were stimulated with heat killed whole bacteria.  In 
contrast to the purified LOS, this does not reveal any difference in potency between 
ganglioside mimicking and non-mimicking strains in inducing IL-10, IL-12 or TNF-α.  
This casts some doubt on the effect or biological relevance of ganglioside mimicry.  In 
the context of multiple separate immunostimulators (LOS, bacterial DNA, RNA, 
flagellum etc) it is possible that subtle effects are lost.  Macrophages pulse stimulated 
with whole C. jejuni show no difference in upregulation of the co-stimulator molecule 
CD40. 
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Exogenous gangliosides directly affect activation of both dendritic cells and macrophages 
through what are believed to be non-receptor specific interactions139,299 (i.e. gangliosides 
may insert into membranes or lipid rafts).  Interestingly, such studies tend to use 
gangliosides at concentrations in the region of tens of micrograms per ml, which is within 
the range at which differences become apparent between ganglioside mimicking and non-
mimicking LOS.  It is possible that both halves of the ganglioside mimicking LOS 
molecule are biologically active at different concentration ranges, with the lipid A portion 
being highly potent and active at sub-microgram concentrations, and the ganglioside 
mimic being less potent and active at tens of micrograms.  Studies of ganglioside effects 
tend to show an inhibitory function which is consistent with the reduced cytokine 
production, and in particular reduced IL-10, seen with ganglioside mimicking LOS.  To 
explore non-receptor specific effects of ganglioside mimicry, dendritic cells and 
macrophages were stimulated with ganglioside alone, ganglioside mimicking LOS or 
non-ganglioside mimicking LOS with exogenous gangliosides added at 10µg/ml.  The 
knock out LOS was first sonicated with the exogenous ganglioside in order to incorporate 
the LOS and gangliosides together in micelles to recapitulate the epitope structure of 
ganglioside mimicking wild type LOS. 
 
In contrast to the reduced potency of ganglioside mimicking LOS, knock out LOS 
combined with exogenous gangliosides has no effect on cytokine production or weakly 
increases cytokine production.  This effectively rules out the hypothesis that differences 
in potency are due to non-receptor specific effects of ganglioside mimicry.   
 
An alternative mechanism for differences in potency is receptor specific signals delivered 
by the ganglioside mimic.  Siglec receptors are generally inhibitory which is consistent 
with the reduced IL-10 production seen with wild type LOS.  In order to test this 
hypothesis, dendritic cells were stimulated with wild type or knock out LOS in the 
presence of blocking antibodies to a restricted set of myeloid expressed siglecs; 
Sialoadhesin, Siglec F and Siglec E.  The presence of blocking antibodies has no effect 
on the amount of IL-10 produced following wild type LOS stimulation.  Although this 
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casts doubt on this hypothesis, it is possible that signalling is taking place via an 
alternative receptor not included in my panel of antibodies.  In addition, these antibodies 
were affinity purified from sheep serum and presumably contain mixed specificities.  
Apart from the anti-Sialoadhesin antibodies, which showed blocking activity in later 
experiments (chapter 6.2.8), it cannot be certain that anti-Siglec E and anti-Siglec F have 
a blocking function as there was no suitable positive control.  It is also possible that the 
antibodies were used at an insufficient concentration. 
 
A possible explanation for the inter-experimental variability seen with TNF-α and IL-12 
production is the extremely high doses of LOS being used to stimulate the cells.  For in 
vitro stimulation of myeloid cells, 10µg/ml of LPS is an exceptionally high concentration 
and possibly toxic, although it is difficult to draw comparisons between the more 
commonly used types of LPS (such as salmonella or E. coli) and C. jejuni.  Experiments 
were done to quantify cell death using both trypan blue exclusion and 7AAD uptake.  
There is no statistical difference in dendritic cell death between either LOS strains or PBS 
although there was a trend seen over a number of experiments for more cell death 
associated with knock out LOS. 
 
Having excluded non-receptor specific ganglioside effects and receptor specific effects 
(as far as is possible with limited reagents) a remaining possibility is that the difference in 
IL-10 production, and indeed the inter-experimental variability, is due to contamination 
present at higher levels in the knock out LOS strains.  An experiment was carried out to 
determine if bacterial capsular polysaccharide was present in the LOS and if this could 
account for differences in potency between wild type and knock out strains.  The 
C3H/HeJ mouse strain is hyporesponsive to LPS due to a mutation in the Tlr4 gene116.  
Before proceeding with this experiment it was recognised that there are a number of 
potential flaws in using this strain. Firstly, C3H/HeJ mice are hyporesponsive but not 
necessarily non-responsive to LPS317 and secondly there has been one report that 
C3H/HeJ derived cells remain sensitive to R-type LPS318.  In addition, if the ganglioside 
mimic is delivering an additional signal it may be impossible to distinguish this signal 
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from signals due to contamination.  A better model may have been the TLR4 -/- mouse, 
but it was not available.   
 
My results show that neither the wild type nor the knock out LOS stimulates IL-10 
secretion from dendritic cells derived from the C3H/HeJ strain. This indicates that 
contamination is not present in the LOS and does not account for the difference in IL-10 
secretion that is demonstrated in the C3H/HeN control strain.  To confirm this 
interpretation, dendritic cells derived from a TLR2-/- mouse strain were stimulated with 
LOS.  The TLR2 receptor senses capsular polysaccharide although it is more 
promiscuous than TLR4 in its specificity216.  If capsular polysaccharide contamination is 
responsible for the differences in IL-10 secretion then there should be no difference in 
IL10 production by TLR2-/- dendritic cells stimulated with wild type or knock out LOS.  
This is what was found. 
 
It was noted that TLR2-/- dendritic cells produce IL-10 at a lower level than the C57BL/6 
controls.  However, this phenomenon, and the resultant IL-10 levels, are entirely 
consistent with a previous publication using E. coli LPS and TLR2-/- derived dendritic 
cells319.  These results suggest that a TLR2 ligand, such as capsular polysaccharide, could 
be responsible for the difference in IL-10 production and therefore this finding is at odds 
with my interpretation of the C3H/HeJ results.   
 
A recent study shows that bone marrow derived dendritic cells produce large quantities of 
TNF-α and IL-12 in response to highly purified LPS signalling through TLR4, but that 
IL-10 is only produced in very low quantities unless there is additional signalling through 
TLR2.  The same study demonstrates that TLR2 signalling alone (achieved using the 
TLR2 agonist Pam3CSK4) does not lead to IL-10 secretion.  TLR2 was shown to act 
synergistically with TLR4 to increase IL-10 but not TNF-α or IL-12 secretion from 
dendritic cells319.  Applying this paradigm to the data presented here suggests that the 
C3H/HeJ experiment does not exclude the presence of a TLR2 agonist as the cytokine 
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tested was IL-10, which a TLR2 agonist alone does not induce in dendritic cells.  
However, this contrasts with previous published work, again using Pam3CSK4 to 
stimulate dendritic cells, which shows ample IL-10 production in response to TLR2 
signalling320.  These conflicting studies used substantially different techniques to purify 
dendritic cells with the former paper bearing a closer protocol to my own, while the latter 
paper used spleen derived dendritic cells. 
 
In order to definitively exclude TLR2 signalling in the C3H/HeJ experiment, the 
supernatant should also have been tested for an additional cytokine such as TNF-α or IL-
12.  Although a TNF-α assay was done on the supernatant, none could be detected in 
either the C3H/HeJ or the control C3H/HeN cells.  Unfortunately, the supernatants had 
undergone multiple freeze/thaw cycles and the need for additional assays only became 
apparent at a late stage.  This would be a suitable experiment to exclude contamination, 
however due to pressing limitations in time and reagents, these experiments have not 
been carried out. 
 
The presence of a TLR2 agonist contaminating the knock out LOS is in keeping with a 
number of observations.  Firstly, the difference in potency was only consistent for IL-10.  
This can be explained in the context of TLR2 signalling acting synergistically to boost 
IL-10, but not TNF-α or IL-12319.  Secondly, the difference in potency only emerges at 
high concentrations.  This can be explained if trace concentrations of contamination reach 
an active dose only when the LOS is used at high concentrations.  Thirdly, the difference 
in potency was only consistent in dendritic cells, in which this synergistic action of TLR2 
and TLR4 signalling for IL-10 has been described.  Although ligands for TLR2 and 
TLR4 have been extensively studied it is clear that this is a very complicated area full of 
potential pitfalls. 
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Although it has been assumed that ganglioside mimics will signal through siglec 
receptors, an additional possibility is that the ganglioside mimics signals through TLR2.  
TLR2 is known to be a promiscuous receptor and although GD1a is not a known ligand 
for TLR2 it has been shown to be a co-receptor for TLR2 with certain ligands321.  This 
scenario might explain the results seen in the TLR2-/- cells.  It is also important to 
establish if the ganglioside mimicking LOS actively inhibits IL-10 secretion or simply 
causes less stimulation. 
 
Reduced IL-10 secretion by dendritic cells when stimulated by ganglioside mimicking 
LOS potentially has wide ranging consequences in autoimmune disease.  IL-10 has 
multiple immunosuppressive effects322.  In dendritic cells and macrophages it is a potent 
inhibitor of antigen presentation, reducing MHCII expression and expression of co-
stimulators CD80 and CD86.  Through its inhibitory effects on antigen presenting cells it 
inhibits both Th1 associated cytokines (such as IL-2 and IFN-γ) as well as Th2 associated 
cytokines (such as IL-4 and IL-5).  IL-10 also suppresses myeloid derived pro-
inflammatory cytokines such as IL-1, IL-6, IL-12 and TNF-α.  Modulation of these latter 
two cytokines by IL-10 dependent feedback loops might explain the variability seen in 
my assays looking at these cytokines.  It is conceivable that a localised deficiency of IL-
10 production by dendritic cells could perturb the cytokine milieu sufficiently to facilitate 
greater inflammation and lead to a break in tolerance, leading to autoimmunity.  This 
scenario would be more plausible if it can be shown that ganglioside mimicry actually 
suppresses IL-10 rather than being less potent at inducing it, although the data suggests 
that ganglioside mimicking LOS is less potent in general.  It should of course be noted 
that this a simplification of the properties of IL-10 which is also immunostimulatory 
under certain circumstances with positive effects on B cell survival and class switching as 
well as natural killer cell proliferation and cytokine secretion. 
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In summary, in relation to B cells, I show C. jejuni LOS to be less potent than E. coli LPS 
by a number of measures.  I find no differences in C. jejuni LOS potency related to 
ganglioside mimicry.  In relation to myeloid cells, and in particular dendritic cells, I show 
an intriguing phenomenon of less IL10 production associated with ganglioside mimicking 
LOS.  I am unable to establish a mechanism for this effect but have taken several steps to 
rule out contamination, although so far my experiments fall short of definitively 
excluding this. 
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6 In vitro and in vivo tracking of ganglioside mimicking and 
non-mimicking C. jejuni 
 
6.1 Introduction 
 
The aims of the experiments in this chapter are to establish if differences in receptor 
binding and/or opsonisation between ganglioside mimicking and non-mimicking strains 
of C. jejuni translate into altered cellular association and uptake, both in vitro and in vivo. 
 
My third core hypothesis, that ganglioside mimicry alters C. jejuni trafficking, is not 
without precedent.  The results presented in chapter four demonstrate that ganglioside 
mimicry by C. jejuni enables the bacteria to bind to specific myeloid expressed siglec 
receptors in vitro, namely Sialoadhesin and Siglec F.  It has been shown by other groups 
that Sialoadhesin enhances phagocytosis of sialylated meningococci255 and I aim to 
investigate if this also occurs with C. jejuni.  In addition to receptor mediated effects, the 
reduced natural antibody levels and complement activation directed against the 
ganglioside mimicking C. jejuni could also affect cellular association and trafficking and 
I aim to investigate this further.   
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Figure 48: Analysis of CFSE labelled C. jejuni. 
A(i) A(ii)
B
 
Figure 48. Wild type and knock out C. jejuni were incubated with 2.5 µM CFSE for 30 minutes before heat 
inactivation.  The fluorescence was assessed using FACS analysis.  (A) (i) is a representative forward side 
scatter FACS plot of C. jejuni (ii) is a histogram plot showing CFSE MFI of both strains including 
unlabelled control bacteria.  (B) labelled bacteria visualised using a fluorescent microscope.  Inset - 
mixtures of corkscrew (white arrow), C-shaped bacilli and coccoid morphology were often present. 
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6.2 Results 
 
6.2.1 Fluorophore labelling of C. jejuni 
 
In order to track C. jejuni both in vitro and in vivo, without altering the surface epitopes, 
it was decided to develop a protocol to label the bacteria with the stable intracellular 
fluorophore CFSE.  Ganglioside mimicking and non-mimicking strains were grown as 
before and incubated with CFSE, washed, then heat inactivated.  As the bacteria were 
intended for use in quantification experiments using MFI they were first analysed by 
Flow Cytometry to ensure the GBS associated strains and control strains had acquired an 
equal fluorescence.  Figure 48 (A) shows the dot plot (i) and MFI (ii) of the bacteria.  
This figure shows that both the wild type and knock out bacteria are labelled with an 
equal fluorescence.  All batches were tested for fluorescence to ensure they were suitable 
for comparison.   
 
In addition to ensuring the consistency of fluorescence it is important ensure the bacteria 
have not been damaged by the labelling process.  Figure 48 (B) shows immunocytometry 
of CFSE labelled bacteria.  The bacteria in this particular batch have retained their 
corkscrew morphology (white arrow).  It was noted in subsequent batches that there is a 
phase variation in morphology with coccoid forms being more common in aged agar 
cultures (48 to 72 hours old) and it is known that prolonged culture or oxygen exposure 
can induce this morphological change.  For the purposes of consistency, wild type and 
knock out strains were always grown and labelled simultaneously and bacteria from the 
same batch were used in each experiment.  
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Figure 49: Confirmation of durable CFSE binding. 
A(i) A(ii)
 
Figure 49.  Confirmation that CFSE remains permanently bound to bacteria.  Labelled or unlabelled 
bacteria were incubated in RPMI for 1 hour, removed by centrifugation and then splenocytes were 
incubated with the RPMI.  (A)(i) FACS forward, side scatter dot plot of splenocytes. (ii) Histogram 
showing CFSE MFI of splenocytes following culture in RPMI which had, or had not, been incubated with 
CFSE labelled bacteria.  Single experiment. 
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6.2.2 Confirmation that CFSE is retained by the C. jejuni 
 
CFSE is used as a fluorophore label for mammalian cells and is exceptionally bright.  For 
this reason it is necessary to confirm that it remains durably bound to C. jejuni and will 
not leak into co-cultured cells.  Labelled or unlabelled C. jejuni were incubated in RPMI 
for 1 hour at 37oC then removed by centrifugation.  Mixed splenocytes were then 
cultured in the RPMI for 30 minutes.  The MFI of splenocytes cultured with RPMI from 
non-labelled C. jejuni was compared to the MFI of splenocytes cultured in RPMI from 
labelled C. jejuni.  Figure 49 shows a FACS plot of the mixed splenocytes (i) and the 
MFI of the cells (ii).  The histograms show no increase in MFI of the splenocytes 
cultured with RPMI which had previously been exposed to labelled C. jejuni indicating 
that leakage of fluorophore and subsequent uptake by cells is not a confounding factor. 
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Figure 50: Quantification of C. jejuni by optical density. 
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Figure 50.  Quantification of C. jejuni.  Graph showing dry weight v OD600.  Mean calculated from two 
tubes.  Single experiment. 
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6.2.3 Development of a convenient and reliable method for quantification 
of C. jejuni 
 
C. jejuni had to be grown off-site (in a fully regulated diagnostic microbiology facility) 
because of restrictions on the use of genetically modified class 2 pathogens in my 
laboratory complex. In addition, GBS associated C. jejuni are rough mutant which 
rapidly form an amorphous growth pattern making quantification by traditional colony 
forming units impractical.  Due to these difficulties a convenient method of quantifying 
killed C. jejuni was established.  A mixed population of C. jejuni were heat killed, 
lyophilised and the dry weight established.  After being resuspended in PBS, a doubling 
dilution was carried out and OD600 measured.  Figure 50 shows a linear relationship 
between dry weight and OD600.  For experiments where an estimate of bacteria to cell 
ratio was required, the mass of one organism was taken to be 1x10-12g (the estimated 
mass of an E. coli cell208).   
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Figure 51: Association of opsonised C. jejuni with B cells. 
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Figure  51.  Heat inactivated, CFSE labelled, C. jejuni were opsonised for 1 minute in fresh autologous 
mouse serum, heat inactivated serum or heat inactivated serum with added exogenous purified mouse 
serum complement.  They were then incubated with mixed splenocytes derived from collagenase treated 
spleens.  Association of C. jejuni with B cells was assayed using FACS.  (A) Representative FACS plots 
showing (i) Splenocyte gate, (ii) CD19 positive B cells, (iii) B cells incubated without bacteria, (iv) B cells 
incubated with opsonised wild type bacteria and (v) B cells incubated with opsonised knock out bacteria.  
(B) Graph showing the percentage of B cells associated with C. jejuni following different opsonisation 
conditions (corrected for background A(iii)).  Following opsonisation, more B cells were associated with 
knock out bacteria than wild type bacteria (p<0.001).  There is no difference following heat inactivation of 
serum.  The difference reappears following addition of exogenous complement (p<0.001).  Mean and SEM 
calculated from triplicate wells.  Analysed using two way ANOVA with Bonferroni’s posttests. 
(***=p<0.001).  Representative of three experiments. 
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6.2.4 Effect of complement opsonisation of C. jejuni on B cell association 
in vitro 
 
My previous results demonstrate that non-ganglioside mimicking strains of C. jejuni are 
more readily opsonised by complement and that this corresponds with increased natural 
antibody present in naïve sera against these strains.  In order to establish if this is likely to 
affect C. jejuni cell association in vivo it was decided to opsonise CFSE labelled bacteria 
and track cell association in vitro in a mixed splenocyte population derived from 
collagenase treated spleens.  B cells were chosen as the target cell as they are considered 
the main effector cell in GBS and express complement receptors. 
 
Wild type and knock out C. jejuni were opsonised for 1 minute in fresh homologous 
mouse serum before being incubated with splenocytes at a 3:1 ratio.  The cells were kept 
at 4oC in the presence of 5mM Na Azide and 5mM EDTA to prevent phagocytosis by 
other populations and to prevent further complement activation.  Figure 51(A) shows 
representative FACS plots.  (A)(i) is the splenocyte gate.  (A)(ii) shows the CD19 
positive gate (B cells) and A(iii), (iv) and (v) show the percentage of C. jejuni positive B 
cells following incubation with no bacteria (used for background correction), wild type 
bacteria and knock out bacteria respectively.  Figure 51(B) is the graphed data and shows 
the percentage of B cells with associated C. jejuni under different opsonisation 
conditions. 
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The results show that opsonisation of knock out C. jejuni leads to greater association with 
B cells than wild type C. jejuni (p<0.001).  To confirm the role of complement in this 
association, heat inactivated homologous serum was used to opsonise the bacteria.  
Inactivation results in no difference between wild type and knock out C. jejuni B cell 
association.  When exogenous purified-mouse-serum-complement was reintroduced into 
the heat inactivated serum prior to opsonisation, the increased B cell association of non-
ganglioside mimicking strains is restored (p<0.001).  This experiment also shows the 
same trend when the data is analysed using the MFI of B cells rather than percentage 
positive. 
 
These results support the earlier finding that ganglioside mimicking strains show less 
opsonisation and indicate that this will potentially affect cell association and trafficking 
in vivo. 
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Figure 52: Immunocytometry of Sialoadhesin on bone marrow derived macrophages. 
A(i) F4/80 Alexa 647 A(ii) MOMA1 FITC A(iii) DAPI
B Isotype controls merged
A(iv) Merged images
 
Figure 52. Detection of Sialoadhesin expression by bone marrow derived macrophages.  A cytospin of 
formalin fixed bone marrow derived macrophages was prepared then labelled overnight with F4/80 and 
MOMA1.  Sialoadhesin could be detected on some, but not all F4/80 positive macrophages (white arrow 
shows Sialoadhesin negative cell).  (A)(i) to (iii) Single labels. (iv) Merged images.  (B) Merged isotype 
controls.  Single experiment. 
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6.2.5 Identification of the Sialoadhesin receptor on bone marrow derived 
macrophages 
 
High levels of Sialoadhesin expression are found on specific subpopulations of 
macrophage, notably the lymph node subcapsular sinus macrophages and splenic 
metallophilic macrophages.  Sialoadhesin is also expressed at low levels by conventional 
populations of macrophages209,248.  In order to establish if bone marrow derived 
macrophages would be a suitable population to study Sialoadhesin-C. jejuni interactions, 
a population of these macrophages was labelled with the Sialoadhesin specific antibody 
MOMA1 and the macrophage marker F4/80, and analysed using immunofluorescence 
microscopy. 
 
Figure 52 shows immunocytology of these macrophages.  Image (A) (i) to (iii) are single 
stains.  (A)(iv) shows that, following overnight incubation with the MOMA1 antibody, 
Sialoadhesin expression by F4/80 positive macrophages could be detected.  Interestingly 
Sialoadhesin could not be detected on all of the F4/80 positive cells (white arrow).  
Although labelling with MOMA1 appeared weak and patchy, the MOMA1 isotype 
control was negative.  The fluorophore used in conjunction with F4/80 was AlexaFluor-
647 which is adversely affected by DAPI (present in the mounting medium) and this is 
probably the reason for the weak F4/80 signal. 
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Figure 53: Macrophage phagocytosis of C. jejuni analysed by FACS. 
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Figure 53.  Bone marrow derived macrophages were incubated with wild type or knock out C. jejuni (20:1 
bacteria:cell ratio) and phagocytosis was measured using the increase in CFSE MFI of the macrophages.  
The fluorescence of cells kept at 4oC in cRPMI with 5mM NaAzide was subtracted as the control. (A)(i) 
and (ii) Cell gate and F4/80 positive gate with isotype control.  (B) Histogram FACS plots showing the 
CFSE MFI of macrophages at (i) 0 minutes, (ii) 15 minutes, (iii) 30 minutes and (iv) 60 minutes.  
4oC/NaAzide controls are included and were subtracted from the final MFI.  (C)(i) Graph of the MFI 
against time. There is increased phagocytosis of the wild type strain after 15 and 30 minutes compared to 
knock out.  C(ii) Graph showing the rate of phagocytosis over each time period and demonstrates an initial 
rapid uptake of wild type C. jejuni greater than knock out.  Mean and SEM calculated from triplicate tubes.  
Analysed using 2way ANOVA with Bonferroni’s posttests (*=p<0.05, ***=p<0.001).  Representative of 
three experiments. 
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6.2.6 Bone marrow derived macrophage phagocytosis of C. jejuni 
 
Sialoadhesin has been shown to facilitate phagocytosis255.  Results presented earlier in 
this thesis (chapter 4.2.1) demonstrate Sialoadhesin binding to ganglioside mimicking C. 
jejuni.  In order to test the hypothesis that Sialoadhesin binding will increase the rate of 
phagocytosis of ganglioside mimicking C. jejuni, bone marrow derived macrophages 
were cultured with CFSE labelled wild type or knock out C. jejuni at a 20:1 bacteria to 
cell ratio and phagocytosis was assessed by measuring the increase in CFSE MFI in the 
macrophages.  To exclude confounding effects of natural antibody opsonisation, ultra-
low immunoglobulin foetal bovine serum was used to supplement the media.  In addition, 
to eliminate the effect of surface binding without phagocytosis, a control population of 
macrophages was incubated with C. jejuni at 4oC in the presence of 5mM Na Azide. 
 
Figure 53 (A) shows the F4/80 positive macrophage population.  Figure 53(B) (i) to (iv) 
shows representative histograms of the MFI of the macrophages following incubation 
with CFSE labelled bacteria at 0, 15, 30 and 60 minutes.  As the MFI increases, it can be 
seen that phagocytosis of the ganglioside mimicking strain is more rapid than the non-
ganglioside mimicking strain. Figure 53(C)(i) illustrates the increase in MFI graphically 
and is corrected for background fluorescence (the shaded histograms in figure 53(B)).  
The difference between wild type and knock out is statistically significant after 15 
minutes (p<0.05) and 30 minutes (p<0.01).  Of three experiments, the wild type and 
knock out reached equivalent phagocytosis by sixty minutes in one, and were close to 
equivalent in two, with the wild type still being ahead.  Figure 53(C) (ii) shows the same 
data illustrated as a rate of phagocytosis over each time period and shows that the 
enhanced rate of uptake of the ganglioside mimicking strain is an early phenomenon 
(p<0.001) with the rate equalising, and then reversing.  
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Figure 54: Immunocytometry of phagocytosed C. jejuni. 
(ii)(i)
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Figure 54.  Visualised of macrophage phagocytosis of C. jejuni using light and fluorescent microscopy with 
Z-stacking to demonstrate the intracellular location of the bacteria.  (i) to (iv) is a Z-stack in which multiple 
bacteria can be seen in levels (ii) and (iii) which are absent in (i) and (iv) indicating their presence inside 
the cytoplasm (see inset).  This was confirmed for wild type and knock out strains in single experiments. 
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6.2.7 Microscopy of phagocytosed C. jejuni 
 
To confirm that phagocytosis of C. jejuni was occurring, a cytospin was made of 
macrophages that had been incubated with C. jejuni for 1 hour.  The cytospins were 
examined using light microscopy with overlaid fluorescence microscopy to identify the 
bacteria.  A Z-stack was made to confirm the intracellular location of the bacteria. 
 
Figure 54 (i) to (iv) shows selected images from the Z-stack of a representative slide.  A 
number of bacteria can be seen present in the middle two layers (highlighted by the 
insert) which are absent in the external layers, confirming that at least a proportion of the 
bacteria are intracellular.  Phagocytosis of both wild type and knock out strains was 
confirmed by this method. 
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Figure 55: Inhibition of phagocytosis by Sialoadhesin blockade. 
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Figure 55. Bone marrow derived macrophages were incubated with labelled C. jejuni (10:1 bacteria to cell 
ratio) for 40 minutes in the presence of a single concentration or a titrated dose of Sialoadhesin blocking 
antibodies SER4 and 3D6 and phagocytosis was measured as before.  (A)(i) and (ii) shows the MFI of 
macrophages incubated with labelled wild type and knock out bacteria respectively.  The unbroken line is 
with no blocking antibody, the broken is with Sialoadhesin blocking antibody and the shaded histogram is 
the isotype control.  4oC/NaAzide controls are not included in the histogram for clarity, but were subtracted 
for the final MFI calculation. (B) Graph showing inhibition of phagocytosis of wild type C. jejuni in the 
presence of a single concentration of Sialoadhesin blocking antibody with no effect on knock out 
phagocytosis.  (C) Titration of blocking antibody until equivalence is reached. Mean and SEM calculated 
from triplicate tubes.  Analysed using 2way ANOVA with Bonferroni’s posttests (***=p<0.001).  (B) 
representative of three experiments, (C) single experiment. 
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6.2.8 Phagocytosis following incubation with Sialoadhesin blocking 
antibodies 
 
To confirm that Sialoadhesin is the receptor mediating the enhanced phagocytosis of 
ganglioside mimicking C. jejuni, a phagocytosis assay was carried out at a single time 
point, at a bacteria to cell ratio of 10:1, in the presence of the Sialoadhesin blocking 
antibodies 3D6 and SER-4. 
 
Figures 55(A) (i) and (ii) respectively show representative histograms of the MFI of 
macrophages incubated for 40 minutes with labelled wild type (red lines) and knock out 
(blue lines) C. jejuni.  The histograms show bacterial uptake.  The unbroken line is 
phagocytosis with no blocking antibody.  The broken line is phagocytosis following prior 
incubation with 3D6 and SER-4.  The shaded histogram is a 3D6 and SER-4 isotype 
control.  The 4oC, Na Azide controls are not shown in the histogram to aid clarity, but 
were subtracted from the final fluorescence.  This figure shows a reduction in the right-
shift of the wild type histogram in the presence of blocking antibodies with no such 
reduction in the knock out histogram. 
 
Figure 55(B) shows a phagocytosis blocking experiment at a single concentration of 
blocking antibody (0.3µg/million cells) (4oC controls subtracted) and shows a statistically 
significant reduction in phagocytosis of wild type C. jejuni (p<0.001) with no reduction 
in knock out phagocytosis when Sialoadhesin blocking antibodies are present. 
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After it was established that Sialoadhesin blocking antibody inhibited wild type but not 
knock out C. jejuni phagocytosis, it was decided to do a titration of blocking antibody to 
establish if the rate of wild type phagocytosis could be reduced to match that of knock 
out.  Figure 55(C) shows the effect of increasing the dose of blocking antibody on the 
amount of wild type and knock out phagocytosis.  At 0.5µg/ml each of blocking 
antibodies 3D6 and SER-4, there is no statistical difference between phagocytosis of wild 
type and knock out C. jejuni. 
 
 214 
6.2.9 In vivo tracking of i.v. injected C. jejuni to metallophilic 
macrophages 
 
Having established in vitro differences in complement opsonisation and cell association 
as well as differences in receptor mediated phagocytosis of ganglioside mimicking and 
non-mimicking strains of C. jejuni it was decided to inject the bacteria into mice i.v. and 
establish which cell populations the ganglioside mimicking or non-mimicking bacteria 
associate with.  As Sialoadhesin is expressed at high levels by metallophilic macrophages 
I hypothesised that the wild type strains would associate with this cell population.  As the 
knock out strain is targeted by complement, I hypothesised that these bacteria would 
either be rapidly lysed in the serum or associate with complement receptor expressing 
cells such as marginal zone macrophages or MZ B cells.  
 
Age and sex matched C57BL/6 mice were injected i.v. with 200µl of heat inactivated 
bacteria at an OD600 of 0.6 in PBS.  Control mice were injected with PBS alone.  After 1 
hour or 3 hours the mice were sacrificed and the spleen, lymphoid tissue and serum 
harvested and stored at -80oC.  Following sectioning, the spleen was stained with a B220 
specific antibody to identify the follicles and a MOMA1 antibody to identify the 
metallophilic macrophages.   
 
Figure 56(A) (i) to (iii) shows single stains.  (A)(iv) shows a representative image of a 
splenic follicle from a wild type strain injected mouse.  The inset shows labelled C. jejuni 
lying in association with MOMA1 positive macrophages (white arrows (a)).  In addition, 
bacteria can also be seen lying external to the MOMA1 positive population (white arrow 
(b)).  Figure 56(B) shows a representative section from a PBS injected mouse and the 
inset illustrates the background auto-fluorescence that can be distinguished from bacteria. 
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Figure 57(A) (iv) shows a representative image of a splenic follicle from a knock out 
strain injected mouse.  The inset shows that knock out bacteria are also found in 
association with the MOMA1 positive metallophilic macrophages. 
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Figure 56: In vivo association of wild type C. jejuni with metallophilic macrophages. 
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Figure 56.  Fluorescent microscopy images of spleens from wild type C. jejuni injected mice after 1 hour.  
Spleen was stained for metallophilic macrophages (MOMA1) and B cells (B220).  (A) (i) to (iii) are single 
stains. (iv) Shows the merged images of a splenic B cell follicle and the inset shows wild type C. jejuni in 
association with metallophilic macrophages (a) and external to the metallophilic macrophages (b).  (B) Is a 
splenic section following i.v. PBS injection and the inset shows FITC auto-fluorescence clearly 
distinguishable from the labelled bacteria in (A)(iv). (n=4 for 1 hour time point and n=2 for 3 hour time 
point). 
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Figure 57: In vivo association of knock out C. jejuni with metallophilic macrophages. 
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Figure 57.  Fluorescent microscopy images of spleens from knock out C. jejuni injected mice after 1 hour.  
Spleen was stained for metallophilic macrophages (MOMA1) and B cells (B220).  (A) (i) to (iii) is single 
stains. (iv) Shows the merged images of a splenic B cell follicle and the inset shows knock out C. jejuni in 
association with metallophilic macrophages. (n=4 for 1 hour time point, n=2 for 3 hour time point). 
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6.2.10 In vivo tracking of i.v. injected C. jejuni to marginal zone 
macrophages 
 
Both wild type and knock out bacteria were identified outside the rim of metallophilic 
macrophages, lying in a region which is populated by marginal zone macrophages.  To 
test if these bacteria were associating with marginal zone macrophages the sections were 
stained with the marginal zone macrophage marker ER-TR9.  Figure 58(A) (iv) shows a 
representative image of a follicle from a wild type injected mouse.  Bacteria can be seen 
lying in association with the ER-TR9 positive marginal zone macrophages (inset white 
arrow (a)) and also internal to this population (white arrow (b)) in association with ER-
TR9 negative cells (presumably metallophilic macrophages).  Figure 58(B) shows a 
follicle from a PBS injected control mouse and again illustrates background auto-
fluorescence. 
 
Figure 59 (A) (iv) shows a representative image of a splenic follicle from a mouse 
injected with knock out bacteria.  The inset shows bacteria lying in association with ER-
TR9 positive marginal zone macrophages (white arrow (a)) and also lying internal to this 
(white arrow (b)) in association with ER-TR9 negative cells (again, presumably 
metallophilic macrophages). 
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Figure 58: In vivo association of wild type C. jejuni with marginal zone macrophages. 
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Figure 58.  Fluorescent microscopy images of splenic sections 1 hour following i.v. administration of 
labelled wild type C. jejuni.  Spleen was stained for marginal zone macrophages (ER-TR9) and B cells 
(B220).  (A) (i) to (iii) are single stains.  (iv) Shows the merged images of a splenic B cell follicle and the 
inset shows wild type C. jejuni in association with marginal zone macrophages (a) and internal to the 
marginal zone macrophages (b).  (B) Is a splenic section following i.v. PBS injection and the inset shows 
FITC auto-fluorescence clearly distinguishable from the labelled bacteria in (A)(iv). (n=4 for 1 hour time 
point, n=2 for 3 hour time point). 
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Figure 59: In vivo association of knock out C. jejuni with marginal zone macrophages. 
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Figure 59.  Fluorescent microscopy images of splenic sections 1 hour following i.v. administration of 
labelled knock out C. jejuni.  Spleen was stained for marginal zone macrophages (ER-TR9) and B cells 
(B220).  (A) (i) to (iii) show single stains.  (iv) Shows the merged images of a splenic B cell follicle and the 
inset shows knock out C. jejuni in association with marginal zone macrophages (a) and internal to the 
marginal zone macrophages (b).  (n=4 at 1 hour time point, n=2 at 3 hour time point). 
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Figure 60: Analysis of C. jejuni and macrophage in vivo co-localisation. 
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Figure 60.  The co-localisation of wild type and knock out C. jejuni with metallophilic and marginal zone 
macrophage populations was quantified.  A(i) representative follicle. (A)(ii) representative scatter plot 
analysis. Co-localisation software identified the number of pixels in which CFSE (bacteria) and TRITC 
(macrophage population) were co-localised. (B) Metallophilic macrophages (i) Shows the total CFSE 
positive area after 1 hour and 3 hours.  (B)(ii) Shows the percentage of C. jejuni and metallophilic 
macrophage co-localisation ((co-localised area/total CFSE area) *100)).  There is no statistical difference 
between wild type and knock out C. jejuni at either time point.  (C) Marginal zone macrophages. (i) Shows 
the total CFSE positive area after 1 hour and 3 hours in the ER-TR9 stained sections. (C) (ii) Shows the 
percentage of C. jejuni and marginal zone macrophage co-localisation ((co-localised area/total CFSE area) 
*100)).  There is no statistical difference between wild type and knock out C. jejuni at either time point.  
Analysed using two way ANOVA with Bonferroni’s posttest.  (n=4 at 1 hour, n=2 at 3 hours. 3 follicles in 
each of 2 sections analysed per mouse). 
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6.2.11 Quantification of C. jejuni association with macrophage populations 
 
In order to determine if there are quantitative differences in the association of the 
different strains of C. jejuni with metallophilic and marginal zone macrophages, co-
localisation software was used to quantify amount of CFSE (C. jejuni) positive area and 
establish how much it co-localises with the different macrophage populations.   
 
Figure 60 (A) (i) shows a representative follicle and figure 60 (A) (ii) shows the scatter 
plot generated when a follicle is analysed.  The number of pixels positive for both CFSE 
and TRITC are identified in the top right quadrant.  Two sections were taken per spleen 
and three follicles were analysed per section.  Four wild type and four knock out C. jejuni 
injected mice spleens were analysed at 1 hour and two each at 3 hours. 
 
Figure 60 (B) (i) shows the average total CFSE positive area per follicle in the MOMA1 
stained sections at 1 hour and 3 hours post injection, and demonstrates the steep drop off 
in fluorescence over this time period.  This rapid loss of fluorescence demonstrates one of 
the technical challenges in tracking the labelled bacteria.  There is no statistical difference 
between the total CFSE positive area for wild type and knock out injected mice at either 
time point showing that the same quantity of bacteria reached, and were retained in, the 
spleen for both wild type and knock out strains. 
 
Figure 60 (B) (ii) shows the percentage of C. jejuni co-localising with metallophilic 
macrophages.  This demonstrates that both strains of bacteria localise to this macrophage 
population and that these macrophages are associated with approximately half of all the 
bacteria that are present in the spleen.  There is no statistical difference between the two 
strains of C. jejuni at either time point. 
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Figure 60 (C) (i) shows the average total CFSE positive area per follicle in the ER-TR9 
stained sections at 1 hour and 3 hours post injection.  As expected, the results are similar 
to the MOMA1 stained sections with no statistical difference between the total CFSE 
positive area for wild type and knock out injected mice at either time point. 
 
Figure 60 (C) (ii) shows the percentage of C. jejuni co-localising with marginal zone 
macrophages.  Both C. jejuni strains localise with this macrophage population.  There is 
no statistical difference between the two strains at either time point.  A smaller 
percentage of the bacteria localise with marginal zone macrophages than with the 
metallophilic macrophages.  However, between the metallophils and marginal zone 
macrophages it appears that that virtually all of the C. jejuni depositing in the spleen will 
be associated with these populations.   
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Figure 61: FACS analysis of C. jejuni co-localisation with splenocytes in vivo. 
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Figure  61.  Mice were injected i.v. with 200µl of labelled wild type or knock out bacteria at an OD600 of 
0.6. The mice were sacrificed after 1 hour and a single cell suspension was made of the spleens without 
collagenase.  The cells were briefly fixed with paraformaldahyde then labelled for various cell populations.  
(A) to (F) Representative FACS plots. (A) Lymphocyte gate, (B) F4/80 positive cells (macrophages), (C) 
CD11c positive cells (dendritic cells), (D) GR1 positive cells (granulocytes), (E) MOMA 1 positive cells 
(metallophilic macrophages), (F) CD19 positive cells (B cells). Column (i) isotype control (not available 
for CD19), (ii) antibody marker for lymphocyte population (x axis, all APC), (iii) CFSE (C. jejuni) high in 
PBS injected mouse (negative control) and (iv) CFSE high from C. jejuni injected mouse.   
 
(G) (i) to (v) graphical representation of FACS data comparing association of wild type C. jejuni and knock 
out C. jejuni with different spleen populations  (i) F4/80 positive, C. jejuni positive, (ii) CD11c positive, C. 
jejuni positive, (iii) GR1 positive, C. jejuni positive, (iv) MOMA1 positive, C. jejuni positive and (v) CD19 
positive, C. jejuni positive.  There are no statistically significant differences between wild type and knock 
out populations.  Analysed using 1 way ANOVA with Bonferroni’s multiple comparison test. (n=3 mice for 
each injection, FACS tubes in triplicate).   
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6.2.12 Analysis of C. jejuni association with different splenic cell 
populations using FACS 
 
In order to confirm the immunohistology results and to test a broader range of cell types, 
spleens from injected mice were analysed using Flow Cytometry. 
 
Nine age and sex matched C57BL/6 mice were divided into three groups and injected 
with C. jejuni or PBS as before.  After one hour the spleens were harvested and a single 
cell suspension was made.  The immunohistology results and pilot FACS studies had 
shown that bacteria, or the CFSE fluorescence, disappear rapidly in vivo.  The spleens 
were therefore fixed for 15 minutes in 1% paraformaldahyde and the usual red cell lysis 
step was omitted so that surface associated bacteria would remain intact.  
 
The cell populations studied were F4/80 high macrophages, CD11c high dendritic cells, 
GR1 positive granulocytes (using the anti-Ly-6G neutrophil specific clone 1A8), 
MOMA1 high metallophilic macrophages and CD19 positive B cells.  Figures 61 (A) to 
(F) show representative FACS plots (detailed in the figure legend) and includes isotype 
controls where available and PBS injected controls. 
 
Figure 61 (G) (i) to (v) shows the percentage of CFSE (C. jejuni) positive cells in each of 
the populations studied.  There is no statistical difference in the association of wild type 
or knock out C. jejuni with any of the cell types studied.   
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6.3 Discussion 
 
These results and the technical challenges that were met in achieving them led to a 
number of novel observations.  An ideal method of tracking C. jejuni involves an intrinsic 
fluorophore label which is stable and resistant to bleaching.  Plasmid transformation with 
green fluorescent protein (GFP) is one possible solution with the added advantage that 
the label is stable through multiple rounds of division.  Although such transformations 
have been done, they are technically challenging as commercially available gfp plasmids 
are not suitable for use in C. jejuni because the antibiotic resistance genes and origins of 
replication are not active in this species323.  In addition, making the C. jejuni chemically 
competent would require prolonged periods of handling which was impossible due to 
safety restrictions which prevented the use of live, genetically modified, pathogens in the 
lab.  The off-site clinical bacteriology lab where the bacteria were cultured does not have 
the facilities to carry out such work. 
 
To overcome these difficulties, the cell tracking fluorophore CFSE was used to label the 
live bacteria which were then heat inactivated to prevent dilution of the dye.  CFSE enters 
bacteria where it is metabolised by esterases resulting in covalent intracellular binding324.  
This makes it a suitable alternative to GFP as it is stable and is unlikely to alter surface 
epitopes.  CFSE has been used to label and track C. trachomatis, borreliae Sp., H. pylori 
and S. pneumoniae 325-328.  However, it shows species specific differences in uptake with 
poor labelling of S. aureus and no labelling of E. coli328.  This is the first time that CFSE 
labelling of C. jejuni is demonstrated and I also show that identical levels of labelling can 
be achieved within related strains of C. jejuni which allows tracking the bacteria while 
comparing individual genetic traits, in this case the expression of ganglioside mimics on 
LOS.  Durable binding of CFSE is important (i.e. the CFSE won’t leak out).  This has 
already been demonstrated using S. pneumoniae328 and I confirm this quality in C. jejuni 
as there is no evidence of CFSE leakage into culture media. 
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Previous studies in this thesis have demonstrated reduced complement deposition on 
ganglioside mimicking strains of C. jejuni compared to control strains (chapter 4.2.10).  
These studies looked at formalin fixed bacteria which had been adsorbed onto an ELISA 
plate.  In this chapter I demonstrate that this difference in complement opsonisation 
affects association of heat inactivated C. jejuni with splenic B cells in vitro.  This study 
suggests that ganglioside mimicry might affect which immune cells the bacteria associate 
with in vivo and that ganglioside mimicry begins to shape the interaction with the 
immune system at a very early stage, i.e. when bacteria are first exposed to serum.  
 
B cells express complement receptors329-331 and complement plays a vital role in B cell 
responses both directly through signalling and indirectly by controlling delivery of 
antigens.  Deficiency of complement components results in defective antibody responses 
332-335
.  There are a number of mechanisms by which complement facilitates humoral 
immunity.  The complement receptors CD21/CD35 link antigen to the B cell, they act 
synergistically with B cell receptor signalling and they co-aggregate with CD19 to 
modulate signalling336-341.  In addition, MZ B cells deliver IgM opsonised antigen to 
follicular dendritic cells in a complement and complement receptor dependent manner289.  
Although the complexities of an in vivo system make it impossible to predict how small 
differences in opsonisation will affect immunity, in theory, my observations regarding 
opsonisation and cell association suggest the ganglioside mimicking strains should be 
less immunogenic due to less opsonisation.   
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The results presented here show relatively more B cell association of non-ganglioside 
mimicking bacteria and that this is complement dependent.  Results presented earlier 
suggest that natural antibody is the important factor determining levels of complement 
opsonisation (chapter 4.2.12).  How efficiently C. jejuni are opsonised and delivered to 
follicular dendritic cells could be down to variations in an individual’s anti-ganglioside 
natural antibody levels and repertoires.  This is an important area for further work as it 
was not proven definitively that natural antibody was the sole cause of differences in 
complement activation.   
 
Sialoadhesin has affinity for ganglioside mimicking C. jejuni (chapter 4.2.1).  
Sialoadhesin mediates phagocytosis of sialylated meningococci255.  The studies presented 
in this chapter show, for the first time, that ganglioside mimicking C. jejuni are 
phagocytosed more rapidly than control strains and that this difference can be completely 
inhibited by blocking Sialoadhesin.  The margin of difference was very small, but had 
consistent statistical significance across several repeats.  The small margin might be due 
to the population of macrophages being used in the assay.  The presence of Sialoadhesin 
on bone marrow derived macrophages was demonstrated by immunocytology.  However, 
the cells required an overnight incubation with the MOMA1 antibody and the receptor 
was not detectable on all of the F4/80 positive cells.  This is not surprising as 
Sialoadhesin is highly expressed by only particular subpopulations of macrophages.  
These populations cannot be isolated and studied without altering their physiology as the 
only reliable marker is Sialoadhesin itself.  It is therefore possible that any biological 
significance is not with the conventional macrophage populations but may lie with the 
specialised subpopulations.  If an assay could be designed to study C. jejuni phagocytosis 
by these cells it might show marked differences when ganglioside mimicry is present. 
 
Up until this point a number of in vitro phenomena have been demonstrated which have 
potential to alter trafficking and delivery of ganglioside mimicking C. jejuni to the 
follicle.  Importantly, differences in behaviour between these strains and control strains 
have been by degree rather than absolute.  In order to establish the biological significance 
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of these observations, ganglioside mimicking and control strains were injected i.v. into 
wild type mice.  It was hypothesised that ganglioside mimicking strains can evade the 
complement cascade and localise to Sialoadhesin positive metallophilic macrophages.  
 
No such study tracking antigen trapping of labelled C. jejuni has been done previously 
and in particular no studies have addressed trapping of a pathogen which expresses 
surface ligands for the metallophilic macrophage receptor, Sialoadhesin.  The studies 
presented here show a trend for increased association of ganglioside mimicking C. jejuni 
with the metallophil population but this is not statistically significant.  There is no 
statistical difference between strains when association with marginal zone macrophages 
is measured either.  In addition, a number of C. jejuni can be seen in the splenic medulla 
not associated with either of these macrophage populations.  Although I did not 
investigate this further, this may be association with medullary macrophages.  The 
methods used in this study cannot reliably distinguish between phagocytosis and surface 
association. 
 
Although not the expected outcome, association of both wild type and knock out strains 
with both the metallophilic and marginal zone populations of macrophages is an 
important finding, demonstrated for the first time.  With hindsight, these findings are 
unsurprising as marginal zone and metallophilic macrophages both contribute to trapping 
of diverse types of particulate antigen342-345.  Marginal zone macrophages are reported to 
express high levels of CR3342 and my own experiments show efficient complement 
opsonisation of both strains of C. jejuni, albeit with inter-strain differences.  The design 
of these experiments was insufficient to demonstrate the contribution of Sialoadhesin 
binding because both strains could be associating with both marginal zone and 
metallophilic macrophage populations via complement receptors.  Another confounding 
factor is that the MOMA1 positive macrophage population overlies and interdigitates 
with the outermost B220 positive MZ B cell population and this might affect the ability 
of co-localisation software to discriminate between metallophil association and B cell 
association. 
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An interesting observation is that the B220 positive MZ B cells are not visible beyond the 
edge of the follicle indicating that the MZ B cells have been mobilised in a manner 
similar to that shown following purified LOS injection (chapter 5.2.1).  Presumably LOS 
is shed from the bacteria during heat inactivation and is present in the injected whole 
bacteria sample.  The rapid kinetics demonstrated here (1 hour versus 18 hours in 5.2.1) 
might be due to the intravenous versus intraperitoneal routes of administration.  
 
Metallophilic macrophages are believed to be less phagocytic than conventional 
macrophages346,347 while their lymph node counterparts, subcapsular sinus macrophages, 
have been shown to transfer intact antigen on their surface into follicles.  Future work 
might establish if ganglioside mimicking C. jejuni are endocytosed (through Sialoadhesin 
mediated phagocytic activity) while control strains might remain surface associated (and 
available to B cell receptors).  There were a number of occasions where both wild type 
and knock out metallophilic macrophage associated C. jejuni appeared convincingly 
intracellular but confocal microscopy is required to formally establish this.  In addition, 
cell sorting was employed to separate out the CFSE positive cells from a splenocyte 
suspension 1 hour after injection.  Cytospins of the sorted cells, which will reveal the 
location of the bacteria, await analysis.   
 
Functional outcomes might also prove important.  The metallophilic macrophage 
population has been shown to be an important source of IFN-α/β following i.v. herpes 
simplex virus injection348.  In my experiments, serum was taken at early and late time 
points, and combined with immunofluoresence labelling of the splenic sections, might yet 
reveal differences between C. jejuni strains at stimulating cytokines in vivo. 
 
The association of C. jejuni with a number of different cell types in vivo was studied 
using FACS analysis.  C. jejuni association with F4/80 positive macrophages, CD11c 
positive dendritic cells, GR1 positive granulocytes, MOMA1 positive macrophages and 
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CD19 positive B cells was measured and no difference between the C. jejuni strains is 
detected.  These studies were difficult for practical reasons.  The CFSE fluorophore is 
very bright and has a tendency to bleed in to other channels.  Each cell type had to 
therefore be analysed as a double stain with C. jejuni in FL1 and the cell identifying 
antibody in FL4 (i.e. as far apart as possible in the spectrum).  In addition, pilot studies 
showed that C. jejuni fluorescence rapidly disappears (presumably due to being destroyed 
by complement lysis or lysosomal enzymes in phagocytes) and we therefore had to omit 
potentially important but time consuming steps in the protocol, such as collagenase 
treatment of the spleens.  As this is used to enhance the release of populations of antigen 
presenting cells it may have affected our results.  Brief paraformaldahyde fixation was 
also used to preserve the bacteria.  Despite these difficulties, the FACS analysis appears 
to confirm the immunohistology results, that is, there is no apparent difference in cell 
association between C. jejuni strains. 
 
In conclusion, I show in vitro differences between ganglioside mimicking and non-
mimicking strains in B cell association and macrophage phagocytosis.  These differences 
are due to differential complement activation and receptor binding.  However, in vivo I 
am unable to demonstrate differences in cell association.  This might be due to practical 
considerations, such as the use of heat inactivated dead bacteria, which can only be 
tracked for a short period of time.  In addition, alternative measures of outcome, such as 
IFN production, might yield positive results. 
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7 Conclusion 
 
The experiments presented in this thesis were intended to address the following 
hypotheses:  
 
1. LOS derived from a GBS associated strain of C. jejuni is able to bind to cellular 
or humoral ganglioside specific receptors through the ganglioside mimicking core 
sugars. 
2. Binding of LOS to these ganglioside specific receptors alters the potency or 
polarising properties of ganglioside mimicking LOS compared to non-mimicking 
LOS. 
3. Binding of ganglioside mimics to these ganglioside receptors alters trafficking of 
the C. jejuni within the immune system. 
 
The maintenance of self-tolerance is an active process which is tightly regulated by the 
immune system.  The over-arching hypothesis is that the breaking of tolerance which 
occurs in GBS following exposure to C. jejuni LOS is not an idiopathic event, but is 
driven by both Lipid A-TLR4 stimulation and ganglioside mimic-ganglioside receptor 
interactions.  It is these additional signals that subvert the normal immune system 
homeostasis, and allow, or promote, the survival and expansion of auto-reactive B cell 
clones. 
 
Studies of GBS are numerous, but until now have focussed largely on the clinical aspects 
of the disease or the function and fine specificity of the anti-ganglioside/anti-LOS 
antibodies and their role in neuroinflammation233,349,350.  In addition, the physiology of C. 
jejuni has been well studied with particular reference to the biochemical synthesis of 
ganglioside mimicking LOS101,202,203.  The general immunology of C. jejuni infection has 
also been the subject of much interest due to its role as an important food borne 
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pathogen76,351,352.  However, very few studies have looked closely at the induction phase 
of GBS, how ganglioside mimicking C. jejuni, specifically, interact with the immune 
system and if the ganglioside mimic is simply a passive target for autoreactive B cell 
receptors (antibodies) or if it influences the evolution of the response via ganglioside 
receptor interactions. 
 
Studying potential interactions between ganglioside mimicking LOS and the immune 
system has become possible in recent years due to the identification and characterisation 
of ganglioside specific receptors such as members of the siglec family144,240 or galectin 
1353.  In addition, an understanding of the biochemical pathways involved in LOS 
synthesis allowed the generation of C. jejuni control strains, isogenic with the GBS 
associated ganglioside mimicking strains, which lack the CSTII enzyme required to add 
sialic acid to the LOS and generate a ganglioside mimic101.  These provide an excellent 
source of non-ganglioside mimicking control LOS with which to compare the ganglioside 
mimicking LOS in function and potency. 
 
To the best of my knowledge there is currently only one study which has reported 
binding of a ganglioside mimicking C. jejuni strain and its LOS to a lymphocyte 
expressed ganglioside receptor (a GM1/GT1a mimicking strain binding to the NK cell 
receptor, Siglec 7)148 and no functional outcomes were measured.  I sought to investigate 
LOS and C. jejuni interactions with ganglioside specific receptors and identify functional 
outcomes dependent on these interactions and idiosyncratic to ganglioside mimicking 
strains.  It was hoped that this study would improve our understanding of the immune 
response to ganglioside mimicking C. jejuni and shed light on the evolution of 
autoimmunity in GBS. 
 
 235 
7.1.1 LOS purification 
 
In order to test my hypothesis I needed highly pure forms of wild type and CSTII knock 
out LOS which were standardised both by primary structure (the actual concentration of 
LOS molecules) and by secondary structure (the size and nature of the spontaneous LOS 
aggregates that form during hot phenol extraction).  The secondary aggregate structures 
are important because they affect the rate at which LPS is taken up by cells106 and LPS 
stimulated cytokine secretion232. 
 
Protocols for purifying LOS are well established316, however this turned out to be a 
frustratingly difficult task.  The nature of my experiments, comparing two strains of LOS, 
meant that quantification, purity and secondary structures were of paramount importance 
which contrasts with previous studies in which the chemical structure of the LOS was the 
prime concern.  The thiobarbituric acid assay, for example, is commonly used to quantify 
LOS.  However, I demonstrated that ganglioside derived sialic acid interferes with this 
assay making it inappropriate for comparing concentrations of ganglioside mimicking 
and non-mimicking strains.  It is debatable whether the ganglioside effect is sufficient to 
render this assay useless.  However, when dry weight and the thiobarbituric acid assay 
gave contrasting results (as they did) it was decided to work with dry weight as this is the 
standard method of quantifying LOS/LPS in immunological methods. 
 
It was recognised that silver stains and Western blots can only act as surrogate markers 
when trying to determine the nature of the aggregate structures adopted by the LOS in 
aqueous solution.  This level of organic chemistry is beyond the scope of the study and 
beyond the levels of expertise available in the department.  However, the interpretation 
that “dimers” present in the silver stain represented two LOS molecules in a hydrophobic 
embrace, via their extensive acyl chains, is in fact consistent with previous, more 
specialised, work showing that dispersed LPS forms dimers, dependent on hydrophobic 
interactions, when in solution226,354.  The nature of such secondary structures is an 
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important consideration in the light of recent work showing that juxtaposed gangliosides 
form complexes which can dramatically alter the binding properties of antibodies and 
receptors233,355,356 and this might also be the case for ganglioside mimicking LOS.  More 
importantly, when LOS forming dense precipitates was used in pilot studies it proved 
virtually inactive, or highly toxic, as the cells barely responded.   
 
It is impossible to predict how the micelle structure of LOS will be affected by culture 
conditions.  Clearly tissue culture media will contain cations.  However, the LOS is 
diluted massively when added to culture media which presumably makes secondary 
structures less likely to form de novo.  However, if they are already present they may not 
be affected.  In addition, the serum added to RPMI media to make complete RPMI will 
contain numerous proteins and lipoproteins (such as high density lipoprotein, 
chylomicrons and LPS binding protein) which are known to have a physiological 
capacity to bind LPS and affect its transport, activity and detoxification357-361.  Provided 
the wild type and knock out strains have comparable micelle structures before addition to 
cultures then any of these immeasurable considerations should be controlled for. 
 
The initial attempts to regulate aggregate structure by dispersal with Triton X detergent 
were stymied by an inability to remove the large detergent molecule using dialysis.  Pilot 
studies using the small planar detergent, sodium cholate (used frequently for this very 
purpose232) looked more promising.  However, an alternative strategy, which avoided 
adding divalent cations, which facilitate aggregate formation362,363, was used by a 
collaborating group who provided us with the aforementioned wild type and CSTII knock 
out C. jejuni and LOS.  The fact that the enzymes remained active can be explained by 
the high concentrations of Ca2+ and Mg2+ which associate with LPS during purification 
from bacteria354.  I showed in my silver stain and Western blot analysis that using this 
technique resulted in only faint dimers and, combined with the visual appearance of the 
solution, interpreted this as meaning the LOS was no longer forming large secondary 
structures.  This purification could have been improved by combining the strategies of 
avoiding cations in the enzyme buffer with using cholate dispersal to produce mono-
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disperse LOS which could then be reconstituted into its spontaneous micelle forms under 
controlled buffer conditions to ensure parity between the wild type and knock out strains.   
 
Bacterial LPS is frequently contaminated by other bacterial immunostimulators364-366.  
Glycolipids, such as capsular polysaccharide, represent the most tenacious contaminants 
because of their similar chemical properties to LPS, meaning that they do not necessarily 
partition differently during chemical extraction techniques such as hot phenol.  In 
addition, it cannot be digested out using enzymes, and although some protocols use 
lysozyme for this purpose, I showed it to be inappropriate with my R-form LOS where it 
caused dramatic changes to the secondary LOS structures.  Prolonged ultra-centrifugation 
is included in many protocols possibly to take advantage of differing solubilities between 
LOS and capsular polysaccharide.  However, in my hands this resulted in a significant 
loss of reagent.  It was not included in my collaborators protocol as it was thought to be 
of dubious benefit. 
 
I established that contamination of my LOS is minimal using silver stain for 
protein/nucleic acids (sensitive to picogram quantities), alcian blue staining for capsular 
polysaccharide and spectrophotometry (again for protein and nucleic acids).  A biological 
assay was also employed by stimulating dendritic cells from the LPS hyporesponsive 
C3H/HeJ mouse strain and measuring IL-10 secretion which had been established as a 
cytokine reliably excreted by C. jejuni LOS stimulated C57BL/6 derived dendritic cells.  
 
Establishing purity could have been improved by using a more robust biological assay.  
However, the TLR4-/- strain of mouse was not available and doing more extensive tests 
using the natural Tlr4 mutated C3H/HeJ strain might only have served to muddy the 
waters as this strain is idiosyncratic in its response to LPS.  For example, priming 
C3H/HeJ derived mononuclear cells with IFN-γ restores LPS responsiveness317.  There 
has also been a report of these strains being responsive to rough, but not smooth, forms of 
LPS318.  An alternative and highly sensitive biological method of detecting contamination 
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is using TLR transfected reporter cell lines which are commercially available (for 
example Invivogen’s HEK-Bluetm C3H/WT murine embryonic fibroblasts).  These cells 
are transfected with a TLR of interest and a reporter gene is placed under an NFκB 
inducible promoter which results in visible colour change in the media when the 
transfected TLR receptor is activated.  This represents a more definitive method of 
excluding contamination or demonstrating that the contamination is present in equal 
amounts in wild type and knock out purified LOS. 
 
I believe that I achieved a high standard of purity and that the GBS associated and control 
strains of LOS were comparable in purity, concentration and secondary structures.  Any 
subtle differences in concentration, due to the differing molecular weights of the two 
strains, could be best addressed by using titrations of LOS.  I therefore felt it was possible 
to compare these strains of LOS to each other to establish if the ganglioside mimicking 
strain exhibited any unique receptor binding or immune stimulating properties.   
 
7.1.2 Binding of LOS to ganglioside specific receptors 
 
Using ganglioside specific antibodies, I demonstrated that the expected ganglioside 
epitopes were present on LOS.  My first task in confirming my central hypothesis was to 
show that ganglioside specific receptors can also bind to the ganglioside mimicking 
epitopes.  As is common in carbohydrate immunology, receptor specificity for 
gangliosides is not clear-cut and often defined by relative levels of affinity for closely 
related glycan structures, or indeed complexes of different glycan structures144,146,356.  A 
number of receptors showing affinity for GD1a and GM1 exist and are expressed on 
several lineages of immune cells.  It was decided to focus on siglecs expressed by 
myeloid cells as these cells play an important role in B cell responses367,368 and the 
necessary reagents were kindly provided by a collaborating group. 
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Surprisingly, I could not demonstrate binding of the macrophage expressed siglec, 
Sialoadhesin, to either native ganglioside or purified LOS under a number of conditions.  
In contrast to the native ganglioside and LOS findings, Sialoadhesin showed clear affinity 
for ganglioside mimicking whole bacteria, demonstrating dose dependent binding.  The 
ganglioside mimic was confirmed as the epitope.  Firstly, the Sialoadhesin did not bind to 
the control CSTII knock out strain which differs only in its lack of ganglioside mimicry 
and secondly because Sialoadhesin binding was lost when the GD1a epitope was 
converted to GM1 by neuraminidase treatment.  This experiment demonstrated perfectly 
the difficulties in studying carbohydrate interactions where the context of the antigen (i.e. 
on a whole bacterium) appears to be crucial for binding to occur in this particular system.   
 
It is possible that the lack of binding to LOS is due to the Sialoadhesin-Fc fusion protein 
reagent, which is a truncated form of the mouse molecule comprising the distal three Ig 
domains rather than the entire seventeen Ig domain molecule.  This may reduce spacing 
of the Sialoadhesin molecule leading to a requirement for the target GD1a to be closely 
packed, which might be the case on the bacteria surface but not with native GD1a in an 
ELISA.  The binding of Sialoadhesin to C. jejuni could have been further characterised 
and the specificity proven definitively by the use of the SnR97A mutant Sialoadhesin 
reagent which has an amino acid substitution in the sialic acid binding pocket which 
obliterates sialic acid binding369.  This reagent was not available for my experiments. 
 
Binding of Sialoadhesin to ganglioside mimicking C. jejuni is an interesting finding for a 
number of reasons.  GBS is an antibody mediated autoimmune disease370 in which the 
target is a carbohydrate371-373 TI antigen.  The antibody isotypes commonly, but not 
exclusively, associated with GBS are the Th1 associated isotypes, IgG1 and IgG353,54,374, 
which is atypical for a carbohydrate antigen as these tend to induce antibodies of the 
IgG2 subclass in humans58,59.  The macrophage populations which constitutively express 
high levels of Sialoadhesin are intimately involved in a number of facets of antibody 
responses and antigen retention by these macrophages greatly enhances B cell 
activation368. 
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Lymph node, Sialoadhesin positive, subcapsular sinus macrophages acquire particulate 
antigen in the sinus and transport it to B cells in the medullary region375 where it is taken 
up by B cells and transported throughout the follicle376,377.  In addition, the macrophages 
appear to discriminate between antigens.  Although subcapsular sinus macrophages 
display a lower phagocytic capacity compared to medullary macrophages378 and appear 
to transport antigen, intact, on their surface to the B cells, degraded viral particles have 
been demonstrated within the macrophages375.  It is not known what discriminates the 
different antigens to their differing fates but it has been suggested that it may be a 
function of different receptor interactions368.  For example, lectin, complement or 
antibody Fc receptor binding might determine whether it is endocytosed or delivered 
intact on the surface.  As Sialoadhesin is a receptor expressed at high levels by these 
cells, and I have demonstrated Sialoadhesin binding to ganglioside mimicking C. jejuni, 
the fact that Sialoadhesin has been shown to enhance phagocytosis on conventional 
macrophages255 might have important implications for how GD1a mimicking, GBS 
associated strains, are presented to B cells. 
 
Sialoadhesin is also constitutively expressed by splenic metallophilic macrophages which 
in mice delineate the marginal zone of the follicles347 and in humans are present in the 
perifollicular zone379.  This places them in an ideal location to interact with MZ B cells 
which are a candidate population for the source of anti-ganglioside antibodies due to their 
participation in responses to T independent antigens and their tendency to harbour auto-
reactive specificities.  Depletion of the metallophilic macrophage population results in a 
marked decrease in antibody responses to T dependent antigens, although responses to T 
independent antigens remain intact but with a notable increased bias towards Th2 
isotypes380.  This can be explained by the findings that metallophils are an important 
source of Type 1 interferons348 and IFN-γ380 which are believed to drive antibody class 
switching towards Th1 isotypes381-384, such as IgG2a in mice (the equivalent of the 
pathogenic human isotypes in GBS). 
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My finding of Sialoadhesin binding to ganglioside mimicking C. jejuni confirms my 
initial hypothesis that the ganglioside mimic can engage endogenous receptors.  It also 
fits well with the over-arching hypothesis that such binding could significantly alter the 
antibody response and subvert tolerance.  My findings specifically link a GBS associated 
strain of C. jejuni with a receptor expressed by a specialised population of macrophages 
which provides antigen to B cells, enhances antibody responses and provides cytokines 
which promote Th1 antibody isotypes.  The specific function of Sialoadhesin in these 
cells is not known.  As GBS is a rare event, it may be that Sialoadhesin functions to 
enhance tolerance by facilitating phagocytosis and promoting degradation to prevent this 
antigen reaching B cells.  Alternatively, it may enhance or polarise immunity by 
delivering C. jejuni to endosomes where endosomal pathogen recognition receptors, such 
as TLR7 or TLR9, night signal to enhance interferon secretion, triggering B cell isotype 
switching.  Interestingly, even in the absence of GBS, infection with C. jejuni expressing 
sialylated LOS is associated with more severe enteric disease385. 
 
An additional ganglioside specific receptor, Siglec F, was shown to bind native 
gangliosides, ganglioside mimicking LOS and ganglioside mimicking C. jejuni, the latter 
two in a dose dependent manner.  This again confirms my initial hypothesis.  The closest 
human equivalent to Siglec F is Siglec 8 which is expressed on eosinophils and mast 
cells146.  Cross linking of Siglec 8 causes apoptosis of eosinophils and counteracts 
stimulatory signals in mast cells146. 
 
Mast cells and eosinophils lie at the front line of the immune system and are ideally 
placed to respond early and drive adaptive responses to mucosal pathogens.  Human 
eosinophils are considered initiators of Th2 responses.  However, eosinophils 
constitutively store an array of pre-formed cytokines associated with Th1, Th2 and 
immunoregulatory functions, including IL-4, IL-13, IL-6, IL-10, IL-12, IFN-γ and TNF-
α
386
.  In addition, there is a differential release of these cytokines in response to different 
stimuli386.  The presence of large quantities of pre-synthesised cytokines allows 
eosinophils to play a crucial role at the initiation of immune responses and an important 
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area of future research is to determine what effect Siglec F (or Siglec 8) signalling has 
both on the differential cytokine release and on subsequent antigen presentation by 
eosinophils387. 
 
In addition to exploring cellular ganglioside receptors I also studied interactions with the 
humoral immune system, specifically looking at fH binding, complement activation and 
natural antibody binding.  Factor H has been reported to bind to sialic acid on cells and 
pathogenic bacteria where it was thought to inhibit complement deposition241,242.  I could 
not demonstrate this with ganglioside mimicking C. jejuni.  However, subsequent studies 
have shown sialic acid to be neither necessary nor sufficient for fH binding to 
bacteria242,245,271 so it is likely that my negative results are accurate. 
 
All of my strains of C. jejuni were opsonised by complement.  However, I showed that 
complement activates less efficiently on ganglioside mimicking C. jejuni than control 
strains.  I believe that this is due to lower levels of natural antibodies in naïve human 
serum specific for the ganglioside mimicking LOS of the GBS associated strains.  My 
experiments stopped short of showing a causative link between natural antibody levels 
and complement deposition, and these studies could have been improved by using 
purified human complement to establish if the differences were only present when 
antibody was present.  It has been shown previously that C. jejuni are very sensitive to 
the bactericidal activity of human serum, in a complement and antibody dependent 
manner, when compared to Campylobacter fetus.  It is therefore no surprise that C. fetus 
is frequently isolated from the bloodstream, whereas C. jejuni is very rarely isolated from 
the bloodstream388.  Additional studies have also shown that sialylated strains of C. jejuni 
are more resistant to complement mediated killing than non-sialylated strains389, which is 
in keeping with my findings of less complement activation on ganglioside mimicking 
strains.  Sialylation might be a strategy adopted by certain strains of C. jejuni to enhance 
their survival by compensating for their inherent complement sensitivity. 
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Complement and natural IgM function to clear self antigen and senescent cells from the 
circulation and complement deficiency is related to autoimmunity through defective 
clearance of self-antigens390,391,392.  Complement resistance in ganglioside mimicking 
strains could be considered analogous to an acquired complement deficiency, resulting in 
persistence of a self-antigen expressed in the context of an immunostimulatory molecule 
i.e. Lipid A.  Natural IgM can enhance or inhibit subsequent IgG responses and does so 
in a complement dependent manner which involves antigen trapping and delivery to B 
cells393-395,396-398.  The role of natural IgM and complement in enhancing class switching 
to IgG is poorly understood, but is likely to be important in autoimmunity as switching 
from IgM to IgG correlates with the onset of autoimmune disease65.  IgM enhances IgG 
responses.  Conversely, low levels or absence of IgM results in enhanced levels of auto-
reactive IgG and increased severity of autoimmune disease in a number of mouse models 
395,399,400
.  How natural IgM protects against IgG mediated autoimmunity while enhancing 
IgG responses is unclear and suggested mechanisms include facilitating rapid clearance 
of self antigen in collaboration with complement, protecting against chronic bacterial 
infections, delivering antigen to immature B cells to enhance central tolerance and 
antigen masking of self epitopes.  Natural antibody and its collaboration with 
complement may be important in C. jejuni associated GBS where individual variations in 
natural antibodies could alter the outcome of infection. 
 
7.1.3 Effect of ganglioside mimicry on LOS potency 
 
By demonstrating in vitro binding of cellular receptors to LOS and whole C. jejuni I 
confirmed my first hypothesis.  Next I decided to test my second hypothesis and establish 
if this ability to bind ganglioside specific receptors affects LOS potency.  Many studies of 
siglec function have relied on antibody cross-linking of receptors or the use of knock out 
animals146.  To the best of my knowledge this is the first time a study has tried to 
demonstrate functional activity of siglecs ligands using a ganglioside mimicking LOS.  
The relative strength of each signal (TLR4 v siglec) and how they might interact was 
unknown and therefore I looked at a broad range of markers in a variety of cell types, 
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including B cell proliferation, CD138 positive cell differentiation, antibody secretion and 
cytokine secretion.  The cytokines chosen were broad markers of immune activity: TNF-
α as an acute phase inflammatory cytokine278,  IL-10 as an inhibitory cytokine322 and IL-
12 as a pro-inflammatory, Th1 polarising, cytokine280. 
 
Within the parameters measured, my studies failed to demonstrate any difference in 
potency between ganglioside mimicking and non-mimicking strains of LOS at 
stimulating B cells.  Although I was measuring very general aspects of potency, the 
greater capacity of E. coli LPS at stimulating B cell proliferation and CD138 positive cell 
differentiation was very clear, which suggests my techniques would have detected 
differences associated with ganglioside mimicry, had they existed.  In fact, the assays 
were sensitive enough to show inter-strain differences in immunoglobulin production 
between GB2 and GB19 derived C. jejuni strains, while the wild type and knock out 
variants within these strains gave remarkably similar results. 
 
Very few studies have looked at direct stimulation of B cells with C. jejuni LOS so 
virtually all of my findings, from its ability to cause proliferation to its ability to mobilise 
MZ B cells in vivo, are new to the field.  The discovery that its properties are 
qualitatively the same as E. coli LPS is not an unexpected finding, although it is 
surprising how low the potency of C. jejuni LOS is.  Low potency had been reported 
before when macrophage stimulation was measured316.  However, when the size of LOS 
is considered (~4 kDa) relative to E. coli LPS (anywhere up to 100 kDa), the C. jejuni 
LOS molarity may have been as much as twenty times greater, and yet was substantially 
less potent.  It may be that mice are very insensitive to C. jejuni LOS, as exposure tends 
to lead to asymptomatic colonisation and clearance rather than the inflammatory response 
seen in humans401. 
 
Myeloid cells express a wide array of ganglioside receptors and it was decided to 
stimulate dendritic cells and macrophages with C. jejuni LOS or whole, killed, bacteria.  
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A number of related studies have been done looking at live C. jejuni and LOS stimulation 
of human dendritic cells and macrophages, although these did not involve comparisons of 
ganglioside mimicking and non-mimicking strains92,352,402,403.  These studies concluded 
that LOS and whole C. jejuni stimulation of dendritic cells induce considerable 
production of IL-10, IL-12 and TNF-α as well as upregulation of costimulatory molecules 
such as CD40.  They also concluded that LOS was a key contributor to cytokine 
production and that high levels of IL-12 production with lower IL-10 production 
suggested a Th1 polarising role.  Monocyte stimulation gave similar results. 
 
My studies on mouse dendritic cells found that LOS stimulation resulted in generally 
comparable IL-10 and IL-12 levels, although IL-12 was greater if whole bacteria were 
used.  My dendritic cells produced large quantities of TNF-α in response to LOS, while 
the macrophages were less responsive.  LOS and whole bacteria caused CD40 
upregulation by dendritic cells and macrophages, respectively.  Therefore, the general 
properties of whole C. jejuni and LOS were comparable to previous work.  However, the 
IL-12 and TNF-α responses I achieved were quite variable and frequently had poor dose 
response curves.  This makes it difficult to draw firm conclusions about the potency of 
wild type and knock out strains in inducing these cytokines.  In contrast to IL-12 and 
TNF-α, IL-10 was a very reliable marker of potency, with levels which were reproducible 
and gave consistently good dose response curves. 
 
A significant difference was noted in dendritic cell IL-10 production in response to 
ganglioside mimicking and non-mimicking LOS.  The ganglioside mimicking strain 
induced half as much IL-10 as the non-mimicking strain, but this was only apparent at 
high concentrations of LOS. This difference was most marked with GB11 LOS but was 
also present with GB2 and GB19 strains.  A number of possible mechanisms were 
explored to try and explain this difference.  Firstly, exogenous gangliosides were added 
to the knock out strains to establish if this was a “ganglioside effect”.  This strategy did 
not reproduce the reduced IL-10.  Secondly, a panel of siglec blocking antibodies was 
used to block potential receptor signalling.  Again, this did not reproduce the reduced IL-
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10.  Possible differences in cell death were also tested but this showed no statistical 
difference between strains.  In addition, whole bacteria were used to stimulate dendritic 
cells, and the difference in IL-10 production between wild type and knock out strains was 
not seen. 
 
In my final experiment designed to try and understand these results, dendritic cells from 
the LPS hyporesponsive C3H/HeJ mouse strain and from a TLR2-/- mouse strain were 
used to establish if the difference in IL-10 could be accounted for by contamination by a 
TLR2 ligand such as capsular polysaccharide.  The results of this assay were conflicting 
as, in the absence of TLR2 signalling, there was no difference in IL-10 production, while 
in the absence of TLR4 signalling (C3H/HeJ cells) no IL-10 was produced to either LOS 
strain.  The former results indicated that a TLR2 agonist mediated the difference in IL-10 
production while the latter result indicated that no TLR2 agonists were present.  
However, a review of the literature reveals conflicting reports on whether TLR2 
signalling alone stimulates IL-10 from dendritic cells319,320,404 which calls into question 
the usefulness of the C3H/HeJ results.  The one study which reports no IL-10 from TLR2 
stimulated dendritic cells has a protocol which is most relevant to my study, however 
studies reporting IL-10 following TLR2 stimulation are more numerous.  
 
In conclusion, this is an interesting and promising observation, but falls short of 
confirming the second part of my hypothesis, that is, that binding to ganglioside receptors 
will lead to altered signalling and responses by immune cells.  Further work needs to be 
done to confirm that no contamination is present and this is a relatively simple set of 
experiments, for example, looking at TNF-α secretion from C3H/HeJ dendritic cells 
stimulated with wild type and knock out LOS. 
 
If these results are taken at face value, they suggest that ganglioside mimicry mediates an 
inhibitory signal, by undetermined means, which is relatively specific for downregulating 
dendritic cell IL-10 (there was no difference in CD40 upregulation and TNF-α and IL-12 
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levels were highly variable).  Such a scenario would fit well with my over-arching 
hypothesis, that altered signalling mediated by the ganglioside mimic can subvert 
tolerance.  Dendritic cells are the most important antigen presenting cells in the immune 
system as they are capable of driving primary responses and of instructing the adaptive 
immune response405-408.  Several bacterial products, including LPS, induce dendritic cell 
maturation409.  Dendritic cells can skew T cell responses towards Th1 or Th2410 and, 
through downstream effects, control the isotypes of antibodies in the ensuing humoral 
response (for example, eliciting IgG2a or IgG1)411.  Dendritic cells can also directly 
activate naïve and memory B cells, are able to induce plasma cell differentiation and can 
trigger antibody isotype class switching in an IL-10 dependent manner412.  Dendritic cells 
exhibit plasticity in function and Th1 polarising dendritic cells can be converted to Th2 
polarising cells when treated with IL-10412.   
 
IL-10 is model example of an anti-inflammatory and tolerogenic cytokine.  Through 
inhibition of accessory cells413 (e.g. macrophages), IL-10 can inhibit inflammatory 
cytokine production by T cells and NK cells414,415, and it inhibits both the Th1 and Th2 
arms of the immune response.  IL-10-/- mice develop inflammatory bowel disease as well 
as other inflammatory conditions416-418 and, interestingly, they are the only mouse model 
of inflammatory C. jejuni enteritis as normal strains are colonised asymptomatically419.  
The main biological action of IL-10 appears to be towards macrophages and dendritic 
cells where it inhibits antigen presentation, secretion of immune polarising cytokines and 
secretion of general inflammatory cytokines, such as TNF-α322  
 
A situation in which ganglioside mimicry inhibits production of this important anti-
inflammatory cytokine from the primary cells driving an immune response could lead to 
a micro-environment where there is greater inflammation, greater antigen presentation 
and higher levels of co-stimulator molecule expression.  A relative lack of IL-10 could 
lead to imbalances in the response and under such circumstances it is easy to imagine that 
auto-reactive B cell clones might be more likely to escape deletion and progress to 
antibody secreting plasma cells. 
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7.1.4 Uptake of ganglioside mimicking C. jejuni 
 
My final hypothesis was that ganglioside mimicking strains of C. jejuni will show 
different immune trafficking than non-ganglioside mimicking strains.  Having 
demonstrated differences in complement opsonisation and cellular receptor binding I 
conducted a number of in vitro studies to establish how this affected interactions with 
cells. 
 
These studies required the development of a means of tracking my C. jejuni.  
Transformation of C. jejuni with gfp plasmid is difficult and I did not have the facilities 
to handle the live pathogens for prolonged periods.  Instead I developed a protocol to 
durably label the bacteria with the cell tracking fluorophore CFSE.  This has been used 
before for a number of bacterial species, but not C. jejuni325-328.  In contrast to these 
previous studies, I wanted to compare two isogenic strains of bacteria and a protocol was 
developed that gave consistent levels of fluorescence regardless of the sialylation status. 
 
Following on from my earlier complement opsonisation studies, I was able to 
demonstrate differences between wild type and knock out strains in their association with 
B cells, in vitro, following opsonisation with normal mouse serum.  These experiments 
showed higher levels of B cell association of a non-ganglioside mimicking strain and 
were dependent on the presence of active complement.  This confirmed my earlier results 
and supports my third hypothesis, that differences in humoral and cellular receptor 
interaction, which are dependent on ganglioside mimicry, will affect trafficking.  It was 
possible to follow B cells within a mixed splenocyte population because they form a 
clearly delineated population when labelled for CD19.  I expect that these differences are 
the same for other complement receptor bearing populations, such as macrophages and 
dendritic cells.  However these proved difficult populations to clearly delineate because 
their markers, F4/80, CD11b and CD11c, show a spectrum in levels of expression, the 
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cells themselves become autofluorescent and the CFSE fluorescence bleeds into other 
channels in the FACS analysis. 
 
Opsonisation by complement is important in enhancing antibody responses partly through 
increased delivery of antigen to antigen presenting cells and B cells262,420.  I would 
therefore predict that ganglioside mimicking strains induce weaker humoral responses, 
and this might be the case in the majority of people exposed to them.  Alternatively, these 
results suggest that non-ganglioside mimicking strains will be cleared more readily 
through complement-receptor-mediated uptake which might ultimately lead to less 
overall inflammation due to less chronic antigen stimulation.  Complement deficiency is 
strongly associated with autoimmunity390,391, and low levels of opsonisation, due to 
ganglioside mimicry and low levels of natural antibody, might result in chronic antigen 
exposure. 
 
In order to expand on my assays showing Sialoadhesin binding to C. jejuni I decided to 
test if this enhanced in vitro phagocytosis as has been shown with Sialoadhesin binding 
strains of meningicocci255.  My experiments showed early enhanced phagocytosis of a 
ganglioside mimicking C. jejuni strain compared to a non-ganglioside mimicking strain 
by bone marrow derived macrophages.  Sialoadhesin was shown to be the receptor 
mediating this by the use of blocking antibodies to reduce phagocytosis of the wild type 
strain to the same rate as the knock out.  Although the difference in phagocytosis was 
small, it remained significant in seven separate repeats (three in progressive time point 
experiments, and four at a single time point).  In addition, the small difference between 
strains can be accounted for by the fact that bone marrow derived macrophages express 
low levels of Sialoadhesin209,248 and this experiment could have been improved by first 
priming the cells with interferons to upregulate Sialoadhesin250. 
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These in vitro observations again support my third hypothesis that ganglioside mimicry 
affects trafficking and there are a number of ways it can be related to my over-arching 
hypothesis about subverting tolerance.  The populations of macrophages with the highest 
expression of Sialoadhesin are the metallophilic marginal zone macrophages and the sub-
capsular sinus lymph node macrophages.  They have been shown to be intimately 
involved in B cell activation and antibody production.  Metallophilic macrophages are a 
major source of type I and type II interferons.  These promote antibody isotype class 
switching to the Th1 isotypes (IgG1 and IgG3), which is one of the idiosyncratic features 
of the anti-ganglioside/LOS carbohydrate response often associated with GBS53,54.  TLR4 
activation from inside endosomes (as oppose to the plasma membrane) triggers selective 
signalling through the TRIF/TRAM pathway which drives type I interferon production421.  
Therefore efficient phagocytosis of ganglioside mimicking strains into these macrophage 
populations (which normally have low phagocytic activity) might enhance these 
cytokines within the B cell micro-environment.  In contrast to the anti-ganglioside 
mimicking LOS response seen in GBS patients, anti-LOS antibodies to non-GBS 
associated C. jejuni enteritis strains are predominantly IgG260, as would be expected 
towards a glycolipid antigen.   
 
The Th1 isotypes (IgG1 and IgG3) are the most efficient at fixing complement64, which is 
thought to be a key part of GBS pathogenesis350.  They are also more commonly 
associated with viral infections422,423.  It is possible that ganglioside mimicking C. jejuni 
induces a more viral-like, interferon driven, response than non-mimicking strains because 
of the way they are sensed by the immune system.  The function of Sialoadhesin remains 
obscure, but one possible explanation for why the immune system expresses a receptor 
for a self molecule is because enveloped virus particles carry gangliosides with them 
when they bud from the host plasma membrane424 and Sialoadhesin may have evolved to 
detect these.  Atypical isotype switching is not loss of tolerance per se (as it still requires 
an antigen specific component), and clearly cannot be the whole story, but class 
switching has been shown to be a crucial event in murine models of autoimmunty65. 
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The final test of whether ganglioside mimicry affects trafficking was in vivo inoculation 
of mice.  It was hoped that the ganglioside mimicking strains would engage Sialoadhesin 
on the metallophilic macrophages where I would be able to co-localise them using the 
metallophilic macrophage specific antibody MOMA1.  The non-mimicking strains were 
expected to be rapidly removed by the reticuloendothelial system.  Because the bacteria 
were rapidly destroyed or lost fluorescence, I was restricted to looking at early time 
points of 1 and 3 hours post-injection.   
 
Analysis of splenic sections using co-localisation software revealed no difference 
between my strains in localisation to either metallophilic or marginal zone macrophages 
and both strains were found in association with both cell types.  In addition, I used FACS 
analysis to study C. jejuni association with a number of cell types and was unable to 
demonstrate any difference between strains.  This result was disappointing in the light of 
the positive results in my in vitro experiments leading up to the in vivo test.  However, 
with hindsight, this result could have been predicted given that my complement binding 
tests had shown both strains to be opsonised efficiently, albeit it with inter-strain 
differences in levels.  It is likely that both the ganglioside mimicking and non-mimicking 
strains were associating with both macrophage populations via complement mediated 
interactions making it impossible to determine a role for Sialoadhesin interactions.   
 
A number of studies have looked at antigen localisation in subcapsular sinus 
macrophages, metallophilic macrophages and marginal zone macrophages.  There appear 
to be subtle but distinct differences between these populations which require complex 
investigations to tease out.  For example, while marginal zone macrophages and 
subcapsular sinus macrophages both capture vesicular stomatitis virus (VSV), the 
marginal zone macrophages require IgM and C3 to achieve this.  These are not required 
by subcapsular sinus macrophages375 suggesting other receptors are involved.  To the best 
of my knowledge this is the first time a ganglioside mimicking bacterial pathogen has 
been used to study these cells.  More complex studies, eliminating complement using 
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cobra venom factor for example, might have shown the ganglioside mimicking bacteria 
localising to the metallophilic but not marginal zone population. 
 
These results do not conclusively disprove my third hypothesis or the over-arching 
hypothesis.  For example, the bacteria used were heat inactivated using a harsh protocol 
(the same one used for LOS extraction) which will have left them vulnerable to 
complement binding and lysis, which might have reduced differences between the strains 
and reduced the time window to analyse the spleens.  An improvement would be to use 
an alternative method of inactivation such as U.V cross linking or sodium azide 
poisoning.  As the initial experiments were very promising, it would be worthwhile 
transforming the bacteria to fluoresce, preferably using separate colours for each strain to 
allow simultaneous inoculation with live bacteria.  In addition, I was hoping different 
receptor binding would have functional outcomes in terms of cytokine production.  
Serum was retained from these experiments to test this hypothesis.  
 
In conclusion, the experiments presented in this thesis have successfully expanded our 
knowledge of how C. jejuni in general, and GBS associated ganglioside mimicking 
strains specifically, interact with the mammalian immune system at a number of levels.  I 
have demonstrated basic properties of C. jejuni LOS which had not been formally shown 
before, for example B cell proliferation, antibody secretion and mobilisation of MZ B 
cells in vivo.   
 
The experiments successfully addressed my three core hypotheses. I conclusively showed 
that the ganglioside mimic in LOS is able to interact with cellular receptors in vitro, and 
also that the mimic affects the interaction of the bacteria with innate humoral components 
of the immune system.  While I did not conclusively show that the ganglioside mimic 
affected potency, I have gathered results which strongly support this hypothesis.  Finally, 
I presented conclusive in vitro evidence that ganglioside mimicry affects trafficking of 
the bacteria.  I was unable to show in vivo effects of ganglioside mimicry on bacterial 
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trafficking although I identified several technical reasons that might account for the 
discrepancy between the in vitro and in vivo results.  My over-arching hypothesis is that 
additional signalling /interactions of the ganglioside mimicking epitopes on LOS might 
contribute to the breaking of tolerance in GBS.  The results presented here neither 
confirm nor refute this, although they provide a foundation for the hypothesis, in that 
such interactions have now been shown to exist.  Like much research, this ends with 
more questions than it started with, and the project can be carried forward addressing the 
precise effects of the ganglioside mimicking LOS receptor interactions. 
 
7.1.5 Future experiments 
 
Many of the findings in this project merit further investigation.  Firstly, the effects of 
ganglioside-mimicking C. jejuni binding to Siglec F were not explored.  This binding 
may result in apoptosis of eosinophils or basophils, and/or alterations of cytokine 
secretion.  These could be important events in GBS.  Secondly, although Sialoadhesin 
mediated phagocytosis was demonstrated, I did not measure many functional outcomes in 
vivo or in vitro.  For example, it would be of interest to establish if IFN production was 
affected by the route of phagocytosis in metallophilic macrophages, or if the ganglioside 
mimicking and non-mimicking C. jejuni strains are trafficked into the same antigen 
processing pathways.  Thirdly, the role of natural antibodies in determining the epitopes 
targeted by the adaptive immune response should also be explored further, for example 
by immunising mice with ganglioside antigens in the presence of blocking antibodies of 
known epitope specificity.  Such studies could not only shed light on the evolution of 
GBS but also open potential avenues for therapeutic interventions.   
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Appendix 1 – Buffers and media 
 
Complete RPMI (cRPMI) 
 
RPMI 1640 media (Gibco, UK) with 10% Foetal Bovine Serum (FBS) (Sigma, UK), 
100µg/ml Penicillin, 100µg/ml Streptomycin and 2mM L-glutamine (all Gibco, UK). 
 
Supplemented cRPMI 
 
RPMI 1640 media with 10% Foetal Bovine Serum, 100µg/ml Penicillin, 100µg/ml 
Streptomycin and 2mM L-glutamine supplemented with 500µl 2-mercaptoethanol and 
5ml non-essential amino acids (both Gibco, UK) per 500ml of media. 
  
FACS Buffer 
 
3% Bovine Serum Albumin (BSA) in PBS (phosphate buffered saline) with 0.05% 
sodium azide (NaN3). 
 
Complete RPMI for phagocytosis experiments 
 
RPMI 1640 media (Gibco, UK) with 10% Ultra-low IgG Foetal Bovine Serum 
(Invitrogen, UK), 100µg/ml Penicillin, 100µg/ml Streptomycin and 2mM L-glutamine 
(all Gibco, UK). 
0.1 M Sodium Carbonate buffer for Ig ELISAs  
 
8.40 g NaHCO3, 3.56 g Na2CO3; dilute to 1.0 L in distilled water; pH to 9.5.  
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Appendix 2 – Structure and expression of siglecs 
 
Human siglecs 
Sialoadhesin
(Siglec 1, CD169)
Siglec 2
(CD22)
Siglec 4
(MAG)
Siglec 15
Siglec 3
(CD33)
Siglec 6
(CD327)
Siglec 5
(CD170)
Siglec 7
(CD328)
Siglec 8 Siglec 10Siglec 9
(CD329)
Siglec 11 Siglec 14
Conserved Siglecs
CD33 related Siglecs
V-set Ig domain
Sialic-acid binding
C2-set Ig
domain
ITIM
ITIM-like
GRB2 binding
motif
FYN kinase
Phosophorylation site
DAP12
Mac
B
Oligo D
Schw
Mac,
DC
MyP
Mo
N, 
Mo
(B)
Troph
(B)
NK
(Mo)
Eo
(Ba)
Mo, N,
cDC
(NK) B(Mo, 
Eo)
Mac Gran,
Mo
DAP12
 
Human siglecs and their cellular expression 144,425,426.  Siglecs are type 1 membrane proteins with an amino-
terminal V-set immunoglobulin domain that mediates sialic acid recognition and varying numbers of C2-set 
immunoglobulin domains.  Siglecs can be divided into two groups – those which show conservation 
between species (Sialoadhesin, CD22, MAG and Siglec 15) and those which differ between species (the 
CD33 related siglecs).  Cell expression has been determined by antibodies (brackets indicate low levels of 
expression).  B–B cells, Mac–macrophages, Mo-monocytes, Oligo-oligodendrocytes, Schw-schwann cells, 
DC-dendritic cells, MyP-myeloid progenitors, N-neutrophils, Troph-trophoblasts, NK-natural killer cells, 
Eo-eosinophils, Ba-basophils, cDC-conventional dendritic cells, Gran-granulocytes, ITIM-immunoreceptor 
tyrosine-based inhibitory motif, GRB2-growth-factor-receptor-bound protein 2.  DAP12 interacts with 
siglec 14 and 15 through charged residues.  Figure adapted with permission 144. 
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Murine siglecs 
Sialoadhesin
(Siglec 1, CD169)
Siglec 2
(CD22)
Siglec 4
(MAG)
Siglec 15
Siglec 3
(CD33)
Siglec E Siglec G Siglec H
Conserved Siglecs
CD33 related Siglecs
V-set Ig domain
Sialic-acid binding
C2-set Ig
domain
ITIM
ITIM-like
GRB2 binding
motif
FYN kinase
Phosophorylation site
DAP12
Mac
B
Oligo D
Schw
Mac,
DC
N
Siglec F
EoN, 
Mo
cDC B
pDC
(Mac)
DAP12
 
Murine siglecs and their cellular expression144,425,426 .  Cell expression has been determined by antibodies 
(brackets indicate low levels of expression).  B–B cells, Mac–macrophages, Mo-monocytes, Oligo-
oligodendrocytes, Schw-schwann cells, DC-dendritic cells, N-neutrophils, Eo-eosinophils, cDC-
conventional dendritic cells, ITIM-immunoreceptor tyrosine-based inhibitory motif, GRB2-growth-factor-
receptor-bound protein 2.  DAP12 interacts with siglec H and 15 through charged residues.  Figure adapted 
with permission 144. 
 283 
 
Appendix 3 – Binding specificities of siglecs 
Sialic Acid Configurations 
Human                                                           Murine
0+00+++0+ND
+++++000+++++ND
0++000++++0
0+++++++++++++
+/-+++++++++++
++++0++++0
Siglec FSiglec ECD22Siglec 10Siglec 9Siglec 8Siglec 7CD22
α3 β4
α6 β4
α6 β4
α3 β4α8
α3 β4
6S
α3
α3 β4
6S
α3
Sequence
Neu5AC Galactose GlcNac Fucose S  Sulphate
Neu5Gc
 
Siglec sialoside binding specificities determined by glycan array analysis.  Sequences are present in 
glycoproteins or glycolipids. +++ strong binding.  ++ moderate binding.  + low binding.  +/- detectable 
binding.  0 no binding.  ND not determined.  GlcNac N-acetylglucosamine.  Neu5Gc N-glycolylneuraminic 
acid.  Neu5AC  N-acetylneuraminic acid.  (Neuraminic acid = sialic acid) Figure adapted with permission 
144
. 
 
Siglec binding to native gangliosides 
 GT1b GQ1b GD3 GM2 GM3 GD1a 
Siglec 5 + ++     
Siglec 7 ++ ++ ++    
Siglec 8       
Siglec 9 ++ ++ ++  ++  
Siglec 10 ++      
Sialoadhesin      ++ 
Siglec F ++     ++ 
Siglec E +     ++ 
 
Siglec binding to gangliosides369,427.  (blue is human siglecs, green is murine siglecs).  Sialoadhesin, Siglec 
F and Siglec E binding to gangliosides had not been demonstrated prior to this thesis.  (+  weaker binding, 
++  stronger binding). 
 
Siglecs do not have specificities for gangliosides per se.  Siglecs have specificity for sialic acid and the 
binding affinity is determined by the sialic acid linkages to the surrounding molecules.  A siglec can bind to 
sialic acid with the correct configuration whether on gangliosides, other glycolipids or glycoproteins. 
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Appendix 4 – Structures of siglec-human-Fc fusion proteins 
Native murine siglecs
Siglec-human-Fc fusion proteins
Sialoadhesin Siglec F Siglec E
Sialoadhesin Siglec F Siglec E
-V-set Ig domain
Sialic-acid binding
-C2-set Ig
domain
-ITIM
-ITIM-like -Human IgG
Fc Ig domain
 
Murine siglecs and the structures of siglec-human-Fc fusion protein reagents255,258,428.  Ig, Immunoglobulin. 
Fc, fraction crystallisable.  ITIM, immunoreceptor tyrosine-based inhibitory motif.  
 
 
